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FOREWORD 
 
The School of Pharmacy and Pharmaceutical Sciences, Cardiff University, is the only school 
of pharmacy in Wales and is one of the top schools of pharmacy in the UK. Our students 
graduate well-prepared and satisfied, as seen by the consistently high pass rate in the 
pharmacist registration examination and high ranking in the National Student Survey 
respectively. 
 
In addition to supporting individual pharmacists in their initial and ongoing education and 
development, the School is active in research that has been independently judged to be 
predominantly of international standing, more than half of which is recognised as world-
leading or internationally excellent and with many interdisciplinary and external 
collaborators. Research at the School encompasses medicinal chemistry, drug delivery and 
microbiology, pharmacology and physiology, and pharmacy practice and clinical pharmacy, 
and it impacts on healthcare and pharmaceutical sciences throughout the UK and the world. 
Further information on the School’s research activities and degree programmes, along with 
contact details for academic staff can be found at http://www.cardiff.ac.uk/phrmy. 
 
At the Cardiff School of Pharmacy and Pharmaceutical Sciences, the combination of these 
strengths allows us to successfully deliver research-led learning and teaching. All of our 
MPharm students undertake a significant, independent Masters level research project in the 
final year of the four-year degree, and present and defend their research. The high numbers 
of well-qualified UK, EU and international students that we attract to our postgraduate 
diplomas and degrees also contribute significantly to our research output. 
 
This is the 18th year in which we have published the abstracts of our students’ research. 
Within this publication the student is the first named author, and collaborators and 
supervisors follow. An alphabetical list of authors appears in the index. 
 
Many thanks to our colleagues for their assistance in collating this book. 
 
Dean Routledge, Rhys Thomas & Justine Jenkins 
July 2018 
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Technology in Community Pharmacies: The Perceptions of Pharmacists and the 
Community Pharmacy Team on current Patient Medication Record systems  
Rana Ajaj, MW Smith and M Gumbleton 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF103NB, Wales, UK. 
Community pharmacy services are continuously facing issues in the delivery of more efficient practice. It was 
suggested that smarter technology could be used to empower the pharmacist and allow them to provide better 
patient care.1 There is a push for using swifter technology to bridge knowledge gaps in healthcare.2 The major 
piece of technology used to support pharmacists in delivering pharmaceutical care is the Patient Medication 
Record (PMR) system, which is now in wider use.3 Therefore, this study aims to explore the perceptions of 
pharmacists and the community pharmacy team on current PMR systems and identify key improvements that 
need to be implemented to support the community pharmacist in providing better quality care. 
After attaining ethical approval, pharmacists were invited to take part in this study through purposive sampling. 
A topic guide was developed from the literature review and then trialled in the pilot study. Two focus groups 
were used to explore participant perceptions and were recorded via an audio recorder. Data was transcribed 
ad verbatim and analysed thematically. 
Eleven participants were interviewed in the two focus groups. Two main themes were identified. The first theme 
being existing technology and encapsulated three sub-themes, namely: benefits of PMR systems, limitations 
of PMR systems and then other technologies. The second theme was challenges of community pharmacy and 
contained the following five sub-themes: funding cuts, how community pharmacists are perceived, lack of 
integration, unnecessary paperwork and embracing technology. 
PMR systems were generally perceived as beneficial. However, their limitations have suggested that 
developments are needed to meet the needs of community pharmacists today. This study suggests that future 
PMR systems should be integrated with other healthcare professionals’ systems, easy to use and ensure 
patient safety. In addition, system developers should make training and support more efficient to meet the 
needs of PMR system users.  
1. Dean Franklin, B. medication safety, problems, solutions and challenges. 2015. [accessed 29 Oct 2017]. Available from: 
https://isqua.org/docs/default-source/qatar-info/Qatar-Power-Point-Presentations/tuesday-afternoon-plenary---medication-safety---
problems-solutions-and-challenges---bryony-dean-franklin.pdf?sfvrsn=0 
2. Caldicott, D. F. et al. Information: To share or not to share? The Information Governance Review. 2013. [accessed 29 Nov 2017]. 
Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/192572/2900774_InfoGovernance_accv2.pdf 
3. Royal Pharmaceutical Society England. Electronic Health Records: Guidance for Community Pharmacists and Pharmacy 
Technicians. 2016. [Accessed 20 Oct 2017].  Available 
from:https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Support/EHR-
GuidanceUpdateMar2016.pdf]. 
 
 
The role of Prostaglandin E2 (PGE2) on keratinocyte growth rate 
Assad Al-Bayati, A Moukachar, OK Castell, SA Coulman and CP Thomas. 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Three-dimensional bio-printing of skin and organs using bio-printers has recently showed promising outcomes 
leading to a novel approach towards tissue based research.1 A suitable candidate for printing is human skin, 
as current laboratory skin models have limited use especially in the study of skin cancer. PGE2 has been 
implicated to enhance growth of skin tumours with observations showing overexpression of PGE2 in those skin 
cells.2 Thus, we conducted experiments aimed to test a range of PGE2 concentrations and its effect on the 
increase of HaCaT cell (immortalised keratinocytes) proliferation rate. This will provide important observations 
of how PGE2 effects the surrounding cells firstly in 2D before integration with future 3D models.  
A two-dimensional monolayer culture of HaCaT cells in low calcium (basal-like) and high calcium 
(differentiated) concentration media were seeded into 12 well-plates at 2x104 per well in 6 wells and analysed 
over 6 days. PGE2 was incorporated in the growth medium at concentrations of 1, 10, 50 and 100ng/ml, whilst 
a control group was analysed as a comparison.  
From the results collected, the highest level of confluency and proliferation rate was evidently seen from 
concentration 10ng/ml of PGE2 for both calcium levels (p=0.02). Results were highly significant for low calcium 
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but a non-significant trend was observed with the high calcium HaCaT cells. PGE2 showed a fast onset with 
a long duration of action. 
It can be confirmed PGE2 is an important lipid mediator for keratinocyte proliferation and its production does 
affect neighbouring cells. The addition of concentrations higher than 10ng/ml of PGE2 caused the death of 
cells via necrosis which could be due to desensitisation of prostaglandin receptors. In the future, the role of 
PGE2 in cellular homeostasis would require analysis in a 3D-model for results representative of human skin. 
1. Cubo N, Garcia M, del Cañizo J, Velasco D, Jorcano J. 3D bioprinting of functional human skin: production and in vivoanalysis. 
Biofabrication. 2016;9(1):015006. doi: 10.1088/1758-5090/9/1/015006 
2. Conconi M, Bruno P, Bonali A, De Angeli S, Parnigotto P. Relationship between the proliferation of keratinocytes cultured in vitro 
and prostaglandin E2. Annals of Anatomy - Anatomischer Anzeiger. 1996;178(3):229-236. doi: 10.1016/s0940-9602(96)80055-0 
 
 
Investigating the impact of the outer membrane and efflux pumps on the 
antimicrobial susceptibility profile of carbapenem–resistant Enterobacteria 
Maliha Ali and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
The aim of this project was to investigate the impact of the outer membrane and efflux pumps on the 
antimicrobial susceptibility profile of carbapenem–resistant Enterobacteria. Enterobacteriaceaesuch as 
Escherichia coli and Klebsiella ssp, are Gram-negative bacteria normally found in the intestines.1 
Fifty clinical isolates of E. coli & K. pneumoniae were prepared using R2A broth then tested against varying 
concentrations of chlorhexidine digluconate (CHX) alongside carbonyl cyanide 3-chlorophenylhydrazone 
(CCCP) or ethylenediaminetetraacetic acid (EDTA). Minimum Inhibitory Concentrations (MIC) were 
determined as the lowest concentration that inhibit visible growth. Minimum Bactericidal Concentrations (MBC) 
were determined by plating out the content of wells with no observable growth on TSA plates and incubation 
for 24h at 37C. 
When comparing MICs of EDTA and CCCP alone, the average MIC using CCCP was higher (3.71 µg/ml) than 
EDTA (3.65 µg/ml), which shows at the concentrations used, EDTA was a more effective adjunct to use with 
CHX. When combined with CHX, the average MIC with CCCP was slightly higher, but a smaller range of MICs 
was observed (0.67-8.00 µg/ml) compared to EDTA (1.00-16.00 µg/ml), which shows CCCP had a more 
uniform effect on the test organisms.    
The average MBC using EDTA was a lot higher (11.84 µg/ml) than the MBC when CCCP was used 
(4.34µg/ml). When combined with CHX, the range of MBCs observed with EDTA (1.00-64.00 µg/ml) was larger 
than the range of MBCs observed with CCCP (1.00-8.00 µg/ml). This shows that there was a large variation 
in the effect of CHX when EDTA was used. Out of the strains tested, the K. pneumoniae strains were less 
susceptible to the effects of EDTA and CCCP compared to the E. coli ones. 
In conclusion, the outer membrane of carbapenem-resistant bacteria as well as efflux pumps have a negative 
impact on antimicrobial effectiveness. This was demonstrated by the effect seen on CHX activity when a 
membrane permeabiliser (EDTA) or an efflux pump inhibitor (CCCP) was used.  
1. P. Nordmann et al. 2012a. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends in Molecular Medicine 18(5), 
pp. 263-272.  
 
 
The Knowledge and Perceptions of Undergraduate Pharmacy Students on Drugs in 
Sport 
Louise Allen, R Chalker and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Doping and the use of performance-enhancing drugs in sport is a growing problem.1 If appropriately trained, 
pharmacists can play an important role in doping prevention as well as educating athletes and the general 
public to make informed decisions about their health.2 However, it is unclear how many pharmacy programmes 
include sports pharmacy in their curriculum. The aim of this study was to evaluate the level of knowledge 
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pharmacy students have around the use of drugs in sport. It also intended to gain an insight into knowledge 
gaps across a breadth of students, and question if the current teaching is adequate.  
The study was conducted through an online questionnaire. This was adapted from a questionnaire created for 
a study carried out in Qatar.3 Ethical approval was granted. The questionnaire was circulated by email to four 
universities. Data had previously been obtained from two further institutions, but had not yet been compared. 
Quantitative data was entered into SPSS ® v23 and analysed using the Pearson coefficient.  
A total of 531 students participated, from six universities. The basic level of knowledge across all students was 
similar. Participating in sport did not have an effect on knowledge, however year of study did. Ninety-five 
percent of students believed that sports pharmacy should be part of the MPharm curriculum. Healthcare 
professionals were thought to be the most reliable source of information to obtain safe and effective advice 
about drugs in sport. However, there were clear errors in knowledge, predominately around the prohibited 
status of some substances. 
Students expressed a strong desire to learn more about sports pharmacy and participate in doping prevention. 
However, there are evident gaps in knowledge that need to be addressed before they can provide safe and 
legal advice to athletes and the public. Further sports pharmacy education is recommended in the MPharm 
curriculum. 
1. BBC Sport. Doping in sport: Drug use 'fast becoming a crisis' - Nicole Sapstead. 2017 [accessed 3 January 2018]. Available from: 
http://www.bbc.co.uk/sport/38884801 
2. Ambrose P. An Advanced Pharmacy Practice Experience in Sports Pharmacy. Am J Pharm Educ. 2008;72(1):19. 
3. Awaisu A, Mottram D, Rahhal A, Alemrayat B, Ahmed A, Stuart M et al. Knowledge and Perceptions of Pharmacy Students in 
Qatar on Anti-Doping in Sports and on Sports Pharmacy in Undergraduate Curricula. Am J Pharm Educ. 2015;79(8):119. 
 
 
Molecular cross-talk between coagulation factor and complement C3 
Noor Altaie and M Heurich-Sevcenco 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK 
The coagulation and complement (innate immunity) systems are essential for haemostasis and immune 
defence, and are activated simultaneously following injury.1 In disease, where severe trauma and infection has 
occurred,2 the activation of these two systems can lead to excessive amplification of the clotting and 
inflammatory response, causing damage to the host.1 In this study, we hypothesised that coagulation factor 
will bind and cleave the initiator of the complement alternative pathway, complement C3. 
Indirect and sandwich ligand-binding ELISAs were developed to determine coagulation factor binding to C3, 
in comparison to thrombin. Gel electrophoresis was used to test the cleavage of C3 by activated coagulation 
factor. Cleavage fragments were visualised with Coomassie staining and quantified by densitometry. 
ELISA studies show that coagulation factor can bind to both adsorbed and antibody-captured complement C3 
in a concentration-dependent manner. Activated coagulation factor cleaved complement C3 to C3b as seen 
by the appearance and increase in band intensity of the α’-chain of C3b. Under these conditions, no further 
cleavage of C3b to iC3b was detected. 
Coagulation factors ability to bind and cleave complement C3 to C3b suggests that coagulation factor may 
have complement-stimulatory activity in-vivo. This may contribute to complement alternative pathway 
amplification, and an increased inflammatory response contributing to the pathophysiology in disease. 
1. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? 
Trends Immunol. 2007;28(4):184-92. doi: 10.1016/j.it.2007.02.006 
2. Markiewski MM, DeAngelis RA, Lambris JD. Complexity of complement activation in sepsis. J Cell Mol Med. 2008;12(6A):2245-54. 
doi: 10.1111/j.1582-4934.2008.00504.x 
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Evaluation of a community pharmacy-based asthma care plan 
James Appleby, F Omrani, D Farah, N Rahman and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Asthma is a widely prevalent chronic respiratory condition, with over 5.4 million people diagnosed in the 
UK.1 Asthma control can be achieved through the use of inhalation treatment, although medication is 
commonly misused by the patient population.1,2 The three possible causes of poor asthma control are 
ineffective medications, lack of patient adherence, or inadequate inhaler technique. This study aims to 
evaluate the effectiveness of asthma care plans in the pharmacy setting by examining factors such as 
patient asthma control and inhaler technique. 
A total of 61 patients were recruited to the study by convenience sampling across four pharmacies in 
South Wales. Patients completed an ACT (Asthma Control Test) questionnaire, demonstrated inhaler 
technique using an AIMs (Aerosolised Inhalation Monitor) Vitalograph device, and answered questions 
about their asthma management. Ethical approval was granted by Cardiff School of Pharmacy and 
Pharmaceuticals Sciences' Research Ethics Committee. 
Overall asthma control was found to be poor, with 55% (n=33) of patients presenting with "uncontrolled" 
symptoms. Hospitalisation or use of oral steroids had occurred in 31.3% (n=19) of patients within the last 
year, further highlighting the scale of inadequate control. Following AIMs testing, MDI technique was 
revealed to be significantly worse than DPI devices (60.7% versus 20.0% failing, respectively, p<0.05). 
Asthma control was significantly worse in ex-smokers than non-smoking patients sampled (p<0.05). No 
significant improvement was seen in returning patient populations from the previous year of study. 
Current interventions made by HCPs (Healthcare Practitioners) are failing to adequately address poor asthma 
control across the population. Improvements to current asthma care plans in the community setting are 
needed, with focus on re-education and evaluation of adherence and inhaler technique. 
1. Asthma UK. Asthma facts and statistics. 2015 [accessed 6 January 2018]. Available from: 
https://www.asthma.org.uk/about/media/facts-and-statistics/  
2. Arora P, Kumar L, et al. Evaluating the technique of using inhalation device in COPD and Bronchial Asthma patients. Respiratory 
Medicine. 2014;108(7):992-998. 
3. Melani A, Bonavia M, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. 
Respiratory Medicine. 2011;105(6):930-938. 
 
 
Evaluation of the Community Pharmacy Flu Vaccination Service in Wales over the 
last five years (2012-2017) 
Sam Baker, K Price and R Deslandes. 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward Vii Avenue, Cardiff, CF10 
3NB, Wales, UK. 
Influenza (“Flu”) is a contagious disease most prominent between October-April (“a Flu season”). 
Approximately 600 deaths a year in the United Kingdom result from Flu.1 Annual vaccination is recommended 
as the most effective prevention strategy with a target of 75% vaccination uptake in specific patient populations, 
such as those at risk of conducting severe disease, including sufferers of chronic conditions and the elderly.2 
Before 2012, immunisation in Wales was conducted in General Practice (GP) but vaccination rates remained 
below the 75% target.3 As a result, National Health Service (NHS) Wales introduced the NHS Seasonal Flu 
Vaccination Programme (“the Flu programme”) to Community Pharmacy.4 The aim of this study was to 
evaluate the Flu programme between 2012-2017. 
Secondary data was used in the study and was obtained through online patient forms completed at the time 
of vaccination between 2012-2017. The resulting data included a range of variables from pharmacy location 
to patient gender. The data was coded into a quantitative form and analysed through descriptive tests using 
SPSS Statistics and Microsoft Excel. Ethical approval was not required for anonymised secondary data.   
A resulting 67,714 vaccinations were administered over the study period. Overall, vaccination figures increased 
each season with 1,568 patients immunised in 2012/13 up to 26,889 in 2016/17. In addition, higher proportions 
of patients are benefitting from the service in the early months (September-November). Most vaccinations 
(78.4%) were performed in multiple pharmacies (six or more branches). Most patients were female (57.5%) 
and the largest eligible group using the service was those aged 65 and over with 37,885 (56.0%) vaccinations. 
MPharm 
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Since its introduction in 2012, the Flu programme is becoming a more prominent service with increasing 
numbers of vaccinations performed annually. In addition, more patients are receiving immunisation during the 
earlier months of the Flu season, resulting in protection before Flu begins to circulate.  
1. Evans A, et al. 2013. Can providing NHS flu vaccination in community pharmacies reach people who otherwise would not get 
vaccinated? Experiences from the national community pharmacy seasonal influenza service in Wales. Int J Pharm Pract 2013; 
21(Suppl 2): 120–121. 
2. Loving, S. 2017. Vaccination Knowledge Project – Influenza (Flu). Available at: http://vk.ovg.ox.ac.uk/influenza-flu [Accessed: 2nd 
December 2017]  
3. Public Health Wales Vaccine Preventable Disease Programme. 2012. Seasonal Influenza vaccine uptake in Wales - 2011/12. 
Public Health Wales. Available at: 
http://www2.nphs.wales.nhs.uk:8080/VaccinationsImmunisationProgsDocs.nsf/3dc04669c9e1eaa880257062003b246b/1116fa9ba
81180ea80257a1e00523a2a/$FILE/Wales%20influenza%20immunisation%20uptake%202011-12.pdf [Accessed 17th October 
2017]. 
4. World Health Organization. 2016. Influenza (Seasonal). Available at: http://www.who.int/mediacentre/factsheets/fs211/en/ 
[Accessed 10 Oct. 2017] 
 
 
Investigating the antibacterial effect of Namibian honey samples against clinically 
significant bacterial pathogens, including antibiotic resistant methicillin-resistant 
Staphylococcus aureus (MRSA) and Klebsiella pneumoniae 
Eliana Basini-Gazzi, R Williams, and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
The aim of this project was to investigate the antimicrobial activity of Namibian honey samples against 
pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and multidrug resistant Klebsiella 
pneumoniae, then isolate responsible compounds. Honey is historically renowned for its medical significance.1 
Antibiotic resistance is a significant global threat, with statistics showing that in 2016, some countries had over 
25% MRSA resistant strains and one third of K. pneumoniae isolates were resistant to at least one of these 
antibiotic groups: cephalosporins, fluoroquinolones and aminoglycosides.2 Therefore it’s a logical decision to 
explore honey further.  
An agar disc diffusion assay3 determined the antimicrobial activity of Namibian honey against MRSA, 
methicillin-sensitive Staphylococcus aureus (MSSA), K. pnuemoniae and Escherichia .coli. A rotary evaporator 
for solvent extraction, used methanol, ethyl acetate and hexane to separate compounds differing in polarity. 
Individual compounds were separated using thin layer chromatography (TLC), before a bacterial overlay 
assay4 identified antimicrobial activity. A final agar disc diffusion assay with the methanol extracts in the 
presence and absence of catalase determined the presence of hydrogen peroxide.  
Two out of three Namibian honey samples showed antibacterial activity against target bacterial strains: 
Windhoek honey showed greatest activity against Gram-positive bacteria; Neudamm honey against Gram-
negative. Methanol extracts produced the greatest mass, indicating most honey compounds were polar 
molecules. Despite showing no results on the bacterial overlay assay, methanol extracts demonstrated 
antibacterial activity in the agar diffusion assay, both before and after treatment with catalase, suggesting that 
activity was not due to hydrogen peroxide’s presence. Therefore the majority of antimicrobial properties were 
due to either a synergistic relationship between polar compounds, sugar content or an unknown non-peroxide 
molecule.  
Namibian honey samples demonstrated inhibitory activity against MRSA, MSSA, K.pneumoniae and E.coli. 
Further exploration may establish those exact compounds responsible as promising factors in the fight against 
global antimicrobial resistance. 
1. Kwakman P, Zaat S. Antibacterial components of honey. 2011; 64(1): 48-55. 10.1002/iub.578 
2. Sleeman C. Antibiotic resistance across Europe: E. coli, MRSA and Klebsiella . 2017 [accessed 27 Dec 2017]. Available from: 
http://data-viz.nesta.org.uk/antimicrobial-resistance-2017/index.html 
3. Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 
1966; 45(4): 493-496. 
4. Blaxland, JA. The antibacterial activity of Humulus lupulus against mycobacteria [PhD Thesis]. Cardiff: Cardiff University; 2015. 
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How can technology overcome the barriers faced by community pharmacists to 
fulfil their future role? 
Anya Bowen, M Gumbleton and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
It is evident that community pharmacists’ clinical knowledge is being utilised in the delivery of a variety of 
patient centred services and the role of the pharmacist is particulalry expanding within the primary care 
sector.1,2 While the pharmacy profession is evolving, the community pharmacy environment has been slow to 
catch up as the focus remains on the dispense and supply process.3 Technology has been shown to improve 
efficiency and safety notably through improvements in dispensing and management of medicines.4 This study 
identifies the perceptions of community pharmacists on the future of their profession and identifies the 
technological requirements needed to support and enhance these roles.  
Two focus groups (with eleven participants) were conducted via a semi-structured method, which were then 
transcribed ad verbatim. Thematic analysis with an inductive approach was undertaken and three key themes 
identified.  
The future of community pharmacy, barriers to the future role and future technological requirements were the 
three themes identofied. Moving away from dispensing and towards a more clinical role was identified as an 
aspiration for the future.  The inability to access patient records, time spent accuracy checking, and the recent 
funding cuts were the main barriers discussed. Technological advancements to improve supply, the patient's 
experience, integration and documentation are necessary to support pharmacists in the future. Access to 
electronic health records was also identified as a future requirement to ensure patient safety. 
Technological advancements should aim to overcome the barriers identified and tackle the current limitations 
of technology to ensure that the future role of community pharmacists can be achieved without compromise. 
This study's results can be used by technology developers to improve current practice and enable community 
pharmacists to utilise their skills, which in turn will result in a more efficient NHS system. 
1. Department of Health.  Review of operational productivity in NHS providers (interim report). 2015 [accessed 5 Oct 2017].  Available 
from: https://www.gov.uk/government/publications/productivity-in-nhs-hospitals 
2. Twigg M, Wright D, Kirkdale C, Desborough J, Thornley T. The UK pharmacy care plan service: description, recruitment and initial 
views on a new community pharmacy intervention. PLoS ONE. 2017; 12(4):0174500. doi: 
https://doi.org/10.1371/journal.pone.0174500 
3. The Royal Pharmaceutical Society.  New models of pharmacy: what is emerging and what is possible. A review of the literature. 
2013 [accessed 3 Oct 2017]. Available from: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/References/Now%20or%20Never/Now%20or
%20Never%20-%20Literature%20review.pdf 
4. Hohmeier K, Spivey C, Boldin S, Moore T, Chisholm-Burns M.  Implementation of a health information exchange into community 
pharmacy workflow. J Am Pharm Assoc. 2017; 57(5):608-15. 
 
 
Design and synthesis of novel CYP51 inhibitors as therapeutics for candida 
infections 
Peter Braidley, FAS Binjubair and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
In fungi, the CYP51 enzyme is essential in producing the cell membrane component ergosterol. Inhibition of 
CYP51 with azole drugs leads to loss of ergosterol production, and the production of sterol by-products toxic 
to the fungi.1 However, antifungal resistance to licensed azoles is emerging.2 A new antifungal azole may help 
combat this, and a lead imidazole compound had been successfully developed by Dr. Claire Simons. The 
imidazole lead had been shown to be an effective inhibitor of Candida albicans, the most common pathogenic 
human fungi.3 The aim of this project was to further develop this lead compound. 
To investigate potential structural improvements, nine novel inhibitor candidates based on the lead were 
docked into CYP51’s protein structure,3 using the program Molecular Operating Environment (MOE). Following 
this, the synthesis of three of these compounds was attemtped via a multi-step synthesis. 
The drug candidates bound well with CYP51 in MOE, and whilst the synthesis steps were completed, isolation 
of the final target compounds was not achieved. Fortunately, colleagues in the research group were able to 
synthesise three of the compounds, which were sent to be tested against C. albicans at Swansea University. 
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One of these, 5d, contained a new dichlorophenyl moiety and showed considerably improved activity on the 
lead, reducing the minimum inhibitory concentration required from 4-8 μg/mL to 1 μg/mL.  
Compound 5d warrants further development. Future steps could include extension of the compound’s structure 
to fill unoccupied space in the CYP51 enzyme binding site, or replacing the imidazole with a triazole or tetrazole 
substituent. With continued development a new clinical treatment for Candida infection could be obtained. 
1. Bard, M.; Lees, N.D.; Turi, T.; Craft, D.; Cofrin, L. et al. Sterol synthesis and viability of erg11 (cytochrome P450 lanosterol 
demethylase) mutations in Saccharomyces cerevisiae and Candida albicans. Lipids 1993, 28, 963-7. 
2. Sanglard, D. Emerging threats in antifungal-resistant fungal pathogens. Front. Med. 2016, 3, 11. 
3. Hargrove, T.Y.; Friggeri, L.; Zdzislaw, W.; Aidong, Q.; Hoekstra, W.J. et al. Structural analyses of Candida albicans sterol 14-
demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis.  J. 
Biol. Chem. 2017, 292, 6728-6743. 
 
 
A study of the physical stability of neonatal parenteral nutrition lipid emulsions in 
multilayer mini-bags and plastic syringes. 
Nicola Brown1, P Spark2 and A Cosslett1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edwards V11 Avenue, CF10 3NB, 
Wales, UK.  2St Marys Pharmaceutical Unit, Cardiff and Vale University Health Board, 20 Field Way Cardiff, CF14 4HY, 
Wales, UK. 
In 2014 there were three deaths from Bacillus cereus septicaemia attributed to contaminated neonatal 
parenteral nutrition (PN) manufactured by ITH Pharma, with a further 20 infants becoming seriously ill.1 Cardiff 
and Vale University Health Board currently test neonatal PN formulations for bacterial contamination 
simultaneously with delivery to patients. To improve patient safety the Board wishes to move to testing prior 
to delivery of the PN to the clinical area, requiring formulations to have a longer shelf life than 7 days. 
The aim of this study was to assess the physical stability of two different neonatal formulations, containing two 
lipid emulsions (plus associated vitamin components), when stored in 50ml syringes and 300ml mini-bags over 
variety of time periods and storage temperatures. The aim of the second section of the study was to assess 
whether a “pooling” method of manufacture had any effect on the physical stability of the lipid emulsions 
contained within the formulations. Visual inspection, pH measurement, laser diffraction and microscopic 
globule size determination were used to assess the stability of each test PN formulation. 
Visual changes seen, were easily reversed by shaking therefore were not associated with instability, whilst the 
pH consistently fell with time but on no occasion did it drop below pH5.2 Laser diffraction analysis, identified 
no significant changes in the D[4,3] value apart from the samples based on Intralipid® as the lipid emulsion, 
when the PN was stored at higher temperatures. There was no significant difference in the largest globule size 
or the number of globules greater than 10μm. Visual changes, pH values and laser diffraction showed similar 
results in section two of the study with no clear advantage from the “pooled” method of manufacture being 
demonstrated. 
This study suggests that neonatal PN formulations can have a shelf life longer than 7 days, but was unable to 
demonstrate a clear difference between the individual lipid emulsion products and/or storage/delivery 
conditions. Further work is necessary to confirm the stability of the lipid emulsions with these PN neonatal 
formulations and would be better carried out using 50ml as opposed to 300ml mini-bags. 
1. Boseley,S. and Dodd, V. (2017). Police investigate hospital death of three babies given contaminated feed. The Guardian. 
Available at: https://www.theguardian.com/society/2014/sep12/contaminated-feed-police-investigate-deaths-three-babies-ith-
pharma [Accessed 10 Oct 2017] 
2. Driscoll DF. Pharmaceutical and Clinical Aspects of Lipid Injectable Emulsions.  JPEN J Parenteral Enteral Nutrition. 2016;41:125-
134. [Accessed 27th Dec 2017]. Available from: http://pen.sagepub.com/cgi/doi/10.1177/0148607116673187 
 
 
Development of an aptasensor for the detection of procalcitonin 
 
Clare Bryan, N Demertzis and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Sepsis is a life-threatening illness, killing up to 64000 people in the UK each year.(1) Accurate diagnosis and 
timely initiation of treatment are vital to improve a patient’s chance of recovery. Currently, there is no gold 
standard test to diagnose sepsis. A number of potential biomarkers that could aid in diagnosis have been 
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investigated. Procalcitonin (PCT) is one such example.(2) This research aims to develop a biosensor for PCT 
using aptamers and electrochemical impedance spectroscopy (EIS) which is able to detect clinically relevant 
PCT levels. 
 
Different self-assembled monolayers (SAM) containing anti-PCT aptamer were modified onto a gold surface 
electrode by thiol interaction.(3) Cyclic voltammetry and EIS were used to characterise the different SAMs on 
the surface and evaluate binding performance when challenged with increasing PCT concentrations. EIS 
measured the change in impedance, plotted as Nyquist plots. The equivalent circuit of the EIS Nyquist plots 
was used to calculate Rct values and the change in Rct after PCT binding, which was used to evaluate the 
SAM performance as an aptasensor. 
 
Three different approaches were investigated. SAM of aptamer only and co-immobilization of aptamer with 
different alkanethiol ‘spacers’ did not produce consistent results. The third approach was more successful, 
producing an aptasensor with 0.5 M aptamer which was later backfilled with 0.5 M MCH. This sensor 
demonstrated a concentration dependent response between 10 and 100 pg/ml, with an apparent Kd of 3.26 
fM. The limit of detection obtained suggests that the sensor could find utility in clinical testing. 
 
The final aptasensor developed shows promise in PCT detection, however further research will be needed to 
refine sensitivity for sepsis diagnosis. High PCT levels may be indicative of other inflammatory conditions 
and thus cannot be used alone for sepsis diagnosis.(2) A microarray biosensor design capable of detecting 
multiple biomarkers should be investigated going forward. 
 
1. Daniels R. Surviving the first hours in sepsis: getting the basics right (an intensivist's perspective). Journal of Antimicrobial 
Chemotherapy. 2011;66(suppl_2):ii11-ii23.  
2. Larsen FF, Petersen JA. Novel biomarkers for sepsis: A narrative review. European Journal of Internal Medicine. 2017;Nov;45:46-
50 
3. Herne TM, Tarlov MJ. Characterization of DNA Probes Immobilized on Gold Surfaces. Journal of the American Chemical Society. 
1997;119(38):8916-20.  
 
 
Mechanisms of cross-talk between coagulation factor and complement component 
Rosie Burke and M Heurich-Sevcenco 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK. 
 
Complement and coagulation cascades are activated simultaneously by common stimuli, to fight invading 
pathogens and limit bleeding.1,2 Preliminary data showed a potential binding interaction of coagulation factor 
with complement component. This work aimed to confirm binding and begin functional characterisation of the 
coagulation factor-complement component interaction and its potential effects on complement activity, 
including assessing for complement component cleavage and determining effects of coagulation factor on 
complement component activity. 
 
An enzyme-linked immunosorbent assay (ELISA) was developed to confirm coagulation factor- complement 
component binding, detect coagulation factor- complement component   complexes in plasma samples and to 
begin characterisation of binding domains. Enzymatic cleavage assays, monitored by gel electrophoresis, 
were used to determine if coagulation factor cleaves complement component and complement component 
activity was assessed ± coagulation factor. Protein was visualised using Coomassie stain and band intensity 
analysis carried out by densitometry (ImageJ).  
 
ELISA techniques confirmed that coagulation factor specifically binds complement component. The developed 
binding assay detects coagulation factor- complement component complexes in plasma. No cleavage of 
complement component was detected at physiologically relevant concentrations of coagulation factor.  
 
The coagulation factor- complement component binding interaction has a moderate effect on complement 
component activity. The herein developed binding assays can be used to develop a new diagnostic tool for 
detecting complement component -coagulation factor complexes in patient plasma samples. Complement 
component may also influence coagulation factor’s function, which requires further characterisation. 
 
1. Markiewski MM, Nilsson B, Nilsson Ekdahl K, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in 
crime? Trends Immunol. 2007;28(4):184-92. doi: 10.1016/j.it.2007.02.006 
2. Tanaka KA, Key NS, Levy JH. Blood coagulation: Hemostasis and coagulation factor regulation. Anesth Analg. 2009;108(5):1433-
46. doi: 10.1213/ane.0b013e31819bcc9c 
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To develop a rapid diagnostic capable of determining the antibiotic sensitivity of 
Staphylococcus aureus.  
 
Annabelle Bush, L Baillie and E Ahortor  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
 
Methicillin resistant Staphylococcus aureus (MRSA), caused by the presence of the MecA gene1, is a threat 
to human health as patients with infections caused by MRSA are an estimated 64% more likely to die from 
their infection compared to those caused by methicillin sensitive Staphylococcus aureus (MSSA).2 Therefore 
rapid detection of the causative bacterium and subsequent informed antibiotic prescribing is imperative to 
ensure effective treatment. Despite this, there is currently no single test to guarantee reliable identification of 
MRSA meaning detection of the bacterium can often take several days.3 The aim of this study is to aid in the 
development of a rapid nucleic acid hybridisation assay in the hope to reduce MRSA identification times whilst 
increasing the reliability of diagnoses. 
 
A selection of clinically suspected MRSA isolates and S. aureus control strains were phenotypically 
characterised using Gram-stain, coagulase test and their susceptibility to oxacillin. Isolates were then further 
classified using our diagnostic MecA and S. aureus DNA probes and DNA extracted from each isolate via a 
commercial extraction kit and via microwaves. 
 
Out of a total of 28 S. aureus isolates, 22 were phenotypically identified as MRSA with the remaining six 
isolates classified as MSSA. It was found that, when using DNA extracted via a DNA extraction kit, 70% (n=10) 
of clinical isolates were correctly identified using the MecA probes and 79.1% (n=24) of clinical isolates 
correctly identified using the S. aureus probes. When using DNA extracted via microwaving, both pairs of DNA 
probes detected all clinical isolates (n=5).  
 
Initial data suggests extracting DNA via microwaves produces more reliable results and lends itself to the 
development of a rapid diagnostic assay as DNA can be extracted within a matter of seconds. Despite this, 
repeat experiments using larger sample sizes and a wider range of Staphylococci species is required in order 
to determine the robustness of the assay and the selectivity of the probes. 
 
1. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111(9):1265–1273. 
doi:10.1172/JCI200318535 
2. World Health Organisation (WHO). Antimicrobial Resistance. 2017 [Accessed: 18th November 2017]. Available at: 
http://www.who.int/mediacentre/factsheets/fs194/en/  
3. Kateete DP, Kimani CN, Katabazi FA, Okeng A, Okee MS, Nanteza A et al. Identification of Staphylococcus aureus: DNase and 
Mannitol salt agar improve the efficiency of the tube coagulase test. Ann Clin Microbiol Antimicrob. 2010;9(23):1-7. doi: 
10.1186/1476-0711-9-23 
 
 
The role of simvastatin in targeting FAK, and related proteins in the 
reduction/inhibition of migration seen in triple negative breast cancer 
 William Cervetto, C Smith and SE Hiscox  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, UK.  
Triple negative breast cancer (TNBC) is an aggressive subtype with a poor outcome. Successful treatment of 
TBNC is further confounded by the lack of therapeutic targets (oestrogen and progesterone receptors and 
HER2 receptor). several preclinical and epidemiological studies have further supported the claim that statins 
could be of benefit in TNBC. Most cancer related deaths result from metastasis and there is and 
overexpression of FAK related to TNBC cells.  This study seeks to find the role simvastatin may have in 
inhibiting migratory cells like/associated with focal adhesion kinase (FAK). Unravelling possible specific 
treatment to this this cancer subtype, and subsequently be used to better prognosis of patients.  
MDA231 cells were cultures and lysed for use in methodology processes. These included western blotting, 
used to distinguish protein levels in treated and non-treated cancer cells. This was done to understand the 
possible pathways linked with migration. Migration assay was also carried out to confirm inhibition of migration 
over 24 hours. Finally, immunofluorescence was conducted to view the subcellular localisation of specific 
proteins.  
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Simvastatin showed specific targeting of phosphorylated FAK. An important protein in migration and downward 
cell signalling. GTPase proteins associated with FAK were also studied. Bearing results of increased increase 
expression of RhoA and decreased expression of Rac1 in treated cell lines.  
This study reports a relationship between simvastatin’s use, and inhibition of migration seen in triple negative 
breast cancer cells. This could potentially be used as an adjunctive treatment with chemotherapy in the future.  
 
1. Humphries, B et al. 2017. Downregulation by miR-200b supresses metastasis of triple negative breast cancer by enhancing 
activation of RhoA.   
2. Jean-Cheng, K. 2017. Abstract 1877: Coordination of Rac1 and Cdc42 by centrosomal microtubules in focal adhesion dynamics 
and directed cell migration. American Association for cancer research 77, pp.1877 
 
 
The Knowledge and Perceptions of Pharmacy Students on Drugs in Sport 
Rebecca Elizabeth Chalker, L Allen, H Farr, R Patel, C Wynne1 and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edwards VII Avenue, Cardiff CF10 
3NB, Wales, UK and 1University of Birmingham School of Pharmacy, Institute of Clinical Sciences, College of Medical 
and Dental Sciences, Edgbaston, Birmingham, B15 2TT, UK. 
The issue of drug doping is still relevant at all levels of sport1, reflecting an emerging need for pharmacists 
who are well educated in sports pharmacy to provide support and advice regarding the use of drugs in sport.2  
This study aims to compare the knowledge and perceptions of students across several pharmacy schools in 
order to determine the current level of sport pharmacy education in the UK.  
The study consists of a questionnaire which has been adapted from one previously conducted in Qatar.3   The 
questionnaire was circulated to: Cardiff University, University of Birmingham, University of Reading, Kingston 
University London, Aston University and University of Bath. Data generated was mostly quantitative and was 
analysed using SPSS v23. The Pearson correlation coefficient was used to analyse respondents’ knowledge, 
at the significance levels p<0.01 and p<0.05.  
Across the six schools, there was a total of 531 respondents. Results showed a statistically significant 
relationship between year of study and correctly identifying the prohibited status of amphetamines, anabolic 
steroids and codeine at the level p<0.01. 92% of respondents correctly identified the prohibited status of 
anabolic steroids but only 12% correctly identified the status of insulin. 97% of respondents believed that 
pharmacists should be used as healthcare professionals to provide advice to athletes and 95% stated they 
thought sports pharmacy should be included in their curriculum, as either a core or elective module. Results 
showed disparity in the quantity of teaching on sports pharmacy that different schools provide. 
Knowledge of students is good but gaps in knowledge need to be addressed. In order to be pharmacists who 
are better equipped for the effective administration of advice to athletes within local communities, clearer 
guidelines which enable the provision of quality teaching on drugs in sport should be employed. 
1. ComRes. BBC Sport Amateur Sports Doping Survey. 2017 [accessed 5 Dec 2017]. Available from: 
http://www.comresglobal.com/polls/bbc-sport-amateur-sports-doping-survey/ 
2. International Pharmaceutical Federation. FIP GUIDELINES The role of the pharmacist in the fight against doping in sport. 2014. 
[accessed 20 Oct 2017]. Available from: https://www.fip.org/www/uploads/database_file.php?id=369&table_id= 
3. Awaisu A, Mottram D, Rahhal A, Alemrayat B, Ahmed A, Stuart M, et al. Knowledge and Perceptions of Pharmacy Students in 
Qatar on Anti-Doping in Sports and on Sports Pharmacy in Undergraduate Curricula. Am J Pharm Educ. 2015;79(8):1-7. doi: 
10.5688/ajpe798119 
 
 
Evaluation of the DMR service from April 2013- August 2017 
Yolanda Chikomba, KL Hodson and ML Hughes 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, UK. 
The Discharge medicines review (DMR) service was developed and implemented in Wales by the Welsh 
Government in October 2011.1  The initiative was designed to improve care transitions. The service was 
evaluated in 2014.2   However, since then there have been no evaluations of the service. The aim of this project 
was to evaluate the DMR service from April 2013 – August 2017. 
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Five researchers used the Statistical Package for the social sciences (SPSS) ® software to combine existing 
DMR data. Researchers conducted secondary analysis of the quantitative data individually using SPSS. 
Spearman and Pearson correlations, post hoc tests (ANOVA), and the Mann Whitney test were used to 
statistically analyse data. Ethics approval was not required.3 
Across all Wales, the number of DMRs conducted significantly increased over time (p=0.00). A total of 37425 
DMR claims were submitted. Cwm Taf Health Board had a significantly greater number of claims per 100000 
of the population (p=0.00). It could be suggested that this was influenced by the implementation of a new 
information technology scheme called Choose Pharmacy, which changed the process of the DMR service. 
This scheme was introduced because of suggestions made in the 2014 evaluation.2   Of the accredited 
pharmacies that can provide the DMR service, only 25% participation was observed monthly. As each 
pharmacy can undertake 140 DMR’s per year, an average of 0.71% of these potential DMRs were provided 
across all Wales. The discrepancy rate is still 1 per DMR, as it was in the 2014 evaluation.2  
The results demonstrate that there is still underutilisation of the service. Further studies are required to explore 
the reasons for this as well as the benefits and limitations of the service to inform future improvement. 
1. Cpwales. The Discharge medicines review service. 2011 [accessed 26 Oct 2017]. Available from: 
http://www.cpwales.org.uk/Contract-support-and-IT/Advanced-Services/Discharge-Medicines-Review-(DMR)/Overview-of-the-
DMR-Service.aspx  
2. Hodson K, Blenkinsopp A, Cohen D, Longley M, Fasihul Alam M, Davies P, et al. Evaluation of the Discharge Medicines Review 
Service. 2014 [accessed 10 Oct 2017]. Available from: http://www.cpwales.org.uk/Contract-support-and-IT/Advanced-
Services/Discharge-Medicines-Review-(DMR)/Evaluation-of-the-DMR-Service/Evaluation-of-the-DMR-service.aspx  
3. Denscombe M. The Good research guide. 5th ed. Maidenhead, England: McGraw-Hill/Open University Press; 2014.  
 
The effect of Welsh honey and other natural products on bacterial biofilms 
Mohammed Chowdhury, L Baillie and JA Blaxland 
Cardiff school of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
In the United States, it has been estimated that 65% of all human infectious diseases can be attributed to 
biofilm-forming bacteria.1 These ‘medical biofilms’ are commonly found in catheters and ventilator tubes. They 
are also common among patients with cystic fibrosis.2 Bacteria form biofilms by secreting and growing a 
polysubstance matrix, this affords the bacteria protection from the environment and makes them extremely 
resistant to antibiotics. The aims of this study were to determine the susceptibility of Pseudomonas aeruginosa 
(NCTC 10662) and Klebsiella pneumoniae (clinical isolate) to four natural products: Welsh Redwood honey, 
manuka honey, black tea and hops and to perform biofilm inhibition and elimination assays against these 
bacteria. 
 
To test the susceptibility of the bacteria, a zone of inhibition was performed with the natural products. To 
calculate the phenol coefficient, phenol (1-7% w/v) was also tested. To test the natural products ability to inhibit 
and eliminate biofilms, bacteria were grown in a 96-well titre. Biofilm was quantified by dying it and analysing 
the optical density at 570nm. 
 
Bacteria were susceptible to Redwood and manuka honey. Redwood and manuka honey appear to inhibit 
biofilm formation. Redwood honey at high concentrations eliminates established biofilms. Black tea inhibited 
K. pnuemoniae biofilm formation at concentrations of 12.5% v/v and higher, but was unable to eliminate biofilm. 
The bacteria appear to be unaffected by the presence of hops. 
 
Redwood honey has potency comparable to manuka honey. Black tea shows antibiofilm properties. More 
optimised biofilm assays need to be performed to verify the results. More research needs to be performed on 
Redwood honey and black tea to deduce the active components and their mechanism of action. 
 
1. Wolcott R, Dowd S. The Role of Biofilms: Are We Hitting the Right Target? Plastic and Reconstructive Surgery. 2011; 127:28S-
35S. 
2. Mulcahy L, Isabella V, Lewis K. Pseudomonas aeruginosa Biofilms in Disease. Microbial Ecology. 2013;68(1):1-12. 
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Development of Aspartyl-AMP mimics to treat Multi-Drug Resistant (MDR) 
Pseudomonas aeruginosa 
Silouanos Christodoulou and C Simons  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK 
The incidence of MDR P. aeruginosa has been increasing since 2003, and the World Health Organisation has 
marked the development of new antibiotic to treat it as “critical” in a recent report.1,2 Infections of P. aeruginosa 
increase mortality and morbidity, and are common in very vulnerable groups.3  An infection can lead to 
bacteraemia, which is normally secondary to an untreated infection, making the increase in the incidence of 
MDR resistance a major health concern.4  In this project, the aim was to design and develop two or more novel 
molecules, which are mimics of aspartyl-AMP (Asp-AMP) and would have the potential of inhibiting aspartyl 
tRNA synthetase (AspRS) in P. aeruginosa. 
The molecules were designed based on previous research carried out at Cardiff University. Molecular 
modelling was performed to evaluate the binding of the designed molecules with the target. Chemical synthesis 
consisted of four steps which were based on previous research found in the literature. 
Four mimics of Asp-AMP were designed, but only one was successfully produced which was at a low quantity 
and not up to an acceptable standard to be tested. However, a synthetic route was derived. Furthermore, the 
molecule containing the chloro-substituent was found to be the one with the greatest potential of inhibiting 
AspRS during molecular modelling. 
The derived synthetic route will enable the future development of the designed analogues. Suggestions are 
provided on how the purity and yield of the product could be improved. The impact of our research is highly 
dependent on the results that will be received from biological assays of molecules that will be produced in the 
future using the derived synthetic route. 
1. Suarez C, Peña C, Arch O, Dominguez MA, Tubau F, Juan C, et al. A large sustained endemic outbreak of multiresistant 
Pseudomonas aeruginosa : a new epidemiological scenario for nosocomial acquisition. BMC Infect Dis. 2011;11(1):272. doi: 
10.1186/1471-2334-11-272 
2. World Health Organisation. WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO. 2017 [accessed 13 
Nov 2017]. Available from: http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/doi: 
/entity/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/index.html 
3. Public Health England. Pseudomonas aeruginosa: guidance, data and analysis - GOV.UK. 2017 [accessed 01 Nov 2017]. 
Available from: https://www.gov.uk/government/collections/pseudomonas-aeruginosa-guidance-data-and-analysis 
4. Knott L. Pseudomonas. 2014 [accessed 10 Nov 2017]. Available from: https://patient.info/doctor/pseudomonas 
 
 
Evaluation of Discharge Medication Reviews in 2017 
Sophie Corteville, ML Hughes and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales, UK. 
Discharge Medication Reviews (DMRs) are a service provided by community pharmacists in Wales to ensure 
patients’ medications are accurately prescribed in the community after discharge from hospital. Medicines are 
often altered during hospital admission and this information is not always effectively communicated to the 
patient’s GP or pharmacist.1-3 DMRs identify and resolve discrepancies. They consist of two-parts; a 
pharmacist’s review of the discharge information compared against what has been prescribed by the GP, and 
a consultation with the patient to advise them about their medication3. The aim of the study was to evaluate 
the DMR service since 2013, and identify trends year on year.  
A descriptive and statistical analysis was performed using Statistical Package for Social Sciences (SPSS) with 
secondary data provided by NHS Shared Services. 
Results show the number of DMRs completed has remained constant or slightly increased over the last four 
years, with a mean of around 8,325 per year. When adjusted for population, Cwm Taf carried out the most 
DMRs and Powys the fewest. Consistently around 700 contractors are accredited to provide the service each 
year, but only 200 actively participate. Hospitals account for over 50% of referrals to the service and the main 
reasons for undertaking DMRs were for medicines changed during admission or polypharmacy. A third of 
consultations were conducted over the telephone with the patient.  At least one discrepancy was found on 
average per DMR; a figure which remained constant over the study period. However, 10-20% of DMRs were 
not completed and at least 25% of discrepancies remained unresolved.  
MPharm 
15 
 
DMRs can undoubtedly make a worthwhile contribution to patient safety by identifying discrepancies. However, 
more needs to be done to ensure their resolution. There is also vast underutilisation of the service which, if 
appropriately optimised, could prevent serious harm from medication. The Welsh government should 
commission further research into the barriers for conducting DMR, adequately resource and promote the 
service and introduce outcome-based payments for contractors to address these issues. 
1. Yang S. Impact of pharmacist-led medication management in care transitions. BMC Health Serv Res. 2017;17:722. doi: 
10.1186/s12913-017-2684-3 
2. Dodds LJ. Pharmacist contributions to ensuring safe and accurate transfer of written medicines-related discharge information: 
lessons from a collaborative audit and service evaluation involving 45 hospitals in England. Eur J Hosp Pharm: Sci 
Pract. 2014;21:150-155. doi: 10.1136/ejhpharm-2013-000418 
3. Hodson K, Blenkinsopp A, Cohen D, Longley M, Alan F, Davies P, et al. Evaluation of the discharge medicines review service. 
2014 [accessed 19 October 2017]. Available from: http://www.cpwales.org.uk/Contract-support-and-IT/Advanced-
Services/Discharge-Medicines-Review-(DMR)/Evaluation-of-the-DMR-Service/Evaluation-of-the-DMR-service.aspx 
 
 
‘Welsh language in pharmacy practice: confidence of pharmacists and pre-
registration pharmacists with formal Welsh language undergraduate tuition’ 
Siwan Curran, W Davies, L Doyle and E Jones 
Cardiff school of Pharmacy and Pharmaceutical sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
 
Approximately 19% of the populations in Wales are fluent Welsh speakers.1 In 1993, the Welsh Language act 
enabled both the English and Welsh language to have an equal status in Wales within the public sector.2 The 
Welsh Language measure, introduced in 2011, gave the Welsh language an official status in Wales where 
public bodies had to comply with legal standards to provide a bilingual service.3 ‘More than just words’ is a 
framework which strengthens the use of Welsh language within healthcare followed by the ‘Active offer’ which 
ensures that Welsh speaking patients care is provided through the medium of Welsh without them having to 
request it.4 As a result of the increase in Welsh language services, Cardiff School of Pharmacy introduced 
Welsh language tuition within their undergraduate course in 2012. The aim of this project is to investigate how 
attending Welsh language tuition has affected the confidence of Pharmacists and pre registration Pharmacists 
in communicating in Welsh to patients.  
Ethics approval was obtained, qualitative research was carried out after semi structured interviews were 
undertaken with five participants. Consent was sought and interviews were audio recorded and transcribed 
verbatim and thematically analysed. Bilingual topic guides, consent forms and participant information sheets 
were given to participants prior to interviews. 
Study results showed that all five participants believed that Welsh language tuition provided by the 
undergraduate course increased their confidence in communicating in Welsh to patients. However, there is 
room for improvement in their awareness of Welsh language initiatives, availability of bilingual resources and 
in improving their confidence in initiating Welsh consultations. As a result, participants would like to see more 
Welsh language consultation training being offered during their pre-registration course and greater access to 
bilingual resources. This will help provide them with the tools to meet the needs of Welsh-speaking patients 
and improve and strengthen patient care. 
1. Welsh Assembly Government. Welsh Language (Cymraeg) | wales.com. [Accessed 13th of October]. Available from: 
http://www.wales.com/language 
2. Welsh Language Board. Welsh Language Act. Welsh Language Scheme Welsh Language Scheme. 1993.  
3. Pinnacle. Pinnacle - Welsh Language Scheme. [Accessed 13th of October]; Available from: 
http://www.wales.nhs.uk/bcupinnacle/welsh-language 
4. Welsh Assembly Governemnt. Follow on strategic Framework for Welsh Language Services in Health and Social care. 2016. 
Available from: http://gov.wales/topics/health/publications/health/guidance/words/?lang=en 
 
 
Analysis of the major constituents of UK-grown Artemisia annua for medicinal and 
commercial significance. 
Elizabeth Edmonds and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Artemisinin forms the backbone of malarial treatment, particularly in South-East Asia1, but due to its structural 
complexity, cultivation of the plant Artemisia annua is the only viable source.2  While it grows freely in many 
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parts of the world3, this project investigated if UK grown A. annua could yield artemisinin and other compounds 
in sufficient quantity to be of pharmaceutical significance. 
Leaves, stems and flowers were all investigated. Different solvents and extraction methods were used to obtain 
extracts which were separated using preparative thin layer chromatography. The project was split; one student 
searched for artemisinin, the other student investigated significant bands for a high yielding constituent (bands 
yielding complex mixtures were abandoned). Sephadex LH-20 was used with little success as a scale up 
method. Compounds were characterised by ESI-MS. Standards were not used anywhere in the project due to 
costs. Extracts and fractions were tested against both gram-positive and gram-negative bacteria.  
Artemisinin was found at a maximum yield of 0.28% of the dry weight of A. annua leaves but this was not 
significantly viable. The compounds daphnoretin and isoalantolactone were found though these have not been 
found in this species of Artemisia previously.4 Two compounds showed activity against MRSA, these were 
thought to be parthenolide (not previously found in A. annua4) and one or both of the compounds within the 
isomeric mixture of casticin and chrysosplenetin. 
The antibacterial activity of these compounds should be further investigated as novel antibiotics. However, as 
only trace amounts of artemisinin were found in the UK-grown A. annua it would not be feasible to grow this 
plant on a large scale in Wales. It is unclear what factors may have affected the level of artemisinin produced. 
This could be an area of future research, though a repeat of this project should use plants grown in different 
parts of the UK and under different conditions e.g. outdoor versus greenhouse grown. 
1. Wang J, Xu C, Lun ZR, Meshnick SR. Unpacking ‘artemisinin resistance’. Trends Pharmacol Sci. 2017; 38(6):506-11. doi: 
10.1016/j.tips.2017.03.007 
2. Jessing KK, Duke SO, Cedergreeen N. Potential ecological roles of artemisinin produced by Artemisia annua L. J Chem Ecol. 
2014; 40(2):100-117. doi: 10.1007/s10886-014-0384-6     
3. Ferreira JFS, Luthria DL, Sasaki T, Heyerick A. Flavonoids from Artemisia annua L. as antioxidants and their potential synergism 
with artemisinin against malaria and cancer. Molecules. 2010; 15(5):3135-3170. doi: 10.3390/molecules15053135 
4. Brown GD. The biosynthesis of artemisinin (qinghaosu) and the phytochemistry of Artemisia annua L. (quighao). Molecules. 2010; 
15(11):7603-98. doi: 10.3390/molecules15117603 
 
 
Improving the health of community pharmacy influences on pharmacists’ uptake to 
new technology 
Sophie Edwards, MW Smith and M Gumbleton 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK 
The NHS is promoting the use of technology to improve both patient care and enhance the roles of healthcare 
professionals.1 The role of community pharmacists is also evolving to develop more clinical roles, but new 
technologies are required to aid this advancement.2 As new technologies are produced it is important to know 
what factors influence the pharmacist to uptake new technology, but there is currently no literature that 
describes these factors. This research aimed to identify how pharmacists are influenced to uptake new 
technology. The objectives were to use a literature review to develop a topic guide to for discussions within 
focus groups to discover the main themes to shape a future survey. This information will influence the design 
and marketing strategies of technology companies. 
The literature review used to develop the topic guide was completed using keywords in a Google Scholar 
search and by searching Pharmaceutical Journals. Two focus groups were carried out and recordings were 
transcribed and analysed to extract the main themes and associated subthemes. These were used to construct 
a survey questionnaire.  
The main themes emerging from this research were that pharmacists wanted clarity on: (a) ways of finding out 
about new technology; (b) identification of the benefits of new technologies; (c) features of the PMR system 
and (d) how company policy affected introduction of new technologies. Subthemes of issues emerged that 
were related to each theme.  
The findings identified what factors were important to influence a pharmacists’ decision to uptake new 
technology and these formed the basis of the survey questionnaire. The major finding was the importance of 
company policy, which showed that independent pharmacists make their own decisions to uptake technology, 
but head office would need to be targeted to influence multiples to uptake new technology.  
1. NHS England. The NHS in 2017. 2007 [accessed 8 Jan 2018] Available from: https://www.england.nhs.uk/five-year-forward-
view/next-steps-on-the-nhs-five-year-forward-view/the-nhs-in-2017/ 
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2. The Royal Pharmaceutical Society England. New Models of Pharmacy: what is emerging and what is possible. A review of the 
literature. 2013 [accessed 10 Oct 2017] Available from: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/References/Now%20or%20Never/Now%20or
%20Never%20-%20Literature%20review.pdf 
 
 
Evaluation of a community pharmacy-based asthma care plan 
Dana Farah, N Rahman, F Omrani, JS Appleby and WR Ford. 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Asthma is an incurable inflammatory condition of the airways adversely affecting patient quality of life if not 
treated with medication.1 Medication is usually inhaled using devices such as metered dose inhalers (MDI) 
and dry powder inhalers (DPI). 71% of asthmatics are “poor users” of inhalers, which prevents treatment 
reaching the target site in the lungs and leaving them more liable to exacerbations requiring oral steroids or 
hospital treatment.2 The aims of this study were to evaluate inhaler technique and asthma control and observe 
whether improvement is shown a year following an intervention. 
61 participants were recruited from Cardiff University and four community pharmacies. Participants completed 
an Asthma Control Test (ACT) and a questionnaire, and the Vitalograph Aerosol Inhalation Monitor (AIM) was 
used to measure inhaler technique. Data analysis was completed on SPSS using Mann-Whitney U and 
Kruskal-Wallis supported by Dunn’s post hoc test. Returning participants’ results were analysed using a related 
samples Wilcoxon-signed-rank test. P values <0.05 are considered significant. Ethical approval was obtained. 
Results showed that, regardless of which health care professional instructed them, inhaler technique was 
generally poor, with worse technique in MDIs than DPIs (p=0.012). According to ACTs, 50% of participants 
had uncontrolled asthma. A third of participants have had exacerbations, 75% of which still had uncontrolled 
asthma. There was no correlation between uncontrolled asthma and poor inhaler technique, potentially due to 
non-adherence which was not evaluated in this study. Participants returning from last year’s study (n=8) did 
not show improvement in asthma control or inhaler technique.  
Overall, both inhaler technique and asthma control were poor and need improvement. Only 5% (n=3) of 
participants were shown technique by pharmacists but there is evidence of technique and control improvement 
when patients have a review with a pharmacist.3 Tailored education should be provided to patients more 
frequently than annually as this does not appear to be frequent enough.4  
1. NHS Choices. Asthma. 2016 [Accessed: 13 Oct. 2017]. Available from: 
http://www.nhs.uk/conditions/asthma/Pages/Introduction.aspx  
2. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 
2002;19(2):246-251. 
3. Armour C, Bosnic-Anticevich S, Brillant M, Burton D, Emmerton L, Krass I, et al. Pharmacy Asthma Care Program (PACP) 
improves outcomes for patients in the community. Thorax. 2007;62(6):496-592. 
4. Press V, Arora V, Trela K, Adhikari R, Zadravecz F, Liao C, et al. Effectiveness of Interventions to Teach Metered-Dose and 
Diskus Inhaler Techniques. A Randomized Trial. Ann Am Thorac Soc. 2016;13(6):816-824. 
 
 
The views of Welsh speaking pharmacists who have not received formal Welsh 
undergraduate teaching; use of and confidence in using the Welsh language in 
professional practice. 
Owain Fenn-Jones, L Doyle, W Davies and E Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK 
The linguistic needs of patients are often overlooked in health and social care, with a lack of language provision 
a factor in less favourable patient outcomes.1 In 2012, Welsh medium undergraduate tuition was introduced in 
the School of Pharmacy at Cardiff University. This followed the introduction of frameworks such as ‘More than 
just words…’, to improve Welsh language provision in health and social care.2 The aim of this study was to 
explore the views of Welsh speaking pharmacists that had not received any undergraduate teaching in Welsh, 
on their confidence in using the Welsh language in practice. 
Qualitative research in the form of semi-structured, audio recorded interviews (n=5) was conducted. Interviews 
were transcribed verbatim, coded manually and analysed thematically. All materials used with participants was 
provided bilingually and ethically approved before use. 
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Four major themes were identified: Pharmacists’ perceptions of advantages/disadvantages of Welsh language 
provision for patients, Barriers to Welsh language provision, Confidence in using the Welsh language and 
Increasing future Welsh language provision. Participants showed an overall lack of confidence in using the 
Welsh language in practice. Geographical differences in participants’ confidence and demand for Welsh 
language services was observed. Participants were confident in the use of the Welsh language socially, with 
some describing the challenges in using the Welsh language professionally due their lack of knowledge of 
Welsh language terminology. 
Participants highlighted several regions for change in Welsh language provision, both at undergraduate and 
postgraduate levels, that would be beneficial in increasing their confidence in providing Welsh language 
services. Participants also highlighted the need for more Welsh language resources, in the facilitation of future 
Welsh language services. 
1. Van Rosse F, de Bruijne M, Suurmond J, Essink-Bot M-L, Wagner C. Language barriers and patient safety risks in hospital care. A 
mixed methods study. International Journal of Nursing Studies. 2016; 54:45-53. 
2. Welsh Government. Follow-on Strategic Framework for Welsh Language Services in Health, Social Services and Social Care. 
2016 [accessed 08 Dec 2017]. Available from: http://gov.wales/docs/dhss/publications/160317morethanjustwordsen.pdf 
 
 
The Synthesis of Double Branched Deshydroxy Androgen Receptor Antagonists for 
Potential Prostate Cancer Treatments 
Kathryn Fisher, AD Westwell and S Kandil   
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Prostate cancer is the second highest cause of cancer affecting men across the globe, accounting for a fifth 
of all cancer related deaths in men.1 The androgen receptor (AR) promotes the growth of prostate cancer cells 
providing an ideal target for potential therapies.2, 3 Existing treatments include the non-steroidal androgen 
receptor antagonist for which bicalutamide is favoured due to its superior toxicity profile.4 Unfortunately 
bicalutamide resistance eventually develops leading to terminal cancer.2, 3 This project aims to overcome 
bicalutamide resistance by synthesising a series of novel double branched deshydroxy bicalutamide 
derivatives bearing bulky substituents. 
A homology model of the AR in its antagonistic conformation was created to predict antagonistic activity. The 
derivatives were synthesised using a simple, three step process. The first step involved the synthesis of an 
amide intermediate using methacryloyl chloride and 4-nitro-2-(trifluoromethyl)aniline. The amide intermediate 
was reacted via a Michael addition with a series of thiophenols to produce the sulphide before oxidation to the 
sulphone.  
A double branched derivative of low yield (5 %) was obtained and predicted to have good antagonistic activity 
by homology modelling. The remaining four sulphides were single branched with variable yield (71-52 %) and 
were successfully oxidized to produce two pure and two impure sulphones. Oxidation of the double branched 
compound was unsuccessful. 
The pure compounds will be tested in human prostate cancer cell models to evaluate anti-proliferative activity. 
The synthesis of double branched derivatives was largely unsuccessful, requiring further research to obtain a 
reliable, high yielding method.  
1. International Agency for Research on Cancer. Number of incident cases, males, worldwide (top 10 cancer sites). GLOBOCAN. 
2012 [accessed 13 Nov 2017]. Available from: http://gco.iarc.fr/today/online-analysis-
pie?mode=cancer&mode_population=continents&population=900&sex=1&cancer=29&type=0&statistic=0&prevalence=0&color_pal
ette=default. 
2. Tan M, Li J, Xu E, Melcher K, Yong E. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol 
Sin. 2015;36(1):3-23. doi: 10.1038/aps.2014.18 
3. Yuan X, Cai C, Chen S, Yu Z, Balk S. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of 
resistance to new agents targeting the androgen axis. Oncogene. 2014;33(22):2815-25. doi: 10.1038/onc.2013.235 
4. Dawson N. Alternative endocrine therapies for castration resistant prostate cancer. Post TW ed. Waltham: UpToDate Inc; 2017 
[accessed 13 Nov 2017]. Available from: https://www-uptodate-com.abc.cardiff.ac.uk/contents/alternative-endocrine-therapies-for-
castration-resistant-prostate-cancer?search=Alternative%20endocrine%20therapies%20for%20castration 
%20resistant%20prostate 20cance&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1  
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An ex-vivo investigation into the bladder wall distribution of ketamine using a 
porcine bladder model 
Kar Lai Fong, M Branco and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK.  
Ketamine has been used clinically since 1970, with its primary use in anaesthesia.1 Due to its effects, it has 
been abused recreationally since 1980.2   The use within nightclub settings is increasing and it is known as a 
“date-rape” drug.3   Following reports of lower urinary tract symptoms in ketamine users in 2007, a condition 
known as ‘ketamine-induced cystitis’ (KIC) emerged.4   The aim of this study is to investigate the permeation 
of ketamine across the bladder wall by determining ketamine concentrations achieved in each bladder wall 
layer. Concentration-depth profiles will then be constructed. 
An ex-vivo porcine bladder model was created to replicate normal physiological conditions of the human 
bladder. The method used builds upon models based on intravesical drug instillation, whilst taking into account 
the effects of drug excretion and urine dilution. Following each permeation study, three tissue samples each 
measuring 1.5cm x 1.5cm were taken from each bladder, rapidly frozen and cryosectioned into 50µM sections. 
Quantification of ketamine was carried out following drug extraction from tissue samples and analysed using 
high-performance liquid chromatography-ultraviolet detection. Six bladders were used in each experiment 
(n=6). 
The excretion mimicking study involved calculating ketamine concentrations expected inside the bladder and 
instilling this into the ex vivo bladder every 20 minutes. Ketamine permeated across the entire bladder wall, 
with the highest concentrations observed in the urothelium (167.96 µg/µg). Concentrations of 122.04 µg/µg 
and 70.46 µg/µg were found in the lamina propria and detrusor respectively. Results showed that permeation 
across the bladder wall occurs in a dose and time-dependent manner and support Fick’s 1st law of diffusion. 
As KIC is a potential life-changing and not a well-understood condition, there is the need to raise awareness. 
This study provides an understanding of ketamine distribution within the bladder, aiding future studies to 
explore the pathophysiology.  
1. Gao M, Rejaei D, Liu H. Ketamine use in current clinical practice. Acta Pharmacol Sin. 2016;37(7):865-72. doi: 10.1038/aps.2016.5 
2. Bureau M, Pelletier J, Rousseau A, Bernard G, Chabaud S, Bolduc S. Demonstration of the direct impact of ketamine on 
urothelium using a tissue engineered bladder model. Can Urol Assoc J. 2015;9(9-10):E613-E7. doi: 10.5489/cuaj.2899 
3. Adamowicz P, Kala M. Urinary Excretion Rates of Ketamine and Norketamine Following Therapeutic Ketamine Administration: 
Method and Detection Window Considerations. J Anal Toxicol. 2005;29(5):376-82 
4. Chu PS, Kwok SC, Lam KM, Chu TY, Chan SW, Man CW, et al. ‘Street ketamine’- associated bladder dysfunction: a report of ten 
cases. Hong Kong Med J. 2007;13(4):311-3. 
 
 
Use of a Multi-Asperity Adhesion Model to Determine the Effects of Material 
Properties and the Influence of Adsorbed Albumin on Bacterial Force of Adhesion. 
Oluwakemi Gibson and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Dental plaque, a complex oral microbiome, is the primary causation factor in dental caries.1 The colonisation 
of a tooth surface or dental biomaterial by pioneer bacteria species is initiated by the adsorption of salivary 
proteins on a surface. Surface characteristics and the presence of adsorbed proteins can affect the extent of 
bacteria adhesion. 2,3 The mechanism of bacteria-material surface and bacteria-adsorbed salivary proteins 
interaction is not fully understood.2 Therefore, this study aims to evaluate how material properties affect 
bacteria adhesion and compare the effects of adsorbed albumin (bovine serum albumin) on material surfaces 
on bacteria adhesion. 
A multi-asperity model based on the JKR theory, designed by Dr Prokopovich and Perni4.5 was used to 1. 
Estimate adhesive force between a biomaterial and bacteria and then identify the least fouling biomaterial and 
2. Estimate adhesive force of bacteria adhesion in the presence albumin (bovine serum albumin) coated 
biomaterials. Quantitate data were analysed using SPSS and comparison tests were carried out using Tukey, 
ANOVA and an independent samples t-test.  
In the presence of adsorbed albumin coating on composite resin and titanium, S. mutans and S. salivarius 
showed a significant reduction in adhesion force, whereas S. aureus and A. actinomycetemcomitans showed 
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an increase in adhesion force when compared to uncoated surface. Results also showed that S. mutans was 
the most adhesive bacteria whilst S. aureus was the least adhesive bacteria overall. In general, higher bacteria 
adhesion were observed on surfaces with high surface energy and low surface elasticity.  
In conclusion, Yttria-stabilised Zirconium was the least fouling dental biomaterial. Bacteria ‘stickiness’ is related 
to its surface elasticity. Adsorbed albumin reduces surface hydrophobicity which can either cause an increase 
or decrease in bacteria adhesion force. However, bacteria adhesion is a multi-factorial process; therefore, 
further studies should be performed in the future. 
1. Marsh PD. Microbiology of Dental Plaque Biofilms and Their Role in Oral Health and Caries. Dent Clin North Am. 2010;54(3):441-
54. 
2. Katsikogianni M, Missirlis YF. Concise review of mechanisms of bacterial adhesion to biomaterials and of techniques used in 
estimating bacteria-material interactions. Eur Cell Mater. 2004;8:37-57. 
3. Song F, Koo H, Ren D. Effects of Material Properties on Bacterial Adhesion and Biofilm Formation. J Dent Res. 2015;94(8):1027-
34. 
4. Johnson KL, Sridhar I. Adhesion between a spherical indenter and an elastic solid with a complaint elastic coating. J Phys D: Appl 
Phys 2001:34(5):683-9.  
5. Perni S, Prokopovich P. Multi-asperity elliptical JKR model for adhesion of a surface with non-axially symmetric asperities. Tribol 
Int. 2015;88(Supplement C):107-14. 
 
 
An investigation into the risk factors that may contribute to elderly members of the 
public having a fall 
Owen Lloyd Griffiths, MO Ivory and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Falls amongst the elderly is a common problem resulting in an estimated 230,000 to 460,000 people over the 
age of 60 falling in Wales each year.1 Additionally, 30% of people over the age of 65 and 50% of people over 
the age of 80 fall at least once a year.2 Such figures have contributed to falls becoming the second leading 
cause of accidental or unintentional injury deaths worldwide, with the greatest number of fatal falls coming 
from adults over the age of 65.3 This study aims to identify associations between a number of pre-determined 
risk factors and the occurrence of falls within the last 12 months of patients presenting at community 
pharmacies in Wales.  
All 716 community pharmacies in Wales at the time took part in the national falls campaign ‘Steady On … Stay 
SAFE’ from February through to March 20174 and were sent 20 questionnaires each for members of the public 
to complete. Resulting quantitative data was analysed using the chi-square statistical test to compare the pre-
determined risk factors. Ethics approval was obtained. 
36% of the participants had a fall within the last year, with 80% of those people over the age of 60. Aside from 
blood pressure pills and eye drops for glaucoma all medications provided a p= < 0.001 showing a statistical 
difference in the rate of respondents having a fall in the past 12 months. Polypharmacy (p= < 0.0001), over 
the age of 70 (p= < 0.0001), gender (p= < 0.0001) and 13 of the 14 combinations of the listed drugs/classes 
of drugs also provided a statistical difference.  
Study showed taking medications, combinations of those medications, age and polypharmacy to be the major 
risk factors contributing to falls. Highlights the need for action through medication reviews and interventions. 
1. 1000 lives improvement. Prudent healthcare falls prevention programme. 2017 [accessed 16 Oct 2017]. Available from: 
http://www.1000livesplus.wales.nhs.uk/falls.  
2. National Institute for Health and Care Excellence (NICE). Falls in older people: assessing risk and prevention. 2017 [accessed 16 
Oct 2017]. Available from: http://www.nice.org.uk/Guidance/CG161. 
3. World Health Organisation (WHO). Falls fact sheet. 2018 [accessed 16 Jan 2018]. Available from: 
http://www.who.int/mediacentre/factsheets/fs344/en/. 
4. Public Health Wales. Steady On … Stay SAFE. 2017 [accessed 18 Dec 2017]. Available at: 
http://www.wales.nhs.uk/sitesplus/888/news/43866. 
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Exploring the Relationship between STYK1 and the AKT pathway in ER+ breast 
cancer by monitoring FOXO3A in preclinical models and clinical disease 
 
Jake Groves1, P Finlay1, A Green2 and JMW Gee1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward XVII Avenue, Cardiff, CF10 
3NB, Wales, UK. 2Academic Unit of Oncology, Nottingham City Hospital, Hucknall Road, Nottingham,  
NG5 1PB, UK 
 
Endocrine resistance is a major problem in oestrogen receptor positive (ER+) breast cancer, leading to relapse.  
1 Mechanisms of resistance are poorly understood but researchers in Cardiff University recently found that a 
novel receptor tyrosine kinase, STYK1, is increased and drives endocrine-resistant cells in vitro.  They also 
detected STYK1 in an ER+ clinical breast cancer series, so STYK1 might feasibly contribute to relapse. It is 
believed STYK1 signals in part via the PI3K/AKT pathway 2 but this mechanism is unexplored in clinical 
material. The aim of this project was to explore if there was any association between STYK1 and AKT signalling 
in ER+ breast cancer by monitoring FOXO3a, a transcription factor downstream of the AKT pathway. 
FOXO3a is excluded from the nucleus when AKT is active, blocking its tumour suppressor function.3 An 
immunohistochemical (IHC) assay was thus optimised that could detect nuclear and cytoplasmic FOXO3a in 
stored breast cancer sections. The assay was run on sections from the ER+ clinical series (n=55) pre-assayed 
for STYK1 and endocrine resistant cell pellets and xenografts. H-scoring evaluated nuclear and cytoplasmic 
staining. Statistical analysis explored relationships between FOXO3a, STYK1 and further 
biological/clinicopathological parameters. 
STYK1 and cytoplasmic FOXO3a were significantly correlated (p=0.01) in the clinical samples. Cytoplasmic 
FOXO3a also correlated with ERK1/2 (p=0.044, p=0.009) MAPK expression and activity (p<0.001). There was 
a significant association between nuclear FOXO3a and tumour size (p=0.025). Endocrine resistant pellets and 
xenografts stained for cytoplasmic FOXO3a and where examined, STYK1. 
The optimised IHC assay provides evidence that STYK1 may activate AKT signalling, promoting cytoplasmic 
localisation of FOXO3a, in ER+ breast cancer and preclinical resistant models. Its further mechanistic findings 
are supportive of FOXO3a also lying downstream of MAPK. 4 However, the clinicopathological association with 
nuclear FOXO3a was surprising given its suppressive function, suggesting assay improvements may be 
needed using increased samples with endocrine outcome data. 
1. Nicholson RI, Gee JM, Knowlden  JM, McClelland RA, Madden T, Barrow D et al. The biology of antihormone failure in breast 
cancer. Breast Cancer Res Treat. 2003; 80(1)  29-35. doi: 10.1023/A:1025467500433 
2. Zhao Y, Yang L, He J, Yang H. STYK1 promotes Warburg effect through PI3K/AKT signalling and predicts a poor prognosis in 
nasopharyngeal carcinoma. Tumour Biology. 2017;1-8. doi: 10.1177/1010428317711644 
3. Zhang X, Zhuang T, Liang Z, Li L, Xue M, Liu J, et al. Breast cancer suppression by aplysin is associated with inhibition of 
PI3K/AKT/FOXO3a pathway. Oncotarget. 2017; 8(38) 63923-63634. doi: 10.18632/oncotarget.19209 
4. Yang J, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-
mediated degradation. Nature Cell Biology. 2008; 10(2) 138-148. doi: 10.1038/ncb1676 
 
 
The Repeat and Managed Repeat Prescription Ordering Service: The Patient’s 
Experience 
Melissa Emily Harris, D Higman-James, D Mcrae and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK. Cardiff Metropolitan University, Llandaff Campus, Western Avenue, Cardiff, CF5 2YB. Cwm 
Taf University Health Board. 
With the National Health Service (NHS) under more pressure than ever to deliver services at an acceptable 
standard with intensifying demand by a population with its life expectancy on the rise, the optimisation of 
fundamental services is a priority to ensure the implementation of cost-effective processes such as the Repeat 
Prescription Ordering Service (RPOS) and Managed Repeat Prescription Ordering Service (MRPOS)  1. The 
aim of this study is to determine whether these services are user-friendly and easily understood. 
Participants were initially recruited via stratified sampling followed by snowball sampling2 to recruit the 
remainder. The research was carried out within the Abertawe Bro Morgannwg, Cardiff and Vale and Hywel 
Dda Health Board regions. Semi-structured interviewing3, was used to gather qualitative data on patient views 
and/or experiences. The interview schedule was designed so that questions were focussed on fundamental 
aspects that make up the medication ordering services. Data was analysed qualitatively via thematic analysis4. 
Codes were developed after transcription of interviews were complete and these were categorised into themes. 
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Positive and negative features of the RPOS/MRPOS were successfully identified and possible solutions were 
suggested by participants to overcome these barriers. Firstly, 30% of participants had the inability to identify 
who was responsible when something in the process went awry due to miscommunication between the 
pharmacy and the surgery. A new communication system was suggested by a participant. Secondly, 70% of 
participants appreciated the convenience of RPOS/MRPOS; particularly those who were housebound and 
used the MRPOS. Participants mentioned that the pharmacy were accommodating; requesting a prescription 
from the surgery for a patient going on holiday.  
There is not a unanimous opinion that enables a decision to be made concerning the continuation of these 
services, however, with more research involving a wider population, it is possible that this service will be 
developed or replaced. 
1. PSNC. 2017. Managed repeat. Available at: http://psnc.org.uk/services-commissioning/essential-services/repeat-
dispensing/managed-repeats/ [Accessed: 18th October 2017] 
2. Smith, FJ. 2010. Conducting Your Pharmacy Practice Research Project. 2nd ed. London: Pharmaceutical Press. 
3. Biggam, J. 2015. Succeeding with your Master’s Dissertation. 3rd ed. Berkshire: Open University Press. 
4. Braun, V. and Clarke, V. 2006. Using thematic analysis in psychology. Qualitative Research in Psychology 3(2), pp. 77-101.  
 
 
Assessing the permeation of propranolol hydrochloride cream for the prospective 
treatment of infantile haemangiomas 
Erin Hart and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK. 
Infantile haemangiomas (IH) are raised swellings on the skin and affect around 4-5% of children.1 They usually 
shrink on their own, however, up to 10% of cases can cause problems and require further treatment.2 Since it 
was discovered that oral administration of the drug propranolol was effective in treating IH in 2008, it is now 
the first line treatment.3 However, unwanted systemic side effects can be associated with oral propranolol 
administration. This study aims to determine whether a topical formulation of propranolol hydrochloride (PH) 
could potentially be used for this condition in order to avoid these unwanted systemic side effects.  
Three creams were formulated by adding powdered PH to pre-formed cetrimide creams at the strenghts 
2%w/w, 5%w/w and 10%w/w (termed ‘solid-phase’ creams). A further cream was prepared at 2%w/w PH 
whereby the PH was added to the water phase during formation of the cetrimide cream (termed ‘liquid-phase’ 
cream). Franz-diffusion cells were used to test the permation of the creams permeating through an artificial 
membrane. Samples were taken from the lower chamber of the diffusion cells at designated time intervals and 
used to determine the concentration of PH cream that had permeated through the membrane.  
The ‘solid-phase’ 2%w/w was more permeable than the ‘liquid-phase’ (p=0.992), however, all strenghts 
demonstrated a level of drug permeation. Increasing the strengths of the ‘solid-phase’ creams also increased 
the permeability, which was demonstrated when comparing the 2%w/w and 10%w/w cream (p=0.026). 
From this research, it can be concluded that the manufacturing process and the strength had an effect on the 
permeation of the PH creams. The data from this study provides encouragement that topical formulations may 
be suitable for IH. However, research needs to now test these formulations on skin tissue to determine the 
safe and effective therapy for children.  
1. Fowell C, Monaghan A, Nishikawa H. Infantile haemangiomas of the head and neck: current concepts in management. Br J Oral 
Maxillofacial Surg. 2016; 54(5); pp. 488-495. doi: https://doi.org/10.1016/j.bjoms.2016.02.031 
2. Hoeger P, Harper J, Baselga E, Bonnet D, Boon L, Atti M. et al. Treatment of infantile haemangiomas: recommendations of a 
European expert group. Eur J Pediatr. 2015; 174(7); pp. 855-865. doi: https://doi.org/10.1007/s00431-015-2570-0 
3. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for Severe Hemangiomas of 
Infancy. N Engl J Med. 2008; 358(24); pp. 2649 - 2651. doi: https://doi.org/10.1056/NEJMc0708819 
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The effect of hot and cold drinks on the dissolution of gelatin and hydroxypropyl 
methylcellulose (HPMC) capsules.  
Gemma Henry and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK.  
Oral capsules are a major form of medication delivery and can be manufactured from gelatin, traditionally, or 
HPMC, in more recent years. Gelatin is soluble in stomach fluids at body temperature but its dissolution can 
be adversely impacted by storage conditions.1 HPMC has been shown to be less affected by storage conditions 
but more susceptible to oxygen entry, therefore less suitable for oxidation prone drugs.2 Dissolution of capsules 
releases drug into the stomach for absorption and thus is an important performance consideration. Dissolution 
machines assess the capsules’ ability to release suitable amounts of drug to avoid the need to test in-vivo on 
a regular basis.3 The aim of this study is to determine the impact of hot and cold drinks on the dissolution of 
gelatin and HPMC capsules as this may affect how much drug a patient receives, or at what rate. 
Dissolution testing was performed on dye-filled capsules at various temperatures and imaged using a high-
speed camera to show the exact beginning of dissolution. Further capsules were filled with propranolol 
hydrochloride (as model drug) and samples of dissolution medium analysed using UV VIS spectrometry to 
show the mass of propranolol in solution following capsule dissolution (n=3). A two-way ANOVA with post hoc 
Tukey’s HSD test compared the mass of propranolol in solution between the different temperatures and 
capsule types.  
Imaging showed capsules first break at the shoulders; the weakest point.4 Gelatin dissolution increased at 
higher temperatures while HPMC remained relatively consistent. The mass of propranolol released at 24˚C 
was significantly lower (p<0.05) than at higher temperatures. The cumulative mass of drug released over all 
temperatures from gelatin and HPMC capsules was significantly different but, aside from 24˚C, the mass 
released from each type at the same temperature was not. 
In summary, this tentatively suggests that capsules should not be taken with cold drinks as they can decrease 
drug dissolution, therefore the patient may not receive a full dose.  
 
1. Chiwele I, Jones BE, Podczeck F. The shell dissolution of various empty hard capsules. Chem Pharm Bull. 2000;48(7):951-956. 
doi: 10.1248/cpb.48.951 
2. Gullapalli RP, Mazzitella CL. Gelatin and non-gelatin capsule dosage forms. J Pharm Sci. 2017;106(6):1453-1465. doi: 
10.1016/j.xphs.2017.02.3006 
3. British Pharmacopoeia Commission. SC I E. Dissolution testing of solid oral dosage forms. London: TSO; 2017 [accessed 10 Dec 
2017]. Available from: https://www-pharmacopoeia-com.abc.cardiff.ac.uk/bp-2018/supplementary-chapters/sc-1/sc-i-e--dissolution-
testing-of-solid-oral-dosage-forms.html?published-date=2017-08-01&text=dissolution 
4. Podczeck F, Jones BE. Pharmaceutical Capsules. 2nd ed. London: Pharmaceutical Press; 2004. 
 
 
Development of standardised tests for microneedles 
Olivia Herring and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK.. 
Microneedles are micron-sized needles that facilitate the delivery of macromolecules by penetrating the 
stratum corneum.1,2A huge advantage of this approach is that microneedles can increase skin permeability to 
a drug by up to 10,000 times.3 However, currently there are no approved regulatory tests for microneedles. 
Thus, the purpose of this project is to start developing new standardised regulatory tests for ‘loss of moisture’ 
and ‘dissolution’. The development of such tests will be important when microneedle devices are undergoing 
clinical trials and when marketing authorisation is required.  
Stainless steel microneedles were coated using a formulation of C19-A3, a proinsulin peptide, with an attached 
fluorophore. The ‘loss of moisture’ test was conducted by placing either a 0.2μl or 0.6μl drop of formulation on 
the surface of a microneedle and recording the change of weight with respect to time. The microneedles were 
coated and the coating was then removed in the dissolution studies, using a novel 3D-printed dissolution 
apparatus. Quantification was measured via UV–Vis absorbance or fluorescence spectroscopy. 
Major findings include consistent and linear loss of moisture for both 0.2μl and 0.6μl formulation volumes at a 
rate of 1.3 𝑚𝑔𝑠−1. There was insignificant weight loss after 90 and 360 seconds for the lesser and greater drop 
size respectively. The dissolution studies showed acetic acid worked better as a dissolution solvent than PBS. 
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It was also discovered that conducting a dissolution study in either 200μl or 400μl of solvent or increasing the 
dissolution time did not affect drug dissolution, as the quantity of peptide analysed was measured to be the 
same.  
There is still a long way to go to create standardised tests that can be recognised and adopted by regulators. 
This thesis has demonstrated how some parameters for these tests will be easier to harmonise than others.  
 
1. Graham-Brown, R. and Burns, T. 2011. Lecture Notes: Dermatology. 10th ed. Chichester: Blackwell Science Ltd.  
2. Birchall, J et al. 2005. Cutaneous DNA delivery and gene expression in ex vivo human skin explants via wet-etch microfabricated 
microneedles. Journal of Drug Targetting 13(7), pp.415-21. doi: 10.1080/10611860500383705 
3. Henry, S et al. 1998. Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery. Journal of Pharmaceutical 
Science 87, pp.922-925 
 
 
Investigating the behaviour of keratinocytes in a fibroblast co-culture 
Louise Hill, A Moukachar, O Castell, CP Thomas and SA Coulman  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Bio printing is an exciting new approach in regenerative medicine and printing an authentic skin substitute 
could provide many useful applications in the clinic and the laboratory.1 Keratinocyte and fibroblast cells play 
important roles within the structure of human skin2, therefore their compatibility is integral to constructing a 
physiological 3D representation of the tissue. Cell function is regulated via paracrine signals from soluble 
factors that are secreted by each of these cells in a feedback loop.3 In this study, the cell behaviour in a co-
culture of keratinocytes and fibroblasts is explored via the use of fibroblast conditioned medium (CM). Calcium 
is a major modulator of keratinocyte differentiation4 and so the effects of fibroblast CM on keratinocyte 
behaviour will be investigated in both low calcium (LC) and high calcium (HC) conditions. 
Fibroblasts (HCA2) were grown to 80-90% confluency and fresh medium was conditioned for 24hrs before 
being collected. LC and HC HaCaT keratinocytes were seeded at a density of 2x104 per well and cultured in 
fibroblast CM or commercially available DMEM as the control, the rate of growth and morphological changes 
were observed over 6 days.  
Addition of conditioned medium significantly slowed the rate of proliferation in both HC and LC keratinocytes. 
Morphology changes were observed in both cell types; cells became elongated, spindle shaped and much 
larger in size with visible adherence proteins. 
The results suggest that there may be a growth factor or signalling molecule in the conditioned medium which 
slows proliferation of keratinocytes. This suggests that further work would need to be conducted to optimise 
conditions for a 3D bio printed model. Further experiments are needed to understand these behavioural 
changes. 
1. Cubo, N., Garcia, M., del Cañizo, J., Velasco, D. and Jorcano, J. 2016. 3D bioprinting of functional human skin: production andin 
vivoanalysis. Biofabrication 9(1), p. 015006. 
2. Wang, Z., Wang, Y., Farhangfar, F., Zimmer, M. and Zhang, Y. 2012. Enhanced Keratinocyte Proliferation and Migration in Co-
culture with Fibroblasts. PLoS ONE 7(7), p. e40951. 
3. Werner, S., Krieg, T. and Smola, H. 2007. Keratinocyte–Fibroblast Interactions in Wound Healing. Journal of Investigative 
Dermatology 127(5), pp. 998-1008. 
4. Micallef, L., Belaubre, F., Pinon, A., Jayat-Vignoles, C., Delage, C., Charveron, M. and Simon, A. 2009. Effects of extracellular 
calcium on the growth-differentiation switch in immortalized keratinocyte HaCaT cells compared with normal human 
keratinocytes. Experimental Dermatology 18(2), pp. 143-151. 
 
 
Development of methods to characterise hydrogel properties 
Chun Lok Rock Ho and OK Castell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK. 
The aim of this study was to develop a universal method to characterise at the microscale different hydrogels 
that are produced from a microfluidic system, to understand the relationship between gelation and changing 
of parameters in gel production.  
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Gelled hydrogels were produced in a custom fabricated microfluidic system. The bio-compatibility of hydrogels 
means they are attractive materials for use in many many bio-engineering applications. For example hydrogels 
have been used to encapsulate droplet bilayer networks and encapsulate live cells. However, characterisation 
of the structural and mechanical properties of the gels on the microscale remains challenging. 
The progressive development of a feasible method of characterisation begun with a preliminary method design, 
to measure contact angle in order to quantify the level of gelation. Although only qualitative results were 
produced, apparatus setup were gradually improved and it led to the discovery of the relationship between 
integrity of the hdrogel and their compressive properties. Using Xforce force-measurement system, gelation 
conditions and mechanical properties of the resultant gel were quantified and correlations established. 
The novel method to characterising microfluidically generated hydrogels potentially provides a route to in-
depth understanding of the dependency of hydrogel properties on their manufacture conditions. 
 
 
Generation of a highly sensitive electrochemical biosensor for the detection of C-
Reactive Protein  
Sarah Ingram, JL Bowen and N Demertzis 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Sepsis occurs when localised infection cannot be terminated by the host’s immune system, resulting in the 
development of widespread inflammation.1 The condition affects ~123,000 people and is responsible for 
~37,000 deaths in England annually.2 Promptness of sepsis diagnosis is a key factor that influences clinical 
outcome. C-reactive protein (CRP) is an inflammatory biomarker which has been able to predict organ failure 
and guide therapy for septic patients.3 In this study, an electrochemical aptamer-based biosensor for CRP was 
developed. 
Gold working electrodes were sonicated, polished, and electrochemically activated by cyclic voltammetry in 
0.5 M sulphuric acid. Following cleaning, anti-CRP aptamers, with or without alkanethiol molecules (6-
mercapto-1-hexanol, 4, 4’-dithiodibutyric acid and cysteamine), were chemically immobilised onto the working 
electrode surface by their reduced sulphide functional group to form a self-assembled monolayer (SAM).4 CRP 
was incubated with each SAM for 15 minutes in order to evaluate the binding performance of monolayer. 
Electrochemical impedance spectroscopy and cyclic voltammetry were performed to monitor monolayer 
formation on the electrode surface and the effect of CRP binding. The system’s selectivity for CRP was 
challenged with procalcitonin.  
After screening several alkanethiol molecules, 6-mercapto-1-hexanol (MCH) was selected as the molecule to 
combine with the anti-CRP aptamer in ratios. The 1:1 ratio of MCH:aptamer gave a concentration dependent 
response between CRP concentrations of 1 and 20 pg/mL. The monolayer established acceptable stability. 
An inconsequential response was seen when the 1:1 ratio was challenged with procalcitonin.  
A rapid and sensitive electrochemical sensor has been developed for CRP, although additional optimisation is 
required. As CRP is just one biomarker used to diagnose sepsis, it was considered that, in the future, this 
system would contribute one component of a multi-biomarker sensor, used alongside other diagnostic tools, 
including NEWS and SOFA scores.1,3  
1. Global Sepsis Alliance. Sepsis 3.0 from the perspective of clinicians and quality improvement initiatives. 2017. [Accessed: 11th Oct 
2017] Available from: 
https://static1.squarespace.com/static/58a7025b8419c215b30b2df3/t/593e55c0d1758ea7078c0236/1497257409853/GSA+QIC+St
atement+on+Sepsis-3.pdf 
2. NHS Choices. Sepsis. 2016. [Accessed: 3rd Oct 2017] Available from: http://www.nhs.uk/conditions/Blood-
poisoning/Pages/Introduction.aspx 
3. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit. Care.  2010; 14(1); R15. DOI: 10.1186/cc8872 
4. Herne TM, Tarlov MJ. Characterisation of DNA probes immobilized on gold surfaces. J. Am. Chem. Soc. 1997; 119 (38): 8916- 
8920. DOI: 10.1021/ja9719586 
 
 
Lady’s Mantle – An ancient remedy with the potential to treat modern diseases 
Grace Jackson, JA Blaxland and L Baillie 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK 
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Lady’s Mantle (Alchemilla Vulgaris) is a perennial plant that has been used historically as it was thought to 
possess healing properties. 1 The aim of this project is to establish whether the plant does hold antimicrobial 
properties against both Gram-positive and Gram-negative bacteria. The rise in antibiotic resistance is growing 
into a serious public-health threat, which has caused an increasing demand for new antibiotics to be 
discovered. 2 
In the project two commercially available samples of Lady’s Mantle underwent numerous extractions using 
water, methanol, ethyl acetate and hexane. The water extracts were tested for antimicrobial properties using 
zone of inhibition assays. The solvent extracts were separated out using thin layer chromatography (TLC), 
then any antimicrobial activity was identified using a bacterial overlay assay. The compounds exhibiting 
microbial inhibition were then separated and identified using mass spectrometry.  
The Health Embassy sample of Lady’s Mantle demonstrated activity against MSSA and MRSA in the zone of 
inhibition assay, but showed no activity against E. coli. The Mountain Fresh sample failed to demonstrate 
activity in the zone of inhibition assay against MRSA and only showed minimal activity against MSSA. 
Antibacterial activity was detected in the hexane extracts of both Lady’s Mantle samples when assessed using 
a combined TLC/ bacterial overlay assay. The mass spectrometry result for the active compound showed no 
compounds other than known background compounds and plasticisers. 
The plant did exhibit microbial inhibition during the zone of inhibition assay and the bacterial overlay assay, 
indicating Lady’s Mantle does in fact possess antimicrobial properties. The activity being shown in the hexane 
extract suggests the compounds responsible for the activity are non-polar compounds. Further investigation 
needs to be done to identify the compounds responsible for the antimicrobial properties. 
1. Herbal Resource. [no date]. Lady’s Mantle Uses, Benefits and Side Effects. Available at: https://www.herbal-supplement-
resource.com/ladys-mantle-benefits.html [Accessed: 2 Jan. 18] 
2. World Health Organisation. 2017. Antibiotic resistance fact sheet. Available at: 
http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/ [Accessed: 2 Jan. 18] 
  
 
Evaluation of the Discharge Medicines Review Service 
Lucy Jeffreys, ML Hughes and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Transitioning patients from secondary to primary healthcare settings presents many challenges.1,2  Discharge 
from hospital is a high-risk period for medication discrepancies to occur, affecting around 14-87% patients 
internationally.3 A medication discrepancy can be defined as any differences, intended or unintended, between 
two or more documented drug regimens.4 The Discharge Medicines Review (DMR) service was introduced in 
Wales in 2011. The service involves community pharmacists identifying any discrepancies between the 
medication the patient was discharged from hospital with and the first prescription written by their general 
practitioner. A previous evaluation of the study showed that this was a well-received service overall, but 
barriers were affecting service delivery.3 The service has not been evaluated since 2014 and the aim of this 
study is to evaluate the current practice of the service. 
Secondary data analysis was chosen as the methodological approach. Data was obtained from NHS Wales 
Shared Service Partnership. The data was a combination from databases used by community pharmacies to 
claim payment for the service. Five researchers (L.J., I.Y., Y.C., S.C., R.R.) inputted pre-existing data from 
Microsoft Excel® spreadsheets into IBM® SPSS® Statistics Version 23 to be analysed descriptively. 
Results showed a significant increase in the use of the service since April 2013. More contractors were DMR-
accredited yet only 25% of accredited contractors were being reimbursed. Betsi Cadwaladr and Cwm Taf 
University Health Boards showed significant increases in their number of claims after piloting the Choose 
Pharmacy computer application for DMR submissions.  
This study found improvement in DMR service activity, yet under-utilisation remained. The rate of 
discrepancies per consultation remains approximately the same as previously reported3, confirming the need 
for the service. Possible reasons for lack of engagement by contractors need to be explored to fully realise the 
services potential for improving patient safety. 
1. Coleman EA, Berenson RA. Lost in transition: challenges and opportunities for improving the quality of transitional care. Ann Intern 
Med. 2004;141(7):533-6. 
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2. Coleman EA, Min SJ, Chomiak A, Kramer AM. Posthospital care transitions: patterns, complications, and risk identification. Health 
Serv Res. 2004;39(5):1449-65. doi: 10.1111/j.1475-6773.2004.00298.x 
3. Hodson K, Blenkinsopp A, Cohen D, Longley M, Fasihul Alam M, Davies P, et al. Evaluation of The Discharge Medicines Review 
Service. CPW. 2014 [accessed October 15th 2017]. Available from: http://www.cpwales.org.uk/Contract-support-and-IT/Advanced-
Services/Discharge-Medicines-Review-(DMR)/Evaluation-of-the-DMR-Service/Evaluation-of-the-DMR-service.aspx  
4. Pippins JR, Gandhi TK, Hamann C, Ndumele CD, Labonville SA, Diedrichsen EK, et al. Classifying and predicting errors of 
inpatient medication reconciliation. J Gen Intern Med. 2008;23(9):1414-22. doi: 10.1007/s11606-008-0687-
 
 
Investigations into the Physical Stability of Neonatal Parenteral Nutrition Lipid 
Emulsion Syringes and Mini Bags Manufactured via a Novel Pooling Method 
Bethan Jones, P Spark¹ and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, CF10 3NB, 
Wales, UK and ¹St Mary’s Pharmaceutical Unit, 20 Field Way Cardiff, CF14 4HY. 
Lipid emulsions are crucial components of parenteral nutrition (PN), providing a source of fatty acids to fuel 
the growth and development of neonates.1 To help to prevent possible contamination incidents as experienced 
by ITH Pharma in 2014, which tragically caused three neonatal deaths2, Cardiff and Vale University Health 
Board (CVUHB) has decided to integrate pre-patient rapid microbiological testing into their PN manufacturing 
processes to improve patient safety. It was hypothesized that the ease of testing would be increased by 
adopting a novel pooling manufacturing method, to allow testing of multiple doses simultaneously and storing 
PN in mini bags to extend shelf life, providing additional time for testing. In this investigation, 10ml of 
reconstituted Solivito® N Infant and Vitlipid® N Infant solution and 40ml Intralipid® 20% or Smoflipid® 20% were 
used to make test formulations using conventional and pooling methods and the resulting 50ml syringes and 
300ml mini bags (50ml unavailable) were stored at temperatures mimicking ward storage and delivery to 
neonates. Due to time constraints, test periods for pooling and conventional methods were 23 and 30 days 
respectively. 
Physical stability was assessed using laser diffraction, light microscopy, visual inspection and pH monitoring. 
An unpaired t-test (n=3) was conducted and average percentage change from baseline at day 0 was expressed 
through XY scatter graphs with 95% confidence intervals. 
No statistically significant differences or indications of emulsion instability such as cracking or a decline in pH 
below 5 were observed, therefore confirming that all PN formulations in each devices physically stable.3,4 
The data illustrates that both devices manufactured by both methods were physically stable and safe for patient 
use for the testing periods examined by statistical analysis. Future studies should utilise 50ml mini bags to 
better emulate CVUHB’s proposed changes to practice, in addition to possessing a longer testing duration and 
greater power, to reduce type II error. This investigation functions as a starting point for future physico-chemical 
research required to facilitate the introduction of rapid microbiological testing of PN formulations to increase 
patient safety. 
1. The Reagents of the University of California. Intensive Care Nursery House Staff Manual: Neonatal Parenteral Nutrition. 2006              
[accessed 20 Dec 2017]. Available from: https://www.ucsfbenioffchildrens.org/pdf/manuals/47_TPN.pdf 
2. Andalo D. Third Baby Dies Following TPN Contamination. Pharm J. 2014; 293 (7818)                   
doi:http://dx.doi.org/10.1211/PJ.2014.20065659 
3. Marek Pertkiewicz M, Cosslett A, Mühlebach S, Dudrick SJ. Basics in clinical nutrition: Stability of parenteral nutrition admixtures. 
ESPEN J. 2009; 4(3):117-119. doi: 10.1016/j.eclnm.2009.01.010 
4. United States Pharmacopoeial Convention. United States Pharmacopoeia USP38/NF33, Rockville; United States Pharmacopoeial 
Convention 2015. 
 
 
The effect of simvastatin on EGFR and Src kinase family in triple negative breast 
cancer 
Rebecca Kau, C Smith and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Breast cancer is the most common cancer in the UK1 with the triple negative breast cancer (TNBC) occurring 
in 15 out of every 100 cases of breast cancer.2 The lack of expression of ER, PR and HER-2 characterises 
TNBC and ascribes limited treatment options along with poor prognosis and outcomes to such patients. 
Emerging data suggests that statins may exhibit cytotoxicity in TNBC3 which may involve modulation of ErbB 
receptors.4 The aim of this study was to investigate the anti-proliferative and apoptotic effects of simvastatin in 
TNBC, focussing on the ErbB and Src kinase family as a potential mechanism of action. 
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MDA231 and MCF7 cell lines were used to model TNBC and non-TNBC breast tumour subtypes respectively. 
The effectiveness of simvastatin to induce cytotoxicity was analysed by the MTT assay. Western blotting was 
used to investigate the effect of simvastatin on TNBC cells with respect to expression of key mediators of 
proliferation including members of the ErbB family and Src kinase.  
Simvastatin significantly inhibited the cell proliferation in MDA231 cells in a dose-dependent manner whereas 
MCF7 cells were not affected by this agent. Visualisation of cellular morphology confirmed this and suggested 
that statins induced a degree of apoptosis. Both phosphorylated (Y1086, Y1173) and total EGFR were down-
regulated following simvastatin treatment whilst other ErbB members were not affected. The activity of Src 
(Y146) was decreased in response to statin treatment in contrast to other Src members, pLyn (Y507) and pFyn 
(Y530), which were not affected. Additional signalling molecules including pMAPK (T204) were also not 
affected by statin treatment. 
We conclude that simvastatin induces tumour cell growth arrest in TNBC involving the suppression and down 
regulatory activities of EGFR and Src. These findings support the concept for the re-purposing of statins as a 
cancer therapeutic for the aggressive TNBC cancer phenotype.  
1. Cancer Research UK. Cancer incidence for common cancers. 2016 [accessed: 17 Dec 2017] Available from: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared#heading-Five  
2. Cancer Research UK. Triple negative breast cancer. 2017 [accessed: 17 Dec 2017] Available from: 
http://www.cancerresearchuk.org/about-cancer/breast-cancer/stages-types-grades/types/triple-negative-breast-cancer  
3. Kanugula AK, Gollavilli PN, Vasamsetti SB, Karnewar S, Gopoju R, Ummanni R et al. Statin-induced inhibition of breast cancer 
proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms. 
FEBS J. 2014;281(16):3719-3738. doi: 10.1111/febs.12893 
4. Kadi A, Smith C and Hiscox S. unpublished observations 
 
 
Determination of dry biofilms presence on surfaces at healthcare settings 
Kimone Kerr, K Ledwoch and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK 
A biofilm is a mostly sessile community of microbes adhered to each other and to a surface, embedded in a 
protective extracellular polymeric matrix.1 Dry biofilms, formed in moisture-deficient environments are an 
increasing problem in healthcare settings due to their increased resistance to chemical disinfection and 
antibiotics.2  Biofilms account for 65% of healthcare-associated infections (HCAI) and are affiliated with chronic 
infections.3  The aim of this study was to determine if dry biofilms were  present on surfaces at health-care 
settings and to identify the species of bacteria associated with them.  
Samples were rinsed and swabbed under aseptic conditions and incubated in tryptone soy broth at 38°C and 
observed for change in turbidity. Samples were then diluted and filtered using the vacuum manifold system. 
Each sample was plated on 5 selective agars: MacConkey, Vogel-Johnson, multi-drug resistant-Acinetobacter 
(MDR), methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), 
and incubated for 24-48h. Some samples were also analysed using scanning electron microscopy (SEM) to 
visually confirm the presence of a dry biofilm. DNA was extracted from the samples using Maxwell 16® 
instrument and quantified using the Qubit 3.0 fluorometer. Lastly, Ribosomal RNA Intergenic Spacer Analysis 
Polymerase Chain Reaction (RISA-PCR) was used to analyse bacterial DNA present in the samples.  
Dry biofilm was demonstrated on 96% of the samples (48/50) and confirmed by SEM. Growth was attributed 
wholly to the biofilm due to no growth on tryptone soy agar plates after rinsing. Coagulase positive 
Staphylococcus aureus was the most identified microorganism followed by MRSA. Patient folders exhibited 
more growth than keyboard keys and this is hypothesised to be based on location and proximity to the patient.  
Dry biofilms are present on surfaces at health-care settings and are associated with HCAIs. They are affiliated 
with multi-drug resistant organisms and therefore a threat to patients.2 Future research should focus on 
improved methods of detection and a more successful means of disinfection.  
1. Costerton JW, Cheng KJ, Geesey GG, Ladd TI, Nickel JC, Dasqupta M, Marrie TJ. Bacterial biofilms in nature and disease. Annu   
Rev Microbiol. 1987; 41: 435-64. doi: https://doi.org/10.1146/annurev.mi.41.100187.002251 
2. Vickery K, Deva A, Jacombs A, Allan J, Valente P, Gosbell IB. Presence of biofilm containing viable multiresistant organisms 
despite terminal cleaning on clinical surfaces in an intensive care unit. J Hosp Infect. 2012; 80(1): 52-55. doi: 
https://doi.org/10.1016/j.jhin.2011.07.007 
3. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999; 284: 1318-
22. doi: 10.1126/science.284.5418.1318 
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What Factors Affect the Internal Motivation of MPharm Students for the Fourth-Year 
Project and Third-Year Summative Assessments? 
Hinna Khan and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Pharmacy is a profession which requires its students to be life-long learners.1 It is important that those pursuing 
a career in pharmacy remain motivated to study. The aims of this research were to focus on the opinions of 
current MPharm 4 students at Cardiff University to gain an understanding of their motivation for their 4th year 
project and the 3rd year summative assessments. The main research aim was to identify the factors that 
affected internal motivation for summative assessments. 
After gaining ethical approval, pharmacy students were invited by email for interview. Literature on Self-
Determination Theory was used to develop the topic guide. Semi-structured, one to one interviews were then 
conducted. All interviews were audio recorded. Pilot interviews were transcribed. All transcripts were 
anonymised by the researchers before being thematically analysed. 
The major themes identified were: OSCEs, preparedness, assessments being of relevance to future, 
interviewee’s perception of other MPharm students’ views, impact of others, enjoyment & interest, level of 
difficulty, and suggestions to increase motivation.   
This study gives valuable insight to the opinions of MPharm 4 students about the third-year summative 
assessments. The suggestions provided by students, particularly of the need for feedback, may be helpful for 
Cardiff University to increase student’s internal motivation. Furthermore, literature supporting the self-
determination theory suggests that autonomy supported teaching can help increase the internal motivation of 
students, which can also be implemented by educators in the School of Pharmacy. 
1. Kelly W. Pharmacy career one of lifelong learning. Journal of Pharmacy Practice and Research. 2016;46(3):199-200. 
 
 
The design and synthesis of androgen receptor antagonists derived from the 
structure of bicalutamide for potential prostate cancer therapy 
Maisha Khan and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
In the UK, prostate cancer is the most common form of cancer in men and 1 in 8 men will get diagnosed with 
it in their lifetime.1 The androgen receptor doesn’t cause cancer but it can promote the proliferation of tumour 
cells so it’s a target site for treatment. Currently, it is the binding site for non-steroidal anti-androgens such as 
bicalutamide which compete with androgens to inhibit cell growth, however resistance has developed against 
bicalutamide so there is a need for novel prostate cancer antagonists to overcome this.2,3 
The synthesis consists of three steps. Firstly, 4-amino-3- (trifluoromethyl)benzonitrile and methacryloyl 
chloride react to form an amide which is then extracted and purified. The second step consists of reacting the 
amide with a thiophenol through Michael addition to form a sulphide derivative. Finally, the sulphide is oxidized 
to form a sulphone derivative. A homology model was designed to dock potential compounds in the androgen 
receptor and establish interactions prior to synthesising them. 
Most of the sulphides and sulphones were synthesised although some consisted of impurities. One of the 
reactions in step 2 failed to react and due to time constraints the sulphones could not be purified. The yields 
for each compound varies from 16% to 92%, therefore some of the reaction conditions may need to be altered 
to favour a greater yield. The homology model results showed that two of the single addition compounds 
synthesised, docked into the pocket and could potentially have high antagonistic activity. It would be useful to 
test compounds in another homology model which has Arg752 instead of Arg753 before sending off for in-vitro 
testing. 
 Furthermore, the process could be replicated on an industrial scale as it is only a three-step synthesis so it is 
feasible if any of the compounds pass clinical trials. 
1. About prostate cancer [Internet]. Prostate Cancer UK. 2017 [cited 25 December 2017]. Available from: 
https://prostatecanceruk.org/prostate-information/about-prostate-cancer 
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2. Bassetto M, Ferla S, Pertusati F, Kandil S, Westwell AD, Brancale A, et al. Design and synthesis of novel bicalutamide and 
enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer. Eur J Med Chem. 2016; 118:230-43. 
3. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. 
Proc Natl Acad Sci U S A. 2005;102(17):6201-6. 
 
 
The Structural Elucidation of New Psychoactive Substances (NPS) in Wales 
Michael Kirkby, AD Westwell and M Riddle1 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 1 Cardiff Toxicology Laboratories, University Hospital Llandough, Penlan Road, Llandough CF64 
2XX, Wales, UK. 
New psychoactive substances (NPS), also known by market terms such as ‘legal highs’, ‘research chemicals’, 
‘bath salts’, and ‘designer drugs’, are recreational substances that mimic the psychoactive effects of illegal 
drugs (i.e. drugs controlled by the Misuse of Drugs Act 1971). Over the last five years, there has been an 
unprecedented increase in the number, type, and availability of NPS, presenting a significant challenge to 
healthcare, as well as law enforcement and policy.1  
The WEDINOS project, funded by the Welsh Government, is a harm reduction service that allows established 
or prospective drug users (or their representatives) to submit drug samples anonymously for chemical structure 
analysis.2 In this report, five NPS samples submitted to WEDINOS were structurally elucidated, quantified (if 
mixture of multiple constituents) and identified using time-of-flight mass spectrometry (TOF-MS) and nuclear 
magnetic resonance (NMR) techniques. The information obtained was used to investigate the purported ‘lack 
of’ Quality Assurance/Quality Control (QA/QC) associated with NPS, and the subsequent effect this has on 
the health/safety of consumers.  
The results of spectroscopic analysis revealed that, of the five samples tested, all five had notable defects 
relating to a ‘lack of’ QA/QC processes. This included, but was not limited to: presence of impurities (3), 
unknown structure(s) (1), illegal contents (1), dosage non-uniformity (1) and not as advertised (2). Four of the 
five samples also contained one, or more, active ingredients in which limited (if any) pharmacological and 
toxicological data exists. 
It was concluded that the investigation illustrates the variability and uncertainty surrounding the contents of 
each NPS product. It also demonstrates the relative vulnerability of consumers that purchase NPS; they instill 
a level of trust into their respective sources without fully realising the legal (prosecution) and/or health related 
(hospitalisation/death) implications. 
 
1. Corazza O, Roman-Urrestarazu A. Novel Psychoactive Substances: Police, Economics and Drug Regulation. 2017; 21. Doi: 
10.1007/978-3-319-60600-2 
2. Wedinos.org. (2017). WEDINOS - Welsh Emerging Drugs & Identification of Novel Substances Project. Available at: 
http://www.wedinos.org [Accessed 13 Oct. 2017]. 
 
 
Design and Synthesis of Potential CtIP-1 Inhibitors by Structural-Based Lead 
Optimisation 
Jonathan Lamb, A Brancale and S Ferla 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK. 
Cancer is a disease caused by an uncontrolled division of abnormal cells which can occur in any part of the 
body.  This project is intended to research novel approaches of inhibiting the transcriptional regulator C-
terminal binding protein 1-interacting protein (CtIP) protein. CtIP is an important protein in the process of 
homologous recombination, a pathway by which the cell can repair double stranded breaks1. Inhibiting the 
CtIP protein is a novel approach at sensitising cancer cells to DNA damaging agents (like platinum salts2), 
which is needed due to the resistance mechanisms displayed by cancer cells to these agents. The aims of this 
project are to synthesise and investigate a number of potential inhibitors 
Screening of CtIP protein with 300,000 commercially available compounds was untaken and the further 
narrowing of the results, including 3 further assay studies, revealed 2 'hit' inhibitor compounds for the CtIP 
target. Consequently, a range of potential inhibitors were synthesised, using structural-based lead optimisation 
of one of these 'hit' compounds.  Further, molecular docking studies of potential inhibitors with the CtIP target 
was undertaken to investigate the receptor binding.  
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10 potentially optimised CtlP inhibitors were synthesised as well as the 'hit compound' with varying yields. 
Molecular docking studies revealed there are 3 potential major binding positions and the key interactions for 
these positions have been studied. 
Although there is one compound currently undergoing clinical trials that targets CtIP3, there are none that use 
this novel approach. Successfully synthesised compounds in this project are to be sent to the laboratory of Dr 
Staples (School of Medical Sciences, Bangor University) for testing in biological assays so that their activity 
can be further understood. 
1. Davies OR, Forment JV, Sun M, Belotserkovskaya R, Coates J, Galanty Y, Demir M, Morton CR, Rzechorzek NJ, Jackson SP, 
Pellegrini L. CtIP tetramer assembly is required for DNA-end resection and repair. Nature structural & molecular biology. 2015 Feb 
1;22(2):150- 
2. Lord C, Ashworth A. The DNA damage response and cancer therapy. Nature [Internet]. 2012 [cited 17 November 2017];481(287). 
Available from: http://dx.doi.org/10.1038/nature10760 
3. Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer [Internet]. Clinicaltrials.gov. 
2017 [cited 21 December 2017]. Available from: https://clinicaltrials.gov/ct2/show/NCT00941070  
 
 
How Does the Temperature of a Drink Used When Swallowing Capsules Affect the 
Shell Dissolution Rate of Both HPMC and Gelatin Capsules? 
Francisco Lawandy Berna and JC Birchall 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Oral drug delivery offers several advantages and comes in many forms, one of the most common forms being 
capsules, which are commonly comprised of gelatin or, in recent years, can also be HPMC (hydroxypropyl 
methylcellulose). One factor to consider when administering a drug orally is the temperature of a drink used 
when taking an oral solid dosage form and how this affects its ability to dissolve to release the active 
pharmaceutical ingredient. The objectives of this study were to identify how hot and cold drinks which are a 
different temperature to the body may affect capsule dissolution and ultimately how this may affect the delivery 
of a drug.  
Initially, the average temperature of hot and cold drinks was identified in the literature. Liquids at these 
temperatures were added to fixed volumes of dissolution medium, set at 37°C, that represent stomach fluid 
volume in the fasted and non-fasted state. The changes in fluid temperature and time taken for the fluid to 
return to 37°C was measured. HPMC and gelatin capsules were then placed in dissolution medium at 24°C, 
37°C and at 48°C, as guided by the above experiment. Finally, the researcher measured how different 
temperatures affected the dissolution rate of encapsulated paracetamol from both HPMC and gelatin capsules 
using UV-Vis spectrophotometry.  
Results showed that whilst the disintegration rate of HPMC capsules were unaffected by an increase in 
temperature, the disintegration rate of gelatin capsules increased with temperature. Results also showed that 
the dissolution rate of encapsulated paracetamol increased with temperature for both HPMC and gelatin 
capsules, demonstrating how the drink taken with a capsule may influence drug release characteristics. 
 
 
Using Technology to Improve the Health of Community Pharmacy - What is the best 
method of training and support? 
Aaron Lewis, M Gumbleton and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Technology is changing the role of the community pharmacist by providing a greater arsenal of tools.1 As such 
robust training regimes should be available to enable pharmacies to maximise the advantages technology can 
provide. In instances of inadequate training with IT systems it can result in more errors which poses a risk to 
the patient.2 The aim of this study was to explore current methods of Information Technology (IT) training and 
support available to community pharmacists and investigate how these methods can be refined in the future. 
A qualitative methodology was used in this study utilising semi-structured focus groups held with numerous 
pharmacists purposively selected due to their backgrounds in community pharmacy varying and as such will 
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bring about various discussion points and views.3 Focus groups were transcribed ad verbatim and thematically 
analysed using an inductive methodology.4   
In total eleven participants were interviewed over two focus group sessions with a total of six themes being 
identified after thematic analysis, each was then broken down into sub-themes. The six main themes identified 
were namely 1) Training Methods, 2) In-Store Responsibility, 3) Locum / Multi-Branch Pharmacists, 4) 
Customer Support, 5) Customer Success, and 6) Ongoing Feedback. 
Results show the current standard of training and support offered by Patient Medication Record (PMR) system 
providers is perceived to be inadequate. PMR systems consist of many distinctive features integrated into one 
system enabling many services. As such the training provided will dictate how effectively the software system 
is onboarded and determine whether the most is made out of the software’s features. Support mechanisms 
are commonly only used when problems arise, but expectations from some of our participants showed that as 
customers they expect more going forward, in order for them to provide optimised patient care through 
technology.  
1. Goundrey-Smith, S. 2014. Examining the role of new technology in pharmacy: now and in the future. The Pharmaceutical Journal. 
Available at: https://www.pharmaceutical-journal.com/examining-the-role-of-new-technology-in-pharmacy-now-and-in-the-
future/11134174.article [Accessed: 10 January 2018] 
2. Agrawal, A. 2009. Medication errors: prevention using information technology systems. British Journal of Clinical 
Pharmacology 67(6), pp. 681-686. 
3. Gill, P., Stewart, K., Treasure, E. and Chadwick, B. 2008. Methods of data collection in qualitative research: interviews and focus 
groups. British Dental Journal 204(6), pp. 291-295. 
4. Braun, V. and Clarke, V. 2006. Using thematic analysis in psychology. Qualitative Research in Psychology 3(2), pp. 77-101. 
 
 
Spontaneous Reporting of Adverse Drug Reactions: Barriers and Facilitators for 
Dentists 
Bethany Lloyd and ML Hughes  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Yellow cards are part of a vital pharmacovigilance mechanism developed by the Medicines and Healthcare 
products Regulatory Agency (MHRA) in which Adverse Drug Reactions (ADRs) can be spontaneously reported 
via the Yellow Card Scheme. Only one Yellow Card was submitted to Yellow Card Centre Wales in 2016/17 
by a dentist which equates for just 0.04%.1 In previous research, it has been found that there was a lack of 
knowledge regarding ADR reporting2 and additional training needs were identified.3 This project aims to 
explore the views and experiences of dentists on spontaneous ADR reporting including the barriers they face, 
potential facilitators to increase reporting and any previous training received. 
Qualitative research methods were adopted due to the explorative nature of the project. Snowball sampling 
was used to recruit participants. To be included in the study, the dentists had to be working in a community 
based practice. A semi-structured interview schedule was used in the interviews which contained open 
questions and prompts. Interviews were conducted face-to-face or by telephone, audio recorded then 
transcribed ad verbatim. Thematic analysis was then used to identify major themes in the data. Ethics approval 
was obtained for the project. 
Six interviews were carried out; five face-to-face and one via telephone. Some of major barriers identified 
included time pressures, payment of dentists, undergraduate teaching, knowledge and experience. Examples 
of possible facilitators identified were more training, continuing professional development and making Yellow 
Cards easier to complete. 
The results showed that dentists experience multiple barriers to reporting, however recommendations to 
facilitate these changes were also made. Further research into this area would allow better understanding to 
the issues across Wales. Suggestions for improvements have been made and hopefully the amount of 
spontaneous ADR reporting will increase in the coming years.  
1. Yellow Card Centre Wales. 2017. Annual Report 2016-2017. Available at: 
https://openrepository.awttc.org/app/serve/resource/xbxx2183 [Accessed: 7 October 2017] 
2. Yip, J. Radford, D. R. Brown, D. 2013. How do UK dentists deal with adverse drug reaction reporting? British Dental Journal. 
214(22). doi:10.1038/sj.bdj.2013.426 
3. Patel, M. M. Radford, D. R. Brown, D. 2014. Preaching to the converted- optimising adverse drug reaction reporting by dentists. 
British Dental Journal. 217(4). doi:10.1038/sj.bdj.2014.598 
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Stability of Medication in Multi-Compartment Compliance Aids Administered by 
University Hospital, Wales 
Jessica Lynden-Cowley, T Banner1 and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK and 1University Hospital Wales, Heath Park, Cardiff, CF14 4XN, Wales, UK. 
Multi-compartment compliance aids (MCAs) are devices used to deliver solid dosage form medication to 
patients via a series of plastic compartments, aiming to match a patient’s dosage regimen and ease 
administration.1 Despite their popularity, there is a paucity of research into the stability of medications placed 
in an MCA. Their use involves removing a product from its primary packaging and therefore invalidating the 
manufacturer stability guarantee. Medications can be degraded by light, moisture, air and heat.2 Degradation 
of a medicine could lead to changes in active ingredient concentration, degradant accumulation, drug release 
profile or visual appearance. Consequences for a patient could include under-dosing, toxicity or non-
compliance.3 The aim was to use Specialist Pharmacy Service (SPS) database to analyse a sample of UHW 
MCA prescriptions and determine the number of potentially unstable items that were dispensed. Another aim 
was to make risk reduction recommendations based on results and surrounding evidence.  
UHW prescription data spanning 6 months was anonymised and assigned stability codes through SPS, an 
online resource allowing product stability information to be shared between healthcare professionals. The 
frequency of each allocated code was analysed, as well as the formulation and environmental sensitivities. 
The results showed that 17% of items dispensed into the MCAs were deemed unsuitable by SPS, affecting 
66% of MCAs recorded. Dispersible aspirin tablets, levothyroxine tablets and amlodipine tablets made up 49% 
of all unstable items identified and were the focus of the resulting recommendations.  
Based on results and surrounding literature reviews, recommendations were made to reduce the number of 
unstable items and the risk of degradation of items in MCAs. These included educating both patients and 
professionals and maintaining optimum storage conditions throughout MCA assembly and administration. This 
research also highlighted the need for further stability testing to produce National guidelines for medication 
storage and use in MCAs. 
 
1. Oboh L. Frequently Asked Questions (FAQ) on the use of Multi compartment compliance aids (MCAs) in the community: A 
resource for community pharmacists and other health and social care professionals involved in medicines management for older 
people. East and South East England Specialist Pharmacy Services. NHS Lambeth; 2011 [accessed 18 Nov 2017]. Available from: 
https://www.rpharms.com/Portals/0/RPS document library/Open access/Support/toolkit/faqs-on-mcas-nhs-lambeth.pdf 
2. Church C, Smith J. How stable are medicines moved from original packs into compliance aids? Pharm J. 2006;276(7384):75–6. 
3. Glass BD, Haywood A, Llewelyn V, Mangan M. Compliance aids and medicine stability: new evidence of quality assurance. Curr 
Drug Saf. 2009;4(1):74–8. doi: 10.2174/157488609787354459 
 
 
To investigate the factors that influence final year MPharm students’ motivation in 
relation to third year summative assessments and the early stages of the final year 
project 
Maryam Manan and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Several theories exist that seek to explain motivation. According to self-determination theory (SDT), there are 
several types of motivation; amotivation, intrinsic and extrinsic. These all vary in the degree of autonomy. 
Intrinsic motivation is the highest form of motivation and has an internal perceived locus of causality. Motivation 
is maintained or enhanced by satisfying the psychological needs for autonomy, competence and relatedness. 
Intrinsic and internal motivation results in deeper learning, better academic performance and overall 
wellbeing.1,2 SDT has been applied in many different fields, including education, however little research has 
been done in pharmacy context. The aim of the study was to explore the factors that influence final year 
MPharm students’ motivation in relation to third year summative assessments and the early stages of the final 
year project. 
Semi structured, one-to-one interviews were conducted to explore the views of fourth year MPharm students. 
A topic guide, along with an interview schedule, consisting of mainly open-ended questions, were constructed 
to guide the interviews. Non-probability, purposive sampling with an element of convenience was used to 
recruit students. Interviews were audio recorded and transcribed verbatim. Thematic analysis3 was used to 
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analyse data. Themes were derived inductively, and deductively using SDT. Approval from Ethics was 
obtained.  
A total of 18 interviews were conducted. Students identified factors that influenced their motivation in relation 
their final year project and third year summative assessments. Six major themes, and several subthemes, 
were identified. Major themes were final year project, preparedness, influence of lecturers, choice, group work 
and relevance. 
This study has helped provide a valuable insight into fourth year MPharm students’ views at Cardiff University. 
In addition, based on these findings, suggestions have been made to the School to help increase internal 
motivation.  Although, results are not generalisable, it has provided the basis of further research.   
1. Cook DA, Artino AR Jr. Motivation to learn: an overview of contemporary theories. Med Educ. 2016;50(10):997-1014. doi: 
10.1111/medu.13074. 
2. Ryan RM, Deci EL. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. Am 
Psychol. 2000;55(1):68-78. 
3. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77-101. doi: 10.1191/1478088706qp063oa 
 
 
Exploring RET expression in breast cancer 
Stacie Marks1, Z Hudson2, P Finlay1, A Green3 and JMW Gee1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK.  2School of Medicine, Cardiff University, CF10 4XN and 3Academic Unit of Oncology, Nottingham City 
Hospital, Hucknall Road Nottingham NG5 1PB, England. 
Breast cancer is the UK’s most common female cancer with several successful anti-hormonal (AH) treatments, 
for ER+ patients; however, resistance and relapse remains a major problem.1 Mechanisms of resistance have 
been investigated, preclinical models revealing an importance for erbB pathways2, but their targeting has had 
limited clinical success. RET, a further tyrosine kinase, is a newer target, with promising research showing 
increased signalling in a tamoxifen-resistant cell line.3 It is now the target of a clinical trial (FURVA) exploring 
a kinase inhibitor, vandetanib. The key objectives here were to optimise a RET immunohistochemical (IHC) 
assay and use it to determine any signalling or clinicopathological associations for RET in breast cancer 
patients, and to study further pre-clinical models to explore relationships between RET and AH resistance. 
A RET IHC assay was optimized successfully using microwave antigen retrieval (pH9 EDTA buffer) that could 
adequately-stain stored breast cancer sections. It was applied to a historical patient series (n=93) and to a 
panel of AH-resistant cell pellets and xenografts. RET staining was evaluated by H-Scoring. Statistical analysis 
examined relationships between RET staining and biological and clinicopathological data available for the 
patients.  
RET correlated with its co-receptor GFRA1 (p=0.003), and while inverse with erbB signalling, positively 
correlated with STYK1 (p<=0.001) and downstream signaling including Shc (particularly in ER- disease, 
p=0.012) implicated in AH resistant phenotypes. Higher RET levels associated with increased tumour size 
(p=0.03) and recurrence (p=0.005). All cell lines and xenografts stained for RET, particularly an oestrogen-
deprived resistant model.  
Although the samples were >10 years old and storage effects antigenicity4, data supportive of RET signalling 
and its relationship to AH resistance were obtained from the clinical breast cancers and the xenograft and 
pellets. The direct associations with adverse clinicopathological features affirmed that RET overexpression is 
undesirable, advocating trials like FURVA.  
 
1. Clarke, R. et al. 2015 Endocrine resistance in breast cancer – an overview and update. Molecular Cell Endocrinology 15(418), pp. 
220-234. doi: 10.1016/j.mce.2015.09.035 
2. Zhoa, M. et al. 2014. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World 
Journal of Clinical Oncology 5(3), pp. 248-262. doi:10.5306/wjco.v5.i3.248 
3. Gee, J. et al. 2014. Increased RET signalling and impact of vandetanib in acquired tamoxifen resistant breast cancer. Cancer 
Research 74(19) Doi: 738. 10.1158/1538-7445.AM2014-73 
4. Shi, SR. 1997. Antigen retrieval immunohistochemistry: past, present and future. The Journal of Histochemistry and Cytochemistry 
45(3), pp. 327-343. Doi: 10.1177/002215549704500301 
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Factors associated with falls in a convenience sample of patients and the public 
presenting at community pharmacies in Wales    
Samantha Maurice, T Banner1, MO Ivory and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB and 1Pharmacy, Cardiff & Vale University Health Board, Cardiff Wales, UK. 
The causes of falls are multi-factorial1-3 and include certain medication2 and increasing age.3 The study aimed 
to identify if there is any statistical association between pre-determined risk factors and a fall occurring within 
the past year based on a sample of Welsh community pharmacy patients. 
Data were collected via a questionnaire by community pharmacies as part of a national falls campaign 
conducted in Wales in 2017. The questionnaire focussed on the presence or absence of some associated risk 
factors.1-3 Ethical approval was granted by Cardiff School of Pharmacy and Pharmaceutical Sciences Ethics 
Committee. This project involved coding, data entry and analysis of the completed questionnaires. Following 
validation of data, the chi-square test was used to compare risk factors with whether or not the individual had 
experienced a fall in the previous year.  
A total of 4630 questionnaires were received with 36% of respondents reporting a fall in the past 12 months. 
Individuals taking a number of specific medicines/classes of were significantly more likely to have reported a 
fall in the past year. There was a statistically significant higher proportion of falls reported by respondents over 
70 years old compared with younger respondents. Individuals taking four or more medicines (polypharmacy) 
were significantly more likely to have reported a fall in the past year than those taking three medicines or fewer. 
This study found that certain medications, age and polypharmacy were associated with an increased risk of a 
fall in the previous 12 months in the community setting in Wales. These findings align with those of others. 
Suggestions for changes to the questionnaire have been made. Further research is warranted.  
 
1. National Health Service. Care Homes – Medication and Falls. B87.  London: National Health Service; 2014 [Accessed: 2nd 
October 2017]. Available from: https://www.prescqipp.info/care-homes-medication-and-falls/category/138-care-homes-medication-
and-falls  
2. Kuschel B, Laflamme L, Möller J. The risk of fall injury in relation to commonly prescribed medications among older people – a 
Swedish case-control study. European Journal of Public Health. 2014; 25(3): 527-532. doi:10.1093/eurpub/cku120 
3. Vieira ER, Palmer RC, Chaves P. Prevention of falls in older people living in the community. BMJ. 2016; 353:1419. Doi: 
10.1136/bmj.i1419 
 
 
Synthesis of haemanthamine derivatives as potential leads for drug discovery 
Maeve McKenny and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales 
Galantamine, a drug used to treat mild to moderate Alzheimer’s Disease1, is commercially harvested from 
daffodils.2 The extraction process results in the generation of many by-products some of which have been 
shown to have biological activity. Haemanthamine, one of the by-products resulting from the extraction of 
galantamine has been shown to have anticancer activity. Specifically, haemanthamine shows effects against 
apoptosis resistant cancers which are currently impervious to treatment.3 Haemanthamine displays sub-
optimal lipophilicity (LogP) for oral dosing4, a surrogate for polarity which can determine the amount of 
haemanthamine reaching the systemic circulation and its rate of excretion from the body. The aim of this 
project was to make novel analogues of haemanthamine that improve its properties for oral administration. 
These structural analogues could then be used as potential leads for drug discovery.  
Three chemical reactions were designed to improve the lipophilicity of haemanthamine from a LogP value of 
0.91 to within the range of 1 to 3. These were, an esterification to make a butyl ester of haemanthamine, an 
ether synthesis to make a butyl ether of haemanthamine and lastly a methylenedioxy cleavage reaction. The 
reactions were run and their degree of success judged via thin layer chromatography (TLC), mass 
spectrometry and proton nuclear magnetic resonance (1H NMR).  
Both the esterification and ether synthesis reaction were successful as confirmed by 1H NMR. The 
methylenedioxy cleavage reaction proved slightly harder and was inconsistent.  
The esterification and ether synthesis reactions both showed very positive results, and were highly 
reproducible. The methylenedioxy cleavage reaction requires further work to establish reproducibility.  
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The ester and ether products of haemanthamine are likely to serve as potential useful leads for drug discovery. 
1. Joint Formulary Committee. British National Formulary. 74th ed. London: BMJ Group and Pharmaceutical Press; 2017. 
2. Department for Environment Food & Rural Affairs. Sustainable production of the natural product, galanthamine. 2006 [accessed 12 
Nov 2017]. Available from: 
http://randd.defra.gov.uk/Default.aspx?Menu=Menu&Module=More&Location=None&Completed=0&ProjectID=13350 
3. Van Goietsenoven G, Andolfi A, Lallemand B, Cimmino A, Lamoral-Theys D, Gras T, Abou-Donia A, Dubois J, Lefranc F, Mathieu 
V, Kornienko A, Kiss R, Evidente A. Amaryllidaceae Alkaloids Belonging to Different Structural Subgroups Display Activity against 
Apoptosis-Resistant Cancer Cells. Journal of Natural Products. 2010;73(7):1223-1227.  
4. Arnott J A, Kumar R, Planey S L. Lipophilicity Indices for Drug Development. Journal of Applied Biopharmaceutics and 
Pharmacokinetics. 2013;(1):31-36. 
 
 
Pharmacists’ knowledge and understanding of the use of Image and Performance 
Enhancing Drugs (IPEDs) in sport 
Hannah Mittelberger, S Shahi and R Yemm 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Doping is the use of any prohibited substances and methods determined by the World Anti-Doping Agency to 
enhance performance in amateur and professional sport.1 There has been little research to date regarding 
pharmacists’ knowledge on the use of IPEDs, pharmacy medicines containing banned substances and the 
role of pharmacists in addressing this issue.2,3,4 The aim of this research was therefore to identify practicing 
pharmacists’ knowledge of IPEDs and their perceived need for additional training on this subject. 
Ethical Approval was granted by the School’s Research Ethics Committee. Research was conducted over two 
phases: (1) optimisation of an existing questionnaire and (2) questionnaire distribution to pharmacists. In phase 
1, two focus groups were conducted with teacher practitioners at Cardiff School of Pharmacy to determine the 
feasibility of the questionnaire, appropriateness of questions and ease of completion. The feedback aided 
finalisation of an anonymous postal questionnaire comprising a range of Likert-scale, ranking and open and 
closed questions. The questionnaire was sent to 494 pharmacies across all Health Boards in Wales. 
Participants were given two weeks to respond. Data was analysed using SPSS. 
119 completed responses were received (response rate = 24.3%) The majority of pharmacists (88%) were 
unable to correctly identify banned substances within common over-the-counter medicines. Similarly, 86% of 
pharmacists identified as feeling ‘unsure’ or ‘not confident’ on advising the public and athletes on IPEDs. 
Despite this, 58% of respondents felt pharmacists should be one of the first healthcare professionals to offer 
advice on this issue, demonstrating a need for further training, for which 80% stated they would be interested 
to receive.  
The results obtained through our questionnaire corroborated data in France and Cameroon, with pharmacists’ 
feeling poorly prepared and lacking confidence. However our results regarding advising on IPEDs did not align 
with those obtained elsewhere, therefore further research is required.  
1. WADA. PROHIBITED LIST JANUARY 2017. WADA; 2016 [accessed 1 December 2017]. Available from: https://www.wada-
ama.org/sites/default/files/resources/files/2016-09-29_-_wada_prohibited_list_2017_eng_final.pdf  
2. Laure P, Kriebitzsch-Lejeune A. Retail pharmacists and doping in sports: knowledge and attitudes. A national survey in France. 
Science & Sports. 2000; 15:141-6 [accessed 4 October 2017]. Available from: https://ac-els-cdn-
com.abc.cardiff.ac.uk/S0765159700800180/1-s2.0-S0765159700800180-main.pdf?_tid=6d7e1ac6-ada1-11e7-bcbd-
00000aab0f27&acdnat=1507629629_2dcfaa26a548a2cf66187d2716580b8b  
3. Ama PFM, Ama VJ, Kmaga JP, Sato G, Laure P. Dopage et sport : connaissances et attitudes des pharmaciens, de la ville de 
Yaoundé. Science & Sports. 2002; 17:135-9 [accessed 4 October 2017]. Available from: https://ac-els-cdn-
com.abc.cardiff.ac.uk/S0765159702001326/1-s2.0-S0765159702001326-main.pdf?_tid=4748e5d0-ada5-11e7-8a99-
00000aacb35d&acdnat=1507631283_881543a90b44c715e062b047ca486d0d  
4. Auersperger I, Topič MD, Maver P, Pušnik VK, Osredkar J, Lainščak M. Doping awareness, views, and experience: a comparison 
between general practitioners and pharmacists. Wiener klinische Wochenschrift The Central European Journal of Medicine. 2012; 
124:32-38. 
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Optimisation and biocompatibility of alginate gel for 3D bioprinting 
Shabbir Ahmed Moolla1, A Moukachar1, K Harvey2, CP Thomas1, OK Castell1 and SA Coulman1   
1Cardiff School of Pharmacy and Pharmaceutical Sciences,Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and 2Cardiff School of Engineering, Queen's Buildings, The Parade, Cardiff, CF24 3AA, Wales, UK. 
3D bioprinting is the accurate placement, via spatial control, of encapsulated cells to produce 3D structures.1 
Commercial 3D bioprinters are currently expensive and often sub-optimal and consequently access to this 
technology is limited. The bio-inks utilised to print cells are an important feature of the system. This project 
aims to develop an affordable bio-ink that is compatible with skin cells and thus could be used to 3D print a 
human skin substitute.  
Alginate was selected as the lead candidate bio-ink. It is affordable and approved by both the FDA and MHRA 
for use in medical products.2  Gelling methods were optimised, with the intention of testing the biocompatibility 
of alginate with two types of skin cell, fibroblasts and keratinocytes. Alginate was gelled in a 12-well plate at a 
range of thicknesses, before cells were seeded onto the surface of the gel. Cells were inspected regularly, and 
growth was monitored over 7 days. The functionality of alginate as a bio-ink in a bespoke 3D printer was then 
tested. The  gel was used to print fibroblasts in different spatial orientations, as programmed into the printer. 
Alginate can be gelled in various ways. However, many substances used to gel alginate can influence the 
growth of cells. Method optimisation in gelling alginate allowed for some removal of these substances e.g. 
mineral oil, thus increasing the chances of survival of cells. Alginate was demonstrated to be biocompatible, 
supporting the growth of both fibroblasts and keratinocytes. This allowed the bio-printing of multi-layered 
shapes, showing proof of concept.  
Various grades of alginate are available with different G/M ratios and therefore the effect on biocompatibility 
should be explored. Further optimisation of the alginate is required and future research should, investigate the 
ability of alginate to support less robust cell lines such as melanocytes. 
1. Murphy, S.V. and Atala, A. 2014. 3D bioprinting of tissues and organs. Nature Biotechnology 32, pp. 773-785. DOI: 
10.1038/nbt.2958  
2. MHRA. 2007. Public assessment report Gaviscon liquid sachets. Available at: 
http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con2033375.pdf [Accessed: 07 January 2018] 
 
 
Investigating expression of plasmid DNA and messenger RNA in model human skin 
cells. 
Alys Morgan and MO Ivory 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales, UK. 
The use of plasmid DNA (pDNA) and messenger RNA (mRNA) as vaccines has been of recent interest due 
to eliciting a strong immune response by activation of cytotoxic T cells, T helper cells and antibodies.1 It is a 
step forward in developing modern vaccine technology to overcome limitations2 with traditional vaccine 
therapy. Investigating expression of genes in HaCaT cells provides knowledge on how gene vaccines, when 
delivered into the epidermal layer of the skin, will behave. 
This study investigates the effectiveness of the transfer and the expression of genes coding for green 
fluorescent protein (GFP) into HaCaT cells via mRNA/pDNA transfection. HaCaT cells were cultured in a low-
calcium medium, representative of conditions in the lower epidermis of human skin. Following this, transfection 
of pDNA and mRNA, coding for GFP, with and without delivery systems were conducted. Expression of GFP 
caused by pDNA and mRNA was compared and analysed using fluorescence microscopy and flow cytometer. 
Comparison of the two gene vaccines using analytical techniques indicated that expression of GFP was more 
prevalent when pDNA was combined with Lipofectamine 3000. Adjusting concentrations to investigate cell 
death resulted in a decrease of MessengerMAX to increase GFP expression, although no significance 
difference was seen with other alterations. Comparison against controls measured the desired expression, 
excluding undesired expression, to produce results that can contribute to the field.  
Results produced provide initial data for further research into the development of gene vaccines using primary 
cells. It has shown that in low-calcium HaCaT cells pDNA and Lipofectamine 3000 is the most successful at 
inducing GFP expression when in comparison with mRNA and MessengerMAX.  
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1. Kowalczyk, D. W. and Ertl, H. C. J. 1999. Immune responses to DNA vaccines. Cellular and Molecular Life Sciences 55(5), pp. 
751-770. doi: http://dx.doi.org/10.1007/s000180050330 
2. Liu, M. A. 2010. Immunologic basis of vaccine vectors. Immunity 33(4), pp. 504-515. doi: 
http://dx.doi.org/10.1016/j.immuni.2010.10.004 
 
 
 
Design and synthesis of novel aspartyl tRNA synthetase (AspRS) dual inhibitors as 
novel antibacterial agents 
Julia Moulton and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, U.K. 
Antibiotic drug resistance is becoming an increasing global problem, resulting in the demand for urgent 
discovery of alternative antibacterials. One such example is aminoacyl tRNA synthetase (aaRS) inhibitors 
which target the core process of protein synthesis needed for cell survival.1 This report focuses on aspartyl 
tRNA synthetase (AspRS) enzymes, with the aim to design and synthesise novel dual inhibitors as an 
alternative to current treatments. 
In order to design the compounds the enzyme active site was analysed using molecular modelling software 
(MOE2). The software provided an insight into binding interactions between the natural ligand and enzyme 
which enabled the composition of the compounds to be determined with the intention to fill two pockets - the 
ATP site and the aspartic acid site. The synthesis of the compounds was a four-step reaction: nucleophilic 
substitution to form a sulphonamide bond, nucleophilic substitution with chloroacetonitrile, reduction of nitrile 
to amine using LiAlH4 and amide bond formation using an acyl chloride. The products were confirmed using 
mass spectrometry, 1H NMR and 13C NMR.  
Two compounds were synthesised with the exclusion of the linker group. Step 2 was partially optimised but 
needs further research to prove the reliability of the method. Similarly, an alternative method for step 4 was 
suggested but also needs confirmation of its suitability.  
Although none of the final compounds were produced during the project, there has been useful development 
of the methods and an opportunity for further optimisation of the reaction steps. 
1. Ibba M., Becker, H.D., Stathopoulos, C., Tumbula, D.L. and Söll, D. The adaptor hypothesis revisited. Trends Biochem. Sci. 
2000:25, 311–316. 
2. Molecular Operating Environment (MOE), 2014.0901; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, 
Montreal, QC, Canada, H3A 2R7, 2018.  
 
 
Investigating the effects of Alzheimer’s disease, gender and age on the expression 
of mitochondrial proteins in the human brain 
 
Shashenah Murugathasan, JS Bice and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales, UK. 
Alzheimer’s disease (AD) is the most common form of dementia.1 The pathophysiology of the condition 
involves the accumulation of amyloid beta plaques and neurofibrillary tangles.2 Mitochondrial proteins of the 
electron transport chain (ETC) also play a crucial role in the progression of AD.3 The aim of this study was to 
make comparisons of the expression of these mitochondrial proteins between disease states, genders and 
age groups. 
The semi-quantitative, analytical method known as Western blotting was used for the separation of 
mitochondrial proteins from human brain samples. All proteins were imaged using chemiluminscence. Relative 
densities of bands from the images were determined using Image J. Bands were normalised to GAPDH or 
total Dynamin-related protein 1. Data were statistically analysed using Student’s t-test and ANOVA.  
The expression of complex ll and lV demonstrated a significant decrease in AD compared to non-AD male 
brain samples. An overall trend for a decrease was seen in the expression of all complexes in female old 
compared to male old, and female AD compared to male AD brain samples. The expression of complex V 
demonstrated a significant decrease with age in female brain samples. An alteration in the expression of 
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dynamin-related protein 1 was observed between age groups and disease states in both male and female 
brain samples. 
In AD and age groups, more consistent trends were observed in ETC complex expression in women compared 
to men. This is likely to be related to the decline in oestrogen levels in postmenopausal women leading to 
enhanced amyloid beta production and decreased mitochondrial function. The findings suggest mitochondrial 
proteins likely play a key role in AD pathophysiology. Understanding the link between these proteins and 
oestrogen may help to develop treatment strategies by reversing amyloid beta-induced mitochondrial 
dysfunction. 
1. Dá Mesquita, S. et al. 2016. Insights on the pathophysiology of Alzheimer’s disease: The crosstalk between amyloid pathology, 
neuroinflammation and the peripheral immune system. Neuroscience and Biobehavioral Reviews 68; 547–562.  
2. Nicolson, G. L. 2014. Mitochondrial Dysfunction and Chronic Disease: Treatment With Natural Supplements. Integrative medicine 
13; 35–43.  
3. Grimm, A. et al. 2016. Alzheimer, mitochondria and gender. Neuroscience and Biobehavioral Reviews 67; 89–101.  
 
 
 
Transfection of High Calcium Culture HaCaTs with Gene Vaccines (pDNA and 
mRNA) Encoding Green Fluorescent Protein (GFP) 
Catherine Jane Nutting and MO Ivory 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK. 
Gene vaccines plasmid DNA (pDNA) and messenger RNA (mRNA) present a promising vaccine technology. 
(1) However, in practice they fail to stimulate potent immune responses.1  Keratinocytes in the epidermis are 
in close proximity to large numbers of immune cells, their role in immune cell recruitment suggests their 
transfection with gene vaccines may secure highly potent immune responses.2  However, to date this has not 
been widely investigated. This project investigated transfection of a differentiating keratinocyte model with 
pDNA and mRNA. A concurrent project investigated transfection of a proliferative keratinocyte model. It was 
also investigated whether enhanced transfection efficiency of gene vaccines would be achieved in presence 
of lipofectamine, a gene delivery system. 
A keratinocyte model, immortalised human keratinocytes (HaCaTs) were used. Differentiated HaCaTs were 
achieved through culturing cells in high calcium (2.8mM) medium.  Genes encoding green fluorescent protein 
(GFP) were used thus successful transfection of HaCaTs was indicated by expression of GFP. GFP was 
visualised with epifluorescent microscopy and quantified with flow cytometry. 
pDNA only in presence of a delivery system successfully transfected differentiated HaCaTs. However, in 
contrast to the results of a concurrent project, transfection success was minimal.3  Results following 
transfection of HaCaTs with mRNA were inconclusive. Due to time constraints optimal transfection conditions 
could not be investigated.  Previous studies state that unlike pDNA, nuclear entry is not required for mRNA 
expression, thus greater transfection efficiency would be predicted in non-replicating cells such as 
differentiated HaCaTs. (4) Furthermore, unlike pDNA, mRNA does not present a risk of integrating with the 
cells genes. (4)  
mRNA based vaccines theoretically present a better vaccine technology as opposed to pDNA.4  However, 
whether high transfection efficiency in epidermal skin cells can be achieved and whether administration of 
gene vaccines into the epidermis would secure potent immune responses would require further investigations. 
1. Leitner WW, Ying H, Restifo NP. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine. 1999; 18(9-10): 765-
777.  
2. Mann ER, Smith KM, Bernardo D, Al-Hassi HO, Knight SC, Hart, AL. Review: Skin and the Immune System. J Clin Exp Dermatol 
Res. 2012; S2:003. doi: 10.4172/2155-9554.S2-003  
3. Morgan A. Investigating plasmid DNA and messenger RNA in model human skin. MA, Cardiff Univeristy 
4. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biology . 2012; 9(11): 1319-1330. 
doi: 10.4161/rna.22269 
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Assessment of Inhaler Technique and Asthma Control in a Community Pharmacy 
Setting 
Fatima Omrani, D Farah, JS Appleby, N Rahman and WR Ford 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK. 
Asthma control remains poor in Europe, with studies showing 45% of patients have uncontrolled asthma.1 
Many contributing factors can be considered, including: one third of asthmatic patients do not use their inhalers 
correctly, less than 50% adhere to their preventative inhalers and only 7% of healthcare professionals were 
found able to demonstrate all the steps required to use a MDI correctly and effectively.2-4 The aim of this study 
is to assess asthma control and inhaler technique. 
Sixty-one patients were recruited using convenience sampling across four community pharmacies in South 
Wales. Following consent, a semi-structured interview approach was used to collect biometric data including: 
age, smoking status, past inhaler technique training and history of hospitalisation/oral steroid use due to 
asthma exacerbations. Asthma control was measured using an Asthma Control Test (ACT). Inhaler technique 
was assessed using an Aerosol Inhalation Monitor (AIM device, Vitalograph).  
The main findings were that 55% of participants had uncontrolled asthma in the past four weeks, based on the 
ACT. Moreover, 33% had been hospitalised or prescribed oral steroids due to asthma exacerbations, an 
outcome of severe asthma. Overall, 53% of participants failed their inhaler technique test when using the AIM 
device. The largest number of participants, 61%, demonstrated the wrong technique when use a metre dose 
inhaler (MDI). The majority of participants received inhaler technique training from a doctor or nurse. Only 5% 
received training from a pharmacist and 13% received no inhaler technique training from any health care 
professional (HCP).  
Effective self-management should be encouraged among asthmatic patients. HCP training on inhaler 
technique should be reviewed so that they can effectively and confidently train patients. Shorter review 
intervals could help facilitate regular assessment and reinforcement of inhaler technique. Pharmacist 
intervention in asthma care can prove to be beneficial and should be studied further.  
1. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: The Recognise Asthma and 
Link to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24: 14009. 
2. Asthma UK. Asthma facts and statistics London: Asthma UK; 2017 [Available from: https://www.asthma.org.uk/get-
involved/campaigns/data-portal/. 
3. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, et al. Relationship between adherence to inhaled corticosteroids 
and poor outcomes among adults with asthma. J Allergy Clin Immunol 2004;114(6): 1288-93. 
4. Baverstock M, Woodhall N, Maarman V. Do healthcare professionals have sufficient knowledge of inhaler techniques in order to 
educate their patients effectively in their use? Thorax 2010;65(Suppl 4): A117-A8. 
 
 
Why are manganese and selenium plasma levels not in the optimal range in Home 
Parenteral Nutrition (HPN) patients? 
Veronica Ong, SR Dodington and R Price-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK and St Mary’s Pharmaceutical Unit, Cardiff and Vale University LHB, 20 Field Way, Cardiff, CF14 4HY, 
Wales, UK. 
HPN provides nutrients to patients at home, to meet their nutritional needs when the oral route is inaccessible.1, 
2 Additrace® is a multi-trace element product that has been used for many years to provide micronutrients to 
patients.  A previous study has shown that long-term HPN patients have exhibited some abnormal trace 
element (TE) blood results.3 The aim of this study is to review prescription data and blood test (BT) results for 
PN patients to determine whether their prescriptions are optimal or if there is scope for improvement. 
The TEs targeted in this study were manganese (Mn), selenium (Se), zinc (Zn) and copper (Cu). All patients 
were anonymised, and their PN bags were added either with “Additrace® only”, “extra Se only” or “both 
Additrace® and extra Se”, thus divided into three groups. BT results were taken minimum 3 months after 
initiating the PN regimen, to allow TE levels to be consistent in the body. The results were recorded and 
categorised as “deficient”, “in range” or “in excess”. Data analysis was then carried out. 
Of the 4 TE, most patients did not have “in range” BT results for Mn and Se, hence for further investigations 
were undertaken. Statistics test was conducted, with the null hypothesis ‘There is no relationship between Mn 
and Se’. The highest correlation coefficient of -0.294 in “Additrace® only” indicated that Mn and Se have a 
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strong relationship. Although the test did not indicate whether Mn or Se was the contributing factor to abnormal 
plasma levels, they were closely related to each other when only Additrace® was added into the PN bag.  
Although the relationship was strong, due to the small sample size, the null hypothesis was not rejected. 
Therefore, future work must be performed to include more BT of “Additrace® only”, such as increasing the 
sample size in the study. 
1. Elia M. History of Parenteral Nutrition. In: Bozzetti F, Staun M, Gossum AV, editors. Home parenteral nutrition. 2nd ed. Oxfordshire: 
CAB International; 2015;3-13. 
2. British Association for Parenteral and Enteral Nutrition (BAPEN). Home parenteral nutrition. 2018 [accessed 21 Dec 2017]. 
Available from: http://www.bapen.org.uk/nutrition-support/parenteral-nutrition/home-parenteral-nutrition 
3. Powell A, Dodington SR, Price-Davies R. Are long-term parenteral nutrition (PN) patients receiving enough selenium in their PN? A 
retrospective database analysis. [MSc Dissertation]. Cardiff: Cardiff University; 2016. 
 
 
How temperature and formulation factors affect precipitation in neonatal aqueous 
parenteral nutrition admixtures containing copper and zinc  
Reeya Patani and AG Cosslett 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edwards VII Avenue, CF10 3NB, 
Wales, UK. 
Parenteral nutrition (PN) contains water, amino acids, glucose, lipid emulsions, electrolytes and micronutrients. 
This provides nutritional support to patients with malnourishment risk, due to medical conditions or diet 
inadequency.1 Precipitations in PN can cause patient harm by particulates blocking capillaries and/or result in 
inadequate quantities reaching patients. This project’s aim was to analyse whether a PN admixture’s stability 
was affected by copper and/or zinc additives when combined with amino acids Vaminolact® (containing L-
cysteine) or Aminoven 25®, potentially contributing to precipitation development in test admixtures. 
Using a laminar flow unit, admixtures containing various volumes of glucose and amino acid solutions together 
with copper and zinc dilutions were prepared. Visual inspection, turbidity and pH levels were analysed for 
admixtures stability. Testing occurred on preparation day (0 hour) at room temperature and at 24, 48 and 72 
hours in a stability chamber at 30°C and 35°C. This replicated neonatal PN administration in hospitals. 
Under fibre optic lighting, admixtures containing solely zinc additives, remained clear and colourless whilst 
those containing only copper additives produced a blue tinge (BT). Both these admixtures maintained stability 
according to turbidity and pH level data. A yellow haze (YH) occurred only when copper and zinc sulfate 
additives were in combination. The tyndall effect, indicated that particulates were present in BH and YH 
admixtures.2 Stability in YH admixtures could not be ensured as turbidity values resulted in significant 
differences of >0.5. 
The YH micro-precipitates could be products formed from reactions involving copper and either cysteine or 
hydrogen sulfide (by-product of cysteine degradation).3,4 Glucose had a protective effect, slowing YH’s 
development. Temperature increased solubility within the solution, potentially allowing particulates to re-
disperse. Future chemical stability analysis would be advised alongside using a particle counter and Scanning 
Electron Microscopy with X-ray Energy Spectroscopy (SEM-XES) to assess the size and identity of these 
micro-precipitates.4 
 
1. Walker R, Whittlesea C. Clinical pharmacy and therapeutics. 5th ed. Edinburgh: Churchill Livingstone Elsevier; 2012. 
2. NHS Specialist Pharmacy Service. A STANDARD PROTOCOL for DERIVATION and ASSESSMENT of STABILITY Part 4 – 
Parenteral Nutrition. 2016 [accessed 29 Dec 2017]. Available from: https://www.sps.nhs.uk/wp-content/uploads/2017/06/NHS-
PQAC-YCD-Std-Protocol-Chemical-Stability-Part-4-Parenteral-Nutrition-1st-Edn-2016.pdf. 
3. Allwood, MC, Martin H, Greenwood M, Maunder M. Precipitation of trace elements in parenteral nutritionmixtures. Clin Nutr. 
1998;17(5):223-226. doi: 10.1016/S0261-5614(98)80063-0. 
4. Minton, A.R. 1998. Studies on the stability of parenteral nutrition admixtures. PhD Thesis, Welsh School of Pharmacy. 
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Discovery of potential inhibitors for Chikungunya virus using computational 
approaches  
Adit Patel, B Zonsics and A Brancale  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edwards VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
There have been several Chikungunya virus outbreaks over the last few years with there being more than 1.7 
million suspected cases of it in affected areas since 2013. Contraction of the virus can lead to acute flulike 
symptoms and in some cases to chronic debilitating joint pain. Infants and the elderly are more likely to 
experience severe symptoms which in rare cases can lead to death. Currently there is no drug treatment or 
vaccine for the virus on the market but the macro domain contained within the non-structural protein, nsP3, is 
a potential target for antivirals. 1 The aim of this project is to identify potential inhibitors for this macro domain 
using computational molecular design.  
The co-crystallised structure of the macro domain with ADP-ribose was downloaded from Protein Drug Bank 
(PDB ID: 3GPO) to Molecular Operating Environment (MOE). Three pharmacophore queries were generated 
to screen the SPECS library and the PCL fragment library. The resulting molecules were docked into the 
Chikungunya macro domain using Glide SP. They were then rescored using Glide XP, FlexX and Protein 
Ligand ANT system (PLANTS). A consensus score was taken including only the top 25% ranked molecules 
across all 3 scoring functions. Visual inspection was then performed on the resulting 498 poses.  
13 unique molecules were chosen in the final selection. To ensure that these molecules didn’t bind well with 
human macro domains they were docked into the crystal structures of 4 different human macro domains and 
rescored with Glide XP, FlexX and PLANTS to calculate a consensus score. 2 of the molecules showed some 
indication that they could bind well with the human macro domains however after investigating their protein-
ligand interactions they were deemed suitable to be taken to the next stage.  
The obtained molecules might present new Chikungunya virus inhibitors with none or only little effect on human 
macro domains. Further cell-based evaluation is needed to assess the anti-Chikungunya virus activity and to 
confirm the computational results.  
1. Centers for Disease Control and Prevention. (2016). Symptoms, Diagnosis, & Treatment |Chikungunya virus | CDC. [online] 
Available at: https://www.cdc.gov/chikungunya/symptoms/index.html [Accessed 28 Nov. 2017].  
 
 
Exploring ways in which internal motivation of MPharm students can be increased 
in third year summative assessments from the perspective of current fourth years. 
Bianca Patel and DN John 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK.  
Three main psychological needs of autonomy, competence and relatedness must be met in order to 
develop intrinsic motivation which can then enhance performance.1 According to the self determination 
theory (SDT), intrinsic motivation can optimise enjoyment and interest for a student which as a result can 
benefit them academically by encouraging deeper learning rather than surface learning.2,3 An extrinsically 
motivated student is motivated by factors like rewards or punishments.2 The main aim of this study is 
explore factors that increase internal motivation in assessments and suggest improvements for the school 
of pharmacy to consider in trying to increase internal motivation.  
Non probability (convenience and purposive) sampling was used to recruit fourth year Cardiff MPharm 
students. They were asked to take part in a semi structured interview which was audio recorded and 
ethically approved. The interview explored what motivation was for individuals and their  fourth year 
projects. They were required to rank third year assessments into three piles of most, middle and least, 
according to enjoyment/interest and also separately by relevance to the MPharm degree and/or after 
graduation and provide reasons. All anonymised transcripts were accuracy checked and manually coded 
using thematic analysis.  
Five major themes were identified from transcripts of 18 interviews; ability of having a choice in topic, 
placements, relevance to future, influence of others and preparation and guidance. Students suggested 
changes that could be made to increase or maintain their internal motivation for assessments.  
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Changes that were suggested fit within the SDT and have the potential to fulfil the needs of autonomy, 
competence and relatedness. However, not all changes would be feasible to do and would have to be 
further investigated in order to be carried forward. More research would need to be done on feedback 
and topic choice in order for the school to adopt these suggestions. 
 
1. Cook D, Artino A. Motivation to learn: an overview of contemporary theories. Medical Education. 2016;50(10):997-1014. 
2. Ryan R, Deci E. Intrinsic and Extrinsic Motivations: Classic Definitions and New Directions. Contemporary Educational Psychology. 
2000;25(1):54-67. 
3. Young M. The Motivational Effects of the Classroom Environment in Facilitating Self-Regulated Learning. Journal of Marketing 
Education. 2005;27(1):25-40. 
 
 
Influence of material and surface properties of orthopaedic biomaterials and its 
coatings on bacterial adhesion. 
Pooja Patel and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales and School of Medicine, Cardiff University, UHW Main Building, Heath Park, Cardiff CF14 4XN, 
Wales, UK. 
Bone and joint disorders such as Osteoarthritis affect individuals all around the world and at least 8 million 
people in the UK alone.1 The prevalence is continuing to rise along with obesity and the ageing population. 
Therefore, increasing the number of total joint replacement (TJR) procedures being performed, giving rise to 
an increase in the number of infection cases. 2 This study aims to explore material and surface characteristics 
of biomaterials and coatings used to make joint implants and how these properties influence bacterial 
adhesion.  
Surface adhesion parameters for biomaterials, bacterial strains and coatings relevant to orthopaedic infections 
were found from literature. They were integrated into a computer stimulation model called a multi-asperity 
adhesion model and stimulations were executed using a programme called ‘Force 2.’ This model was derived 
from the Johnson, Kendall and Roberts (JKR) model, a single-asperity model assuming that one surface is 
smooth (bacteria) and another surface is rough (material).3 The output data presented the adhesive 
interactions between bacteria and materials.  
A statistically significant difference (p<0.05) was found for adhesive force averages across all materials. Ultra-
high-molecular-weight polyethylene was found to be the most adhesive with an overall average of 
(52.8±5.7nN) and aluminium oxide was found to be the least adhesive (35.9±6.5nN). Findings on coatings 
demonstrated that chitosan and silver lowered adhesive force even further.   
Material and surface characteristics such as Poisson’s ratio (υ), elastic modulus (E) and surface energy (Δγ) 
were found to influence bacterial adhesion. It was recognised that highly elastic materials were less adhesive 
to bacteria and bacteria with low surface energies were more adhesive towards hydrophobic surfaces. All of 
which justified the importance of surface properties and the effect they have on bacterial adhesion. Therefore, 
material and surface properties of joint implants can influence the prediction and prevention of orthopaedic 
infections.  
1. Arthritis Research UK. Osteoarthritis. 2018 [accessed 10 Dec 2017]. Available from: https://www.arthritisresearchuk.org/arthritis-
information/conditions/osteoarthritis.aspx   
2. Wittenauer R, Smith L, Aden K. Background Paper 6.12 Osteoarthritis. World Health Organisation. 2013. 
3. Prokopovich P, Perni S. Multiasperity contact adhesion model for universal asperity height and radius of curvature distributions. 
Langmuir. 2010;26(22):17028-36.10.1021/la102208y 
 
Design and synthesis of novel human Norovirus RNA-dependent RNA polymerase 
inhibitors 
Usheer Patel, A Brancale and M Bassetto 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK. 
Norovirus is a small, non-enveloped, positive-stranded RNA virus belonging to the Calicivirdae family. This 
virus is a worldwide threat and is responsible for almost 50% of gastroenteritis cases. It is associated with 
increased chance of hospitalisation and mortality.1,2 Currently, there is no effective treatment or 
pharmacological prophylaxis for Norovirus, generating an urgent need for an antiviral therapy.2  RdRp (RNA-
dependent RNA polymerase) is a protein present within Norovirus and has an essential role in synthesis and 
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amplification of additional subgenomic RNA, as well as in genome replication.3  This protein is suggested to 
be a promising antiviral target due to its crucial role in the survival of Norovirus. Furthermore, unlike other 
proposed antiviral targets, research into this protein has identified its crystal structure.2 This study involves 
molecular docking and synthesis of potential antivirals to target Norovirus RdRp, with an aim to inhibit this 
protein. 
A library of compounds was constructed on a molecular modelling software, exploring the structural activity 
relationship and making modifications to lead compounds 1 and 2, to improve their effectiveness and activity. 
These compounds were previously discovered as inhibitors of Norovirus RdRp through virtual screening. 
Analogues were designed and then docked within the crystal structure of RdRp, and each configuration was 
ranked according to its docking score. Taking this score into consideration, all configurations were visually 
inspected assessing its key interactions within the protein binding site, as well as comparing the fit to the known 
inhibitor of RdRp, PPNDS (pyridoxal-5'-phosphate-6-(2'-naphthylazo-6'-nitro-4',8'-disulfonate) tetrasodium 
salt).  
After computer analysis, the most promising compounds were chemically synthesised.  14 compounds were 
successfully prepared and were all over 95% pure. 
All of these compounds are currently being biologically evaluated against Norovirus RdRp activity. The results 
from this study’s computer modelling, chemical synthesis and biological assays, will guide future efforts for the 
development of a treatment for Norovirus.  
1. Eltahla A, Lim K, Eden J, Kelly A, Mackenzie J, White P. Nonnucleoside Inhibitors of Norovirus RNA Polymerase: Scaffolds for 
Rational Drug Design. Antimicrob. Agents Chemother. 2014; 58(6):3115-3123. doi: 10.1128/AAC.02799-13 
2. Rocha-Pereira J, Neyts J, Jochmans D. Norovirus: Targets and tools in antiviral drug discovery. Biochem Pharmacol. 2014; 
91(1):1-11. doi: https://doi.org/10.1016/j.bcp.2014.05.021 
3. Mastrangelo E, Pezzullo M, Tarantino D, Petazzi R, Germani F, Kramer D et al. Structure-Based Inhibition of Norovirus RNA-
Dependent RNA Polymerases. J Mol Bio. 2012; 419(3-4):198-210. doi: 10.1016/j.jmb.2012.03.008 
 
 
An evaluation of the influenza vaccination service, in community pharmacies, over 
the past five years (2012-2017) in Wales 
Keera Price, S Baker and R Deslandes  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales U.K 
Influenza is a respiratory infection that results in numerous cases of serious illness and even deaths every 
year.1 Prior to 2015, Wales was the only part of the UK with a national influenza vaccination scheme, allowing 
community pharmacists to provide free influenza vaccinations.2 There are several categories eligible for a free 
vaccination e.g. aged over 65.3 The Welsh Government has set an immunisation target of 75%4  and the 
introduction of the scheme hoped to aid reaching this target. The aim of this study was to analyse the data 
collected from all community pharmacies who provided vaccinations over the last five years in Wales (2012-
2017).  
Secondary analysis of data was chosen as the most appropriate method of analysis for this study. All data 
were provided in an Excel spreadsheet by the Chief Pharmaceutical Officer, Andrew Evans, after being 
collated by the NHS. It was subsequently coded and exported into SPSS and further excel spreadsheets for 
descriptive statistical analysis. No ethical approval was sought as all raw data had been anonymised prior to 
commencement of the study. 
The results illustrated that uptake of influenza vaccinations in a community pharmacy setting increased year 
on year, from 1568 provision in 2012/13 to 26,889 in 2016/17. Multiple pharmacies (six or more branches) 
were the most popular choice of setting with an average of 78.4% of people choosing to access them over 
independent pharmacies. Individuals over the age of 65 received 55.9% of the total number of vaccinations, 
making them the highest eligibility category immunised. The most popular reason, with 38.9% of the 
responses, for receiving a vaccination at a community pharmacy was due to not needing to make an 
appointment.  
This study concluded that the influenza vaccination service in community pharmacy is being accessed, 
however, pharmacies are still only providing around 4% of the total number of vaccination4. With possible 
further work and research into motivation for accessing the service, it could be utilised further.  
1. World Health Organisation. 2016. Influenza (Seasonal) Fact sheet. Available at: 
http://www.who.int/mediacentre/factsheets/fs211/en  [Accessed: 16 November 2017] 
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2. Evans, A. M. et al. 2016. National community pharmacy NHS influenza vaccination service in Wales: a primary care mixed 
methods study. BR J Gen Pract. 66(645), pp. e248–e257. doi: 10.3399/bjgp16X684349 
3. NHS Choices. 2016. Who should have the flu jab? Available at: https://www.nhs.uk/Conditions/vaccinations/Pages/who-should-
have-flu-vaccine.aspx?tabname=NHS%20vaccination%20schedule [Accessed: 16 November 2017] 
4. Public Health Wales a. 2017. Seasonal influenza in Wales 2016/17 Annual report. Available at: 
http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=55714 [Accessed: 16 November 2017] 
 
 
 
Design and synthesis of novel CYP51 inhibitors as therapeutics for Candida 
infections 
Kalika Puri and C Simons 
School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, 
Wales UK. 
Candida infections are a major problem that healthcare faces. Infections can be superficial and treated 
topically, however more serious infections are life-threatening and require systemic treatment.1 CYP51 
(cytochrome P450 lanosterol 14α-demethylase) is an enzyme involved in the biosynthesis of ergosterol in the 
Candida species, an integral component in the fungal cell membrane.2,3 The azole class of antifungals compete 
with lanosterol, preventing synthesis of ergosterol.1,4 There are challenges in targeting CaCYP51, such as 
azole-resistant and multi-drug resistant strains of Candida species.1,2 The aim of this project is to design and 
synthesise novel inhibitors of the fungal CYP51 enzyme in the Candida species. 
Three compounds that contained imidazole groups were chosen for investigation. The compounds were 
docked in the active site of CaCYP51 using a molecular modelling program, and their binding potential 
compared with a known azole inhibitor, posaconazole. Compounds 5a and 5d were synthesised in three steps: 
an amidation reaction, a mesylation reaction and a nucleophilic substitution reaction that replaced the mesyl 
group with an imidazole ring. Compound 12 required an extra two preparation steps to extend its length and 
remove the Boc group. Successful final compounds were sent for biological testing at Swansea University. 
Molecular modelling showed all three compounds to have promising docking results with CaCYP51. Only the 
chemical synthesis of 5d was successful, and biological testing showed that it had poor effectiveness as an 
inhibitor when compared against fluconazole (IC50 = 6.97 μM, MIC = >16 μg/mL).  Synthesis steps require 
optimisation, such as the addition of molecular sieves to the amidation step. 
The chosen series of inhibitors was successfully investigated by molecular modelling. Since only one final 
compound was successfully synthesised, there is plenty of scope for future work synthesising the other 
inhibitors and investigating their biological activity. 
 
1. Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD. Azole antifungal resistance in Candida albicans and 
emerging non-albicans Candida species. Front. Microbiol. 2016;7(2173). doi: 10.3389/fmicb.2016.02173. 
2. Choi JY, Roush WR. Structure based design of CYP51 inhibitors. Curr. Top. Med. Chem. 2017;17:30-39. doi: 
10.2174/1568026616666160719164933 
3. Rabelo VW, Santos TF, Terra L, Santana MV, Castro HC, Rodrigues CR et al. Targeting CYP51 for drug design by the 
contributions of molecular modelling. Fund. Clin. Pharm. 2016;31(1):37-53. doi: 10.1111/fcp.12230 
4. Hargrove TY, Friggeri L, Wawrzak Z, Qi A, Hoekstra WJ, Schotzinger RJ et al. Structural analyses of Candida albicans sterol 14α-
demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungol sterol biosynthesis. J. 
Biol. Chem. 2017;292(16):6728-43. doi: 10.1074/jbc.M117.778308 
 
 
Evaluation of the discharge medicines review (DMR) service  
Rabia Rafiq, KL Hodson and ML Hughes.  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB 
Discharge medicines review (DMR) service is an enhanced service1 that is provided in community pharmacies 
across Wales. It was introduced in 2011 to address the many issues that patients faced with medication and 
information when they are discharged from a care setting.2 The DMR service aims to overcome the issues 
such as: communication between healthcare professionals and resolving discrepancies in patient ’s 
medication. The aim of the project was to evaluate the usage of this service from April 2013 – August 2017 
and to compare the results to the original evaluation of the service which took place in 2014.4  
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DMR data ranging from April 2013 – August 2017 was obtained via NHS Wales Shared services. The data 
was available in the form of Microsoft Excel® and was transferred to Statistical Package for Social Sciences 
version 23 (SPSS®). Five students undertook this project and therefore the data was evenly split between the 
students to enter into the SPSS software and then to quality assure it. Each student individually analysed the 
whole dataset.  
Several key results were found such as: the number of DMRs have increased each year from April 2013 – 
August 2017 (p<0.05). From the data available on the discharge rate across Wales4, 1.6% of discharges have 
resulted in a DMR being completed from April 2013 – August 2017. The rate of discrepancies per prescription 
across Wales was 1.14 which was similar to the 2014 report.3 The service has a greater uptake in Cwm Taf 
University and Betsi Cadwaladr University Health Boards compared to other Health Boards in Wales.   
In conclusion, although the DMR service is slowly increasing in its usage with time; it is not being utilized to its 
full potential. Further work needs to be undertaken to understand the reasoning behind these results.  
1. NHS Shared services. Enhanced and advanced service claims (NECAF). [Accessed 29/11/17] Available at: 
http://www.primarycareservices.wales.nhs.uk/enhanced-advanced-services-claims-necaf 
2. Community Pharmacy Wales. Discharge medicines review. [Accessed 11/10/17] Available at: http://www.cpwales.org.uk/Services-
and-commissioning/Advanced-Services/Discharge-Medicines-Review-(DMR).aspx 
3. Hodson K, Blenkinsopp A, Cohen D, Longley M, Alam F, Davies P et al. Evaluation of the discharge medicines review service. 
Welsh institute of health and social care, 2014. [Accessed 25/11/17] Available from: http://www.cpwales.org.uk/Contract-support-
and-IT/Advanced-Services/Discharge-Medicines-Review-(DMR)/Evaluation-of-the-DMR-Service/Evaluation-of-the-DMR-
service.aspx  
4. NHS Wales informatics service information services. Annual PEDW data tables. [Accessed 11/12/17] Available from: 
http://www.infoandstats.wales.nhs.uk/ 
 
 
Evaluation of a Community Pharmacy-based Asthma Care Plan 
Nayimur Rahman, F Omrani, D Farah, JS Appleby and WR Ford  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK.  
Asthma is mainly treated via the use of inhaler devices. Poor inhaler technique prevents patients from treating 
their asthma effectively, with up to 92% of patients using inhalers incorrectly.1 This leads to sub-optimal drug 
deposition in the lungs leading to reduced effectiveness of treatment. The study aims to assess both inhaler 
technique and levels of asthma control. 
The study recruited 61 asthmatic patients from several community pharmacies in South Wales by convenience 
sampling. Participants completed an asthma control test (ACT) to determine if their asthma was controlled or 
uncontrolled with an additional biometric data questionnaire being completed. A Vitalograph aerosol inhalation 
monitor (AIM device)2 was used to evaluate participants inhaler technique. Ethical approval was granted by 
Cardiff School of Pharmacy and Pharmaceutical Sciences Research Ethics Committee and the study was 
approved as a service evaluation by the Aneurin Bevan University Health Board. 
55% of the participants interviewed were found to have uncontrolled asthma (19 or less in the ACT) with an 
average ACT score of 18.2. 32.8% of participants were also admitted to hospital or prescribed oral steroids 
due to their asthma. Inhaler technique was poor throughout the different devices tested, particularly with 
metered dose inhalers (MDI) with 61.4% of these patients failing. Participants using dry powder inhalers (DPI) 
performed better than those using MDI’s (P<0.05). 
Using DPI’s as opposed to MDI’s could help overcome issues of poor technique seen with MDI’s, however, 
some patients may not be able to generate the required inspiratory-flow rate to disperse the drug particles3, 
particularly young children and the elderly. The lack of propellent is also disadvantageous in the event of an 
asthma attack, where patients struggle to breathe. More work is needed to improve the overall state of asthma 
and reduce the number of uncontrolled patients to lower levels. 
1. Bonds R, Asawa A, Ghazi A. Misuse of medical devices: a persistent problem in self-management of asthma and allergic disease. 
Annals of Allergy, Asthma & Immunology. 2015; 114:74-76.  [cited 7 January 2018]; Available from: 
http://www.annallergy.org/article/S1081-1206(14)00752-2/pdf 
2. Vitalograph. User Training Manual. 2018 [cited 28 December 2017]. Available from: https://vitalograph.co.uk/downloads/view/41 
3. J Telko M, J Hickey A. Dry Powder Inhaler Formulation. Respiratory Care. 2005;50(9):1209-1227. [cited 2 January 2018]. Available 
from: http://rc.rcjournal.com/content/respcare/50/9/1209.full.pdf 
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Implementing technology in community pharmacy: the impact of Digital Literacy, 
Willingness to Change and Leadership 
Hisham Rasheed, M Gumbleton and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edwards VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
The pharmacy world has developed from a paper-based field to one that is now heavily reliant on technology.1 
Consequently, the importance of having a minimum level of digital literacy, a motivated willingness to change 
and a competent leader to lead this change - are key for technological advancement.2 Investigating these 
characteristics of pharmacy staff is important in order to gauge what actions need to be undertaken in order to 
prevent a lack of advancement in this field.  
In this study, a qualitative approach was taken. Focus groups were conducted with members of the community 
pharmacy team using a semi-structured topic guide. The first focus group consisted of five participants, and 
the second enlisted six participants. Each focus group lasted a total of two hours, and inductive thematic 
analysis was undertaken after transcribing focus groups ad verbatim.  
This study concluded that there were certain barriers to implementation of technology in community pharmacy. 
These were mainly noted to be level of training, strong leadership which will incorporate good communication.  
The impact of digital literacy was very notable in influencing willingness to change towards a technological 
direction. However, digital literacy levels were noted to be dependent on the individual and influenced by age 
and experience with technology.  
Further research should be completed on this topic, specifically what influences digital training. More data is 
also needed for what makes a strong, innovative leader and how such individuals can be trained.  
1. Ridge, K. 2015. NHS England » Role of pharmacists is set to grow and grow. Available at: https://www.england.nhs.uk/blog/keith-
ridge-2/ [Accessed: 15 January 2018]. 
2. NHS Health Education England 2015. Digital literacy Towards a definition. Available at: 
https://www.hee.nhs.uk/sites/default/files/documents/1.%20Digital%20literacy%20Towards%20a%20definition.pdf [Accessed: 20 
January 2018]. 
 
 
To what extent are Welsh medium services being utilised in community pharmacies 
in Wales. 
Sioned-Mair Rees, W Davies, L Doyle and E Jones. 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff,        
CF10 3NB, Wales, UK. 
Wales has two official languages, Welsh and English. In 2011 the Welsh Language Measure was introduced 
and the role of the Welsh Language Commissioner established, with the aim of facilitating and promoting the 
Welsh language.1 In the commissioner’s first report, it was published that only 29% of fluent Welsh speakers 
received their consultation with the pharmacist in Welsh (n=207). 2  Effective communication is central to the 
provision of effective healthcare as set out in the General Pharmaceutical Council’s Standards for Pharmacy 
Professionals.3   In April 2016 the Welsh Government added questions to the National Electronic Claims and 
Audit Forms (NECAF) to track the utilisation of Welsh medium services within community pharmacies. The 
aim of this study was to statistically analyse the number of services requested and conducted in Welsh.  
Quantitative methods were used to analyse this secondary data. The data was provided on a Microsoft Excel 
spread sheet; from this, graphs and tables were created to give descriptive statistics. From April 2016 to 
September 2017, 419,607 services were conducted in Wales all of which have been analysed.  
Over the first 6 months 1.9% of consultations were requested to be conducted in Welsh, in the last 6 months 
only 1.41% were requested. Aneurin Bevan Health Board had the lowest percentage of Welsh requests 0.05% 
and from those 78.12% were denied. In contrast, only 2.51% of the 4.64% requests were denied in Hywel Dda 
Health Board. 
Several suggestions for the low uptake of Welsh medium services included, availability of Welsh language 
resources, patients reluctance to ask for a Welsh service and locality. Further analysis of Welsh language 
service provision should be considered as well as triangulation with qualitative data.   
1. Welsh Language Commissioner. An introduction to the role of the Welsh Language Commissioner. Cardiff; 2012. [Accessed: 2 
January 2018] available from: 
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http://www.comisiynyddygymraeg.cymru/English/Publications%20List/20120319%20GC%20Cyflwyniad%20i%20waith%20Comisiy
nydd%20y%20Gymraeg%20-%20fersiwn%20terfynol.pdf 
2. Welsh Language Commissioner. My language, my health: The Welsh Language Commissioner’s inquiry into the Welsh language 
in primary care. Cardiff; 2014 [Accessed: 2 January 2018] available from: 
http://www.comisiynyddygymraeg.cymru/English/Publications%20List/20120319%20GC%20Cyflwyniad%20i%20waith%20Comisiy
nydd%20y%20Gymraeg%20-%20fersiwn%20terfynol.pdf 
3. General Pharmaceutical Council. Standards for pharmacy professionals. London: General Pharmaceutical Council; 2017 
[Accessed: 2 January 2018] available from: 
https://www.pharmacyregulation.org/sites/default/files/standards_for_pharmacy_professionals_may_2017_0.pdf 
 
 
Investigating the effect of age, gender and Alzheimer’s disease on mitochondrial 
protein expression 
Mary Richards, JS Bice and EJ Kidd 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK.  
Alzheimer’s disease (AD) affects over 46 million people worldwide1, but the cause is mainly unknown. 
Age is the greatest risk factor. As oxidative stress has been implicated in ageing and early AD 2, 
mitochondria are of particular interest, as these organelles represent both the main source and target of 
endogenous reactive oxygen species (ROS). The aim of this project was to compare protein expression 
of the five main mitochondrial complexes (CI-CV) in AD and non-AD brain samples, during aging, and 
within gender, the second largest risk factor. It was hypothesised that protein expression would be 
reduced in AD and with age, due to increased oxidative stress.  
Human prefrontal cortex tissue was used, with AD samples having Braak staging of V-VI. Young (20-32), 
middle-aged (40-49) and old (70-99) samples were used for age comparisons. SDS-PAGE followed by 
Western Blot analysis was performed to visualize mitochondrial proteins. All proteins were normalized to 
GAPDH, using ImageJ software. One-Way ANOVA followed by Tukey post-hoc test or Student’s t-test 
were used. 
In AD samples, significant reductions were reported in CIII in females (p=0.0482), and CII and CIV in male 
samples (p=0.0322 and 0.0074, respectively) when compared to controls (n=4). There was an apparent trend 
for decreasing protein expression with advancing age in female samples, however, only CV expression was 
significant (p=0.0081) between young vs. middle-aged and young vs. old groups (n=3). No significant 
differences or apparent trends were reported in male samples across age.  
The results suggest that mitochondrial protein expression is reduced in AD. However, as no oxidative markers 
were measured, it cannot be concluded that this was due to ROS damage. The apparent trend in females but 
not males across age groups suggests a gender difference to this age-related effect, which supports the 
possible protective role of reproductive hormones against ROS. 
1. Alzheimer’s Disease International. 2018. The Global Impact of Dementia: an analysis of prevalence, incidence, cost 
and trends. World Alzheimer Report 2015. London: Alzheimer’s Disease International (ADI), pp.10-27.  
2. Lin, M. and Beal, M. 2006. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature: 443(7113) pp. 
787-795 
 
 
Deblistering tablets from a problem pack 
Matthew Sargent and B Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK.                 
A Penarth community pharmacy reported that patients were encountering difficulty in opening Aspirin 75mg 
Gastro-Resistant Tablets from their blister packs. Patients requested that tablets be removed during 
dispensing and dispensed in traditional bottles. Aspirin, however, is moisture sensitive and these bottles are 
not appropriate. (1) Blister packs are designed to protect solid dosage forms from their manufacture until used 
by a patient. (2) The aim of the research was to investigate the effect temperature on blister pack performance 
and how accessible users find these blister packs.  
A Zwick-Rowell materials testing machine was used to assess and measure the push-through force required 
to break the foil and eject tablets from the problem aspirin packs. These were stored at three different 
temperatures before testing: 4C, 21C and 35C. A pilot trial was conducted by recruiting members of MPharm 
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IV and involving them in removing doses from six different over the counter (OTC) blister pack medicines, 
tablets and hard capsules. Then filling in a questionnaire to rank the pack in terms of build quality and ease of 
use. 
Blister packets stored at 35C required a force of 53.6 N  6.58 N to eject tablets in the push-through test 
compared to those stored at room temperature of 21C which needed 48.4 N  6.95 N. Cooler temperatures 
at 4C had little effect on the opening force and required 48.3 N  6.47 N to open. The pilot trial identified that 
smaller tablets are harder to eject than larger ones and hard capsules. 63% of volunteers had experienced 
similar patient queries regarding difficult to open packs when working in community pharmacy. 
Blister pack performance is reduced when exposed to temperatures that are not recommended by the 
manufacturer and users find blister packs with larger tablets and hard capsules and with thinner lidding had 
the best performance. 
1. British Pharmacopoeia. Gastro-resistant Aspirin Tablets. London: British Pharmacopoeia; 2018 [accessed 8 January 2018]. 
Available from: https://www-pharmacopoeia-com.abc.cardiff.ac.uk/bp-2018/formulated-specific/gastro-resistant-aspirin-
tablets.html?published-date=2017-08-01&text=aspirin+gastro 
2. Swarbrick J. Encyclopedia of pharmaceutical technology. New York: Informa Healthcare; 2007; 2526-2549. 
 
 
Investigating the use of poly(methyl methacrylate)-co-vinylphenyl boronic acid 
particles to sense for lipopolysaccharide 
Dilraj Sarvaiya, N Demertzis and JL Bowen 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, 
CF10 3NB, Wales, UK. 
Lipopolysaccharide (LPS) is a macromolecule, containing multiple sugar molecules and a lipid moiety, found 
on the outer membrane of Gram-negative bacteria.1 LPS acts a mediator in the pathogenesis of sepsis and 
similar conditions.1 Sepsis incidence rates are increasing and it is estimated that the condition costs the NHS 
£2 billion a year.2 Boronic acids are known to form reversible boronate ester bonds with diols in aqueous 
environments.3 The aim of this study was to investigate the use of a boronic acid-containing copolymer to 
detect lipopolysaccharide. 
Methylmethacrylate (MMA) and 4-vinylphenyl boronic acid (VPBA) were polymerised in a mixture of acetone 
and water using single-step surfactant-free polymerisation.4 The resulting copolymer was incubated with 
multiple concentrations of FITC-labelled LPS, alongside controls. The monomer and solvent ratios were varied, 
and pH studies conducted to establish the factors influencing the binding of LPS and enable optimisation of 
the copolymer. The binding performance of each assay was determined using fluorescence spectroscopy.  
The results of the study were largely disappointing on the whole. Only POLY C, containing 900mg MMA and 
100mg VPBA, showed any considerable binding when compared to the control. Surprisingly POLY D, the pure 
MMA polymer, was capable of binding the most LPS when challenged with various concentrations of FITC-
LPS. A greater yield of copolymer was produced as the amount of water in the solvent mixture increased. 
While it would be expected that greater binding would be observed in more basic environments, the result of 
the pH studies suggested that POLY C performed best at pH 6. 
Currently poly(methylmethacrylate)-co-vinylphenyl boronic acid particles cannot be used to efficiently detect 
lipopolysaccharide. No consistent binding between the copolymer and the LPS was observed throughout the 
investigation. Further studies should be conducted for more definitive results. 
1. Brandenburg K, Wiese A. Endotoxins: Relationships between structure, function, and activity. Current Topics in Medicinal 
Chemistry. 2004;4(11):1127-46. 
2. NHS England. Improving outcomes for patients with sepsis - A cross system action plan. 2015. 
3. Vancoillie G, Hoogenboom R. Synthesis and polymerization of boronic acid containing monomers. Polymer Chemistry. 
2016;7(35):5484-95.  
4. Sakalak H, Ulasan M, Yavuz E, Camli ST, Yavuz MS. One-pot synthesis of biocompatible boronic acid-functionalized poly(methyl 
methacrylate) nanoparticles at sub-100 nm scale for glucose sensing. Journal of Nanoparticle Research. 2014;16(12):2767 
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Image and performance enhancing drugs (IPEDs) in sport: Existing knowledge and 
views of pharmacists in Wales 
Susmita Shahi, HM Mittlelberger and R Yemm 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
 
In the past decade, the use of IPEDs has become more widespread.1  Advanced level athletes have useful 
sources, such as their coaches, to obtain advice about IPEDs.2   However, amateur athletes and the public are 
not aware of the legal consequences and health risks of misusing these drugs. Given their role as experts in 
medicines, pharmacists could potentially play an important role in educating the public on IPEDs to overcome 
these issues. In this study, we look into pharmacists’ current knowledge on IPEDs, their confidence level in 
giving advice on these drugs and their interest in receiving training.  
This study was granted ethical approval by the School of Pharmacy and Pharmaceutical Sciences Research 
Ethics Committee. A total of 494 paper-based questionnaires were sent to community, hospital and academic 
pharmacists practicing in Wales. The questionnaire was divided into three sections, which were the 
pharmacists’ background, current knowledge on IPEDs and interest in education. Data was analysed using 
the statistical software, SPSS.  
A total of 119 respondents completed the questionnaire (24.1% response rate). Only 31.9% respondents had 
received formal education on drugs in sport but 40.3% had been approached for advice on drugs in sport. 
When assessed on knowledge about prohibited over-the-counter drugs in sport, only 11.8% were able to 
answer all questions correctly. Only, 13.4% respondents felt confident providing advice on IPEDs to the public. 
A majority of the respondents (79.8%) showed interest in receiving education on IPEDs and felt drugs in sport 
is a public health issue (66.4%).  
It appears that the public use pharmacists for advice on IPEDs but pharmacists are lacking in confidence when 
it comes to providing advice on this matter. Pharmacists are evidently interested in receiving education on 
IPEDs in sport. So, e-learning modules on IPEDs for pharmacists to complete could be developed.  
1. UK Government. Review of Criminalisation of Doping in Sport. 2017 [accessed 3 Jan 2018]. Available from: 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/654240/Review_of_Criminalisation_of_Doping_in_S
port.pdf 
2. Peters C, Schulz T, Oberhoffer R, Michna H. Doping and doping prevention: knowledge, attitudes and expectations of athletes and 
coaches. Deutsche zeitschrift fur sportmedizin. 2009;60(3):73–8. 
 
 
Investigating the potential of an applicator system for reproducible manual 
application of microneedle patches 
Simran Sirpal and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and School of Medicine, Cardiff University, UHW Main Building, Heath Park, Cardiff CF14 4XN, Wales, 
UK. 
Microneedles are being developed as a method of transdermal drug delivery. Microneedles penetrate the 
stratum corneum barrier to create channels for drug delivery to the viable epidermis, to act locally or 
systemically.1 One advantage of microneedles is self-administration, but this would require an administration 
system that ensured reproducible microneedle application. The aim of this study is to develop a simple 
microneedle applicator that will control the forces used to apply “dummy” microneedle patches (patches without 
penetrative microneedles).  
The study was ethically approved. A simple microneedle applicator was identified and fifty participants were 
recruited. Each participant and the researcher placed the “dummy” patches on their forearms and deltoids. 
The applicator was then used by the participant to apply a force to the patches on both themselves and the 
researcher. The force of each application was measured by a digital force gauge. This was repeated 3 times 
on each site. A reflection form was used to gain participant feedback. The data was collated and statistically 
analysed. 
The results from this study were compared to a control study, where manual application i.e. without an 
applicator, was recorded. The variability in application forces was significantly reduced when using an 
applicator, compared to manual application. There were no significant differences between the forces 
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measured when comparing the participants’ gender, age and previous medical training.  The applicator was 
very well received by the participants. 
The applicator was successful at controlling the forces used when applying the microneedle patch. Self-
administration is likely to be more reproducible when using an applicator such as the one in this study. Further 
studies could measure forces using a pressure pad, could investigate other features of the applicator and 
should evaluate applicator function with penetrative microneedles. 
1. Kalluri H, Banga A. Microneedles and transdermal drug delivery. Journal of Drug Delivery Science and Technology. 2009; 19 
(5):303-310. 
 
 
Developing an ex-vivo test method to assess the efficacy of perineal care 
washcloths for incontinence-associated dermatitis (IAD) 
Kristina Swoboda, J-Y Maillard and L Gwynne 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
 
Incontinence associated dermatitis is a prevalent condition most commonly seen in the elderly and those with 
long term care.1  The damaged skin allows opportunistic pathogens to colonize; a risk factor for pressure 
ulcers. There is a lack of well researched treatment options and little information on a treatment strategy.2,3  
Two antimicrobial wipes, a commercially available chlorhexidine 2%(CHX 2%) wipe and a wipe under 
development by the University of Bath (wipe B) were tested against Staphylococcus aureus and Candida 
albicans using an ex-vivo test method involving pig skin. The immediate and residual activity of these wipes 
was explored.     
  
Pig skin samples were prepared and exposed to the microorganisms. The samples were wiped with either the 
CHX 2% wipe or wipe B using a drill and balance to maintain constant pressure and rotation, mimicking real 
life and reducing variability. After exposure to the wipe the samples were placed onto Franz cells and the 
remaining microorganisms were recovered with Universal Neutraliser. The recovered microorganisms were 
enumerated and the Log reduction of CFU/ml calculated. Suspension tests were also conducted using liquid 
extracted from the wipes. Residual activity was investigated where the skin samples were exposed to the 
wipes and incubated for 1 hour, 2 hours, 4 hours or 24 hours before being inoculated and recovering the 
microorganisms.  
 
Promising activity was observed with the CHX 2% wipes with both pathogens in the ex-vivo and in-vitro tests. 
Mechanical removal of C.albicans from skin samples was observed with the control wipe and as such all wipes 
displayed good Log reduction of CFU/ml. The suspension tests showed that wipe B had little antimicrobial 
efficacy. CHX 2% shows residual activity up to four hours.  
 
Chlorhexidine 2% wipes are effective against microorganisms that cause IAD and provide residual protection. 
More research should be conducted on the activity of Wipe B.  
 
1. Gray M. Optimal management of incontinence-associated dermatitis in the elderly. Am J Clin Dermatol. 2010;11(3):201-10. 
2. Corcoran E, Woodward S. Incontinence-associated dermatitis in the elderly: Treatment options. Br J Nurs. 2013;22(8):450-7.  
3. Voegeli D. Moisture-associated skin damage: An overview for community nurses. Br J Community Nurs. 2013;18(1):6-12.  
 
 
Exploring technology and communication needs in a community pharmacy 
Joanna Sykes, M Gumbleton and MW Smith 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
 
Healthcare technology is advancing, enabling the pharmacist to dedicate more time to patient-oriented 
services, including medicines optimisation services.1 Community pharmacy staff collaborate with healthcare 
professionals (HCPs) across the entire healthcare system, creating a need for information technology (IT) and 
communication systems support.2 Effective communication improves patient outcomes and work efficiency, 
and reduces hospital admissions, polypharmacy and drug wastage.3,4 The aim of this study is to evaluate the 
communication needs in community pharmacy and explore how technology may assist in bridging 
communication gaps. 
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A literature review of online databases, such as Web of Science, was conducted. Findings were used to create 
a topic guide, piloted in a focus group (FG) with community pharmacists (n=5). This was followed by two FGs 
with pharmacists (first FG n=5, second FG n=6). Inductive thematic analysis was used to derive themes and 
sub-themes from focus groups.  
Themes derived from FG data included communication methods, importance and implications of 
communication, communication with other settings, and possible improvements for communication. 
Pharmacists’ views relating to communication with patients, HCPs and internal staff were explored, and 
common forms of communication such as email, telephone, fax, written, patient medical record (PMR) system, 
and verbal were identified. Good communication between HCPs, patients and pharmacy staff was percieved 
to improve patient safety. Participants identified patient confidentiality as a communication barrier and thought 
that there is inadequate communication between healthcare settings.  
This study identified a range of perceived unmet communication needs in community pharmacy including 
communication around monitored dosage systems, access to patient records across health settings, and 
connectivity of pharmacy IT systems. Communications and hospital discharges should have a uniform 
approach and standardised format to collect relevant information. All communication mediums should be 
secure to protect patient data.  
1. Smith J, Picton C, Dayan M. Now or Never: shaping pharmacy for the future. 2013 [accessed 16 Oct 2017]. Available from: 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Publications/Now%20or%20Never%20-
%20Report.pdf 
2. Pharmacy Voice, Pharmaceutical Services Negotiating Committee, Royal Pharmaceutical Society. Community Pharmacy Forward 
View. 2016 [accessed 16 Oct 2017]. Available from: http://psnc.org.uk/wp-content/uploads/2016/08/CPFV-Aug-2016.pdf 
3. Weissenborn M, Haefeli W, Peters-Klimm F, Seidling H. Interprofessional communication between community pharmacists and 
general practitioners: a qualitative study. Int J of Clin Pharm. 2017;39(3):495-506. DOI: 10.1007/s11096-017-0450-6 
4. Oboh, L. Communication during transfer of care of older people. Pharm J. 2016;296:7889. DOI: 10.1211/PJ.2016.20200982 
 
 
Investigating application devices for microneedles to improve patient compliance 
and achieve consistency in force applied 
Callum Thomas and SA Coulman 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK and School of Medicine, Cardiff University, UHW Main Building, Heath Park, Cardiff CF14 
4XN, Wales, UK. 
Microneedle technology was envisioned several decades ago, however the pace of research has increased in 
the last 10 years. Microneedles have many advantages, however a significant disadvantage includes patient 
reservations regarding self-application and whether it has been applied correctly.1 The study aim was to use 
a simple applicator device on 50 individuals and to compare the forces with previous data where no applicator 
was used. 
Fifty individuals were recruited using snowball sampling. Volunteers completed a data collection form 
(specifying gender, age and medical experience). They were then asked to apply a dummy microneedle using 
the applicator to themselves (deltoid and forearm) and to the researcher at the same sites. The forces used 
(Newton’s) were recorded by the researcher and hidden from the volunteer. Variation in forces applied between 
gender and medical experience were measured in SPSS using an independent T-test, whilst age variations 
were analysed using a one-way ANOVA and Tukey test. A questionnaire was provided that allowed individuals 
to rate their experience (1-10) regarding the applicator as well as to provide feedback about their thoughts on 
microneedle technology.  
Results obtained showed a significant improvement when using the applicator. For self-application the mean 
force increased from 21.61N to 27.6N with a reduction in the standard deviation from 12.44 to 4.34. Similar 
findings were obtained when participants applied the microneedle device to the researcher.  Statistically 
significant variation in forces applied between males and females (p=0.01) should be investigated further. 
Eighty percent of those who answered the questionnaire (n=25) expressed a willingness to use microneedles 
in the future, contrary to prior studies which had shown patient tentativeness.2  
This study has demonstrated that the use of an applicator is beneficial in improving the reproducibility of forces 
applied to microneedles, and consequently may increase patient confidence in self-applying microneedles.  
1. Bariyaal, SH et al. 2011. Microneedles: An Emerging Transdermal Drug. Journal of Pharmacy and Pharmacology 64(1), pp. 11-29. 
2. Norman, JJ et al. 2014. Microneedle Patches: Usability and Acceptability for Self-Vaccination Against Influenza. Vaccine; 32(16), 
pp. 1856-1862. 
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Patients’ perceptions, concerns and expectations of stem cell therapy in 
Parkinson’s disease 
Chloe Turner and EL Lane 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VIII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Parkinson’s disease (PD) is a progressive neurodegenerative condition. Current first line drugs produce 
unwanted side effects, becoming less effective with disease progression. The lack of available disease 
modifying strategies, creates need for more effective therapies.1 Stem cell research has led to a novel 
therapeutic approach in PD, which is becoming close to clinic.2   Despite the benefits of patient engagement in 
research, there are limited studies in the field exploring small unrepresentative samples.3 This project aims to 
uncover how PD patients perceive this approach as a future therapy and identify concerns. 
A questionnaire was constructed and emailed to people in the Parkinson’s UK research support network, 
receiving 527 responses. A preliminary analysis led to focus groups which recruited 18 participants also from 
the research network. Qualitative and quantitative questionnaire data was analysed using SPSS. The focus 
groups were transcribed, then analysed thematically.    
Within themes, willingness to consider therapy and expected benefits related to stage of disease. Therapy 
barriers centred around side effects and surgery risk. The individuality of PD symptoms was expressed along 
with trust in consultant opinion. In contrast to the focus groups, questionnaire analysis found no relationship 
between the stage of disease and whether participants would consider therapy or trials. Participants diagnosed 
for 2-5 years were more likely to consider therapy if the minimum benefit was a mild improvement in motor and 
other symptoms. Therapy motivation varied from self-benefit to benefit of both self and others with a small 
proportion having purely altruistic motivation. 
Despite the barriers, participants in this study were open to the possibility of considering this novel approach 
as a future therapy. With unrealistic expectations present among participants, further work should consider the 
best practice of communicating the relevant information and support to prospective PD patients of stem cell 
therapy and clinical trials. 
1. Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. doi:10.1016/S0140-6736(14)61393-3 
2. Lindvall O, Björklund A. Cell Therapy in Parkinson's Disease. NeuroRx. 2004;1(4):382–393. doi: 10.1602/neurorx.1.4.382 
3. Peddie VL, Porter M, Counsell C, Caie L, Pearson D, Bhattacharya S. ‘Not taken in by media hype’: how potential donors, 
recipients and members of the general public perceive stem cell research. Hum Reprod. 2009; 24(5): 1106-1113. doi: 
10.1093/humrep/den496  
 
 
Does UK-grown Artemisia annua produce Artemisinin? 
Eve Walker and AW White 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Natural products have been used throughout history1 and Artemisia annua is an ancient Chinese herb that has 
found a use in contemporary society.2 Artemisinin is a compound extracted from A. annua that has caught the 
attention of many, following the research by Professor Youyou Tu.3 A. annua has be grown in different 
countries, other than China4, to see if more or less artemisinin is produced comparatively as a result of this 
environmental change. This project looks to see if UK-grown A. annua can produce sufficient artemisinin for 
extraction, leading to possible large-scale UK growth for pharmaceutical purposes. 
Samples of UK-grown A. annua were separated into leaf, stem and flower plant material. Extraction was carried 
out using both, soxhlet extraction and magnetic stirrer extraction. Multiple solvents were used for their polarity: 
hexane, ethyl acetate and methanol. Prep thin layer chromatography was then carried out to separate the 
extracts into fractions so a more detailed electrospray ionisation mass spectrometry reading could be 
produced. 
Artemisinin was successfully detected in several extracts from the leaf and flower plant materials. Positive 
results were found in Hexane Flower Stir 2, Ethyl Acetate Flower Stir 1 and Hexane Flower Soxhlet 3 for the 
flower plant material.  For the leaf material, artemisinin was found in Ground Leaf Soxhlet Hexane 6,7,9, and 
10. However there was only a trace quantity detected. There appeared to be a large quantity of an unknown 
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compound at m/z 248 found throughout the plant material and in different solvent systems, which warranted 
further investigation.  
Despite the success of extracting and identifying artemisinin from UK-grown A. annua, only a minimal amount 
of artemisinin was located. A conclusion can be made that A. annua is not a viable option for large-scale growth 
in the UK, with regards to artemisinin being the main compound required. 
1. Harvey, A. (2008). Natural products in drug discovery. Drug Discovery Today, 13(19-20), pp.894-901. 
2. van der Kooy, F. and Sullivan, S. (2013). The complexity of medicinal plants: The traditional Artemisia annua formulation, current 
status and future perspectives. Journal of Ethnopharmacology, 150(1), pp.1-13. 
3. Su, X. and Miller, L. (2015). The discovery of artemisinin and the Nobel Prize in Physiology or Medicine. Science China Life 
Sciences, 58(11), pp.1175-1179. 
4. Bilia, A., Santomauro, F., Sacco, C., Bergonzi, M. and Donato, R. (2014). Essential Oil of Artemisia annual: An Extraordinary 
Component with Numerous Antimicrobial Properties. Evidence-Based Complementary and Alternative Medicine, 2014, pp.1-7. 
 
 
Exploring sampling methods to ensure surfaces are free of dry biofilms 
Samuel Watkins, K Ledwoch and J-Y Maillard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
A biofilm is a complex aggregation of microorganisms encased in extracellular polymeric substances (EPS), 
which are attached to a surface.1  Biofilms exist in wet and dry states. Biofilms are generally found in wet states 
although it has been demonstrated dry biofilms are on many hospital surfaces.1 Bacteria within biofilms are 
highly resistant to antimicrobials and cause healthcare associated infections (HCAI). Fit to purpose sampling 
tests are needed to establish the cleanliness of hospital surfaces. The aim of the study was to establish the 
most effective sampling method at dry biofilm detection from hospital surfaces. 
Experiments on hospital folders and keyboards were conducted. Samples were stroked with sterile swabs, 
three different wipes and sponges. The same pattern of sampling was used for each method and each material. 
A contact plate was also tested but due to its nature, not in the same way. After sampling, each material was 
processed using two methods. In the first method, the material was placed into a stomacher with nutrient broth, 
homogenised then drop-plate counted to calculate colony forming units per ml (CFU/ml) detected from the 
hospital surface. The second method involved placing the material into nutrient broth and observing for a 
turbidity change following incubation at 37C. 
The contact plate and wipe 1 were ineffective at recovering bacterial cells from surfaces. Wipe 2, wipe 3 and 
the sponge were most effective at recovery of dry biofilm. Of these, using the stomacher method, the sponge 
recovered the most bacteria, followed by wipe 3 then wipe 2. Overall, the sponge was the most effective 
method at recovering dry biofilms from surfaces. 
All materials were efficient at recovering a high concentration of biofilms from a control, however when 
reflecting real-world concentrations, many methods were poor. Quick and reliable methods for dry biofilm 
detection need to be developed to combat hospital acquired infections. 
1. Vickery K, Deva A, Jacombs A, Allan J, Valente P, Gosbell IB. Presence of biofilm containing viable multiresistant organisms 
despite terminal cleaning on clinical surfaces in an intensive care unit. Journal of Hospital Infection.80(1):52-5. doi: 
10.1016/j.jhin.2011.07.007 
 
 
Optimising an iPad based app to record electronic Patient Reported Outcome 
Measures (ePROM) for Parkinson’s disease 
Luke Wesley, A Kharladi and EL Lane  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff, CF10 
3NB, Wales, UK. 
People with Parkinson’s disease (PwP) have a mixture of motor and non-motor symptoms (NMS), however 
non-motor symptoms are often overlooked and left untreated in the short appointments with the specialists.1 
This is a major problem as the non-declaration of these symptoms can lead to suboptimal care, an increased 
cost of care and a reduced quality of life.2 An iPad app has been developed to help identify these NMS and 
provide extra information to aid the specialist and has promising initial results.3 The aim of the study is to 
evaluate the current app and provide recommended changes in order to more effectively manage PD. 
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Ethical approval was obtained and 5 focus groups were conducted within South Wales. The focus groups 
included a mix of PwP and their carers and also participants of a similar demographic. These were recorded 
then later transcribed and analysed using transcript-based analysis. Inductive and deductive techniques 
grouped themes from all the focus groups and data was labelled, categorized and interpreted in order to identify 
themes. Finally a combined analysed with the previous research was completed to asses new themes and 
determine saturation.  
Participants had a good knowledge of using technology but insufficient confidence could prove a barrier to the 
continued use. Data safety was a concern and some PwP were not comfortable using the iPad in the waiting 
room. Font size, expanding the NMS questions and additional sections were the main alterations discussed. 
Participant’s attitudes towards technology in a healthcare environment were also reviewed. 
Participants found that the iPad app could be beneficial in clinics. Participants identified some potential 
changes and felt additional sections could progress the app to its full potential. Further exploration of the 
implemented changes and additional sections is needed to ensure the app is fit for use.  
1. Chaudhuri, K. R. et al. 2006. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurology 5(3), pp. 
235-245. doi: 10.1016/S1474-4422(06)70373-8 
2. 2.Chaudhuri. K. R. et al. 2010. The nondeclaration of nonmotor symptoms of Parkinson’s disease to healthcare professionals: An 
international study using the nonmotor symptoms questionnaire. Movement Disorders 25, pp. 704-709. doi: 10.1002/mds.22868 
3. Mohammed, B. et al. 2016. iPad-based preassessment questionnaires are feasible in a Parkinson’s service [abstract]. Movement 
Disorders 31 (suppl 2). Available at: www.mdsabstracts.org/abstract/ipad-based-preassessment-questionnaires-are-feasible-in-a-
parkinsons-service 
 
 
EVALUATION OF THE DISCHARGE MEDICINES REVIEW SERVICE (DMR) 
Ismael Yasin, ML Hughes and KL Hodson 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VIII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Medication errors occur during the transition of care between different providers.1 Therefore, the Discharge 
Medicines Review, an advanced pharmacy service was introduced in 2011. The service was developed by 
utilising the pre-existing Medicines Use Review framework.2 Some of the aims and desired outcomes of the 
service are risk reduction in relation to medication errors and adverse drug events, improve communication 
between parties involved with care transition.3 The aim of this project is to establish a new DMR baseline in 
relation to the previous evaluation of 2014 to identify areas for service improvement.   
Data provided by the National Electronic Claim and Audit Forms from DMR payment claims was used to 
perform secondary data analysis. The data was imported into SPSS, quality assured and then analysed 
descriptively to identify trends as well as changes at times when amendments to the service were introduced. 
Statistical analysis was then applied to determine whether the identified changes were significant.   
Since 2013, 37425 DMRs were carried out in Wales. The monthly numbers have steadily but slowly increased. 
Furthermore, approximately 20-30% of contractors are making claims although almost all contractors in Wales 
are accredited. The data does not contain information regarding individual contractor claims, therefore it is 
difficult to determine the reasons for the lack of engagement.  
In conclusion, the DMR service is still underutilised by healthcare providers. The reasons for this cannot be 
determined by the current available data, however it can be suggested that future engagement with contractors 
in the form of interviews and questionnaires will identify these reasons. Furthermore, the introduction of an 
electronic system has shown to have a significant effect on the DMRs completed. It shows a promising increase 
in engagement with the service which has the potential to enhance the health and wellbeing patients during 
times when NHS resources are limited. 
1. Maxwell K, Harrison S, Scahill S , Braund R. Identifying drug-related problems during transition between secondary and primary 
care in New Zealand. Int J Pharm Pract.. 2013 [Accessed: 5 November 2017]. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23418995.  
2. Hodson K, Blenkinsopp A, Cohen D, Longley M, Alam F, Davies P, et al. 2014. Evaluation of the Discharge Medicines Review 
Service. 2014 [accessed: 5 November 2017]. Available from: http://www.cpwales.org.uk/Contract-support-and-IT/Advanced-
Services/Discharge-Medicines-Review-(DMR)/Evaluation-of-the-DMR-Service/Evaluation-of-the-DMR-service.aspx 
3. Community Pharmacy Wales. The Discharge Medicines Review Service. Wales; 2011 [accessed: 8 November 2017]. Available 
from: http://www.cpwales.org.uk/Contract-support-and-IT/Advanced-Services/Discharge-Medicines-Review-(DMR)/Overview-of-
the-DMR-Service.aspx  
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The following abstracts have been withheld as they have been or will be published 
elsewhere, and/or due to intellectual property or confidentiality issues: 
 
 
An evaluation of the emergency hormonal contraception enhanced service use over 
the last 5 years via the specified PGD in community pharmacies across Wales 
Sarah Alzetani, R Hayward and E Mantzourani  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK.  
 
Binary drug loaded contact lenses to treat acanthamoeba keratitis  
Laura Emily Bolger and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK.  
 
Targeting zinc transporters to inhibit breast cancer cell division 
Nawshin Chowdhury and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK.  
 
A Drug-Loaded Thermosetting Hydrogel to Treat Alveolar Osteitis 
Angharad Crack and CM Heard 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK.  
 
The Development of Mucoadhesive Films to Treat Periodontitis 
Mali Dafydd, CM Heard and EL Board-Davies 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK. 
  
 
Exploring the characterisation, biological function and therapeutic potential of 
receptor clustering 
 
Emily Doe and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK.  
 
An Evaluation of Emergency Hormonal Contraception Supply via a Patient Group 
Direction, as Part of an Enhanced Service in Community Pharmacies in Wales, Over 
the Past 5 Years  
Rebecca Hayward, S Alzetani and E Mantzourani 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK.  
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The reconstitution of functional protein from cell membrane fragments into droplet 
interface bilayers 
Lydia Holloway and OK Castell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK.  
 
Comparing HER family receptor levels, activation, and signalling in HER2+ and 
trastuzumab resistant breast cancer 
 
Ruth Jones, JM Wymant and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK.  
 
Serum starvation and in vitro cell models of drug delivery: where is the 
consistency? 
 
Abbey Lloyd and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK.  
 
Design and manufacture of a fluorescent Nano-pH probe for cell biology and drug 
delivery research 
Rhys Parry, E Sayers and AT Jones 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK.  
 
Development of a 3D Printing Platform for Tissue Bioprinting 
 
Cameron Pool, K Harvey, D Baxani, A Moukachar, OK Castell, SA Coulman and CP Thomas. 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB, Wales UK.  
 
Optimization of print parameters to develop 3D-bioprinting using microfluidics 
 
Katherine Sloan and OK Castell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff  
CF10 3NB Wales UK. 
 
 
Targeting zinc transporters to inhibit breast cancer cell division 
 
Abigail Thompson and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK. 
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Exploring the tumour-stromal interactions to identify novel clinical markers for 
prognosis and therapeutics in colorectal cancer 
Ubah Abdi1 and V Meniel2 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK. and 2European Cancer Stem Cell Research Centre, Cardiff University, Hadyn Ellis Building, Maindy 
Road, Cathays, Cardiff, CF24 4HQ, Wales, UK. 
Colorectal cancer remains one of the most common cancer types in the UK, accounting for over 16,000 deaths 
every year. Although advancements have been made with the production of targeted therapies, treatment still 
relies heavily on chemotherapeutics. The tumour microenvironment (TME) is becoming an increasingly popular 
target for novel clinical targets due to its significant role in carcinogenesis. Several markers have been selected 
to validate any tumour-stromal interactions in tissue and RNA samples from colorectal patients. This was 
determined with the use of immunohistochemical staining and gene expression analysis. Collagen expression 
was found to be significantly higher in the stromal compartment than in the epithelial (p value < 0.0001). PTEN 
analysis of two cohort studies showed contradicting results and CD26, ZFP64 and CLIC3 had different levels 
of expression in the stroma although they were not significant. 3D organoid culture models of colorectal cancer 
were then used utilised to decipher the role of collagen in the stroma. Increasing collagen I concentrations in 
the Matrigel did not affect cell growth. These results indicate some role for stromal interactions in 
tumourigenesis and invasion. Further work will need to be conducted to truly validate these results and possibly 
identify other clinical markers related to TME regulation for the treatment of colorectal cancer.  
 
 
Src family kinases as regulators of breast cancer cell migration. 
Zainab AlQallaf and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK. 
 
1 in 8 women are diagnosed with breast cancer in England and Wales, and breast cancer death rates are 
increasing despite the advances in treatments. Aggressive breast cancers, particularly triple- negative breast 
cancers (TNBC) and endocrine resistant cancers raise a lot of concerns as we face challenges in treating 
those cancer types. Src family kinases (SFKs) are non-receptor tyrosine kinases that phosphorylate various 
proteins and play a major part in cellular signaling pathways such differentiation, migration, invasion and 
proliferation. TNBC and endocrine resistant breast cancers were established to have elevated expression 
levels of SFKs which contribute to their aggressive and metastatic phenotype. Therefore, the aim of this study 
was to investigate whether metastasis is governed by individual SFKs, particularly Src, Lyn and Fyn, or whether 
it is a phenotype that is caused by combined effects of the three SFKs. This was established by testing the 
effects of short-interfering RNA (siRNA) and the broad Src inhibitor AZD0530 on SFK gene and protein levels, 
on the FAK and MAPK protein levels, and also on the proliferation and migration in three cell lines (MDA-
MB231, MDA-MB468, and a 3-year Tamoxifen-resistant cell model of MCF7 knows as TOYA). Wounding 
assays showed that AZD0530 was able to induce migration inhibition in MDA-MB231 in a dose dependent 
manner, with no effect on cell proliferation. Furthermore, Western blotting showed that AZD0530 had a dual 
action by decreasing phosphorylated Src total Lyn protein expression, while Fyn levels remained unchanged. 
In contrast, siRNA treatments was able to knockdown individual SFKs however, Fyn was not fully silenced. 
Moreover, cell migration in the MDA-MB231 treated with siRNA was not affected, which could be due to 
maintained levels of phosphorylated FAK and MAPK, that contribute to cell survival and migration. 
Interestingly, Fyn siRNA caused a 10 fold increase in phosphorylated FAK expression. This lead to the 
conclusion that Fyn kinase could be the member of SFKs that majorly contribute to the aggressive phenotype 
in breast cancers, and that individual SFKs knockdown was not as effective as AZD0530 in inhibiting cell 
migration.  
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TEAD Signalling in Endocrine Resistant Breast Cancer 
Tara Al-Taie and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff 
CF10 3NB, Wales UK. 
 
Resistance can be acquired during antihormone (AH) therapy of ER+ breast cancer culminating in relapse. 
VGLL1 is upregulated and growth-contributory in some novel cell models resistant to prolonged AH exposure. 
VGLL1 is a coactivator for TEAD1-4 transcription factors, which also interact with further coactivators regulated 
by the Hippo pathway. TEAD signalling has not been explored in AH resistance and this comprised the project’s 
overall aim using AH resistant cell lines and clinical breast cancer samples.  
Affymetrix microarray analysis using Genesifter and RT-PCR monitored ER and VGLL1 in luminal A and B-
derived faslodex, tamoxifen or oestrogen-deprivation resistant models and also determined the most promising 
deregulated mRNA profiles for further VGLLs, TEAD1-4 and Hippo elements. Immunohistochemistry was 
optimized using a pan-TEAD antibody, applied to 93 clinical breast cancers and HScored to explore TEAD 
versus signalling biomarkers and clinicopathology. KM plotter determined any TEAD members related to 
shortened relapse-free survival (RFS) in endocrine-treated patients.  
VGLL1 was induced only in luminal A-derived models that lost ER during prolonged AH. VGLL3 and TEAD1 
were induced in faslodex resistant models, while TEAD4 modestly increased in further antioestrogen resistant 
lines. Some Hippo pathway changes (TAZ/YAP gain; tumour-suppressive element decline) were found 
primarily in antiestrogen resistant cells. Nuclear TEAD was expressed in most clinical samples. There were 
few clinicopathological associations, but TEAD correlated with growth factor signalling biomarkers (e.g. HER4, 
MAPK activity, Fos in ER+ and STYK1 in ER- patients respectively). TEAD 1 and 4 mRNA related to shortened 
RFS in luminal A patients.  
This considerable deregulation of VGLL/TEAD/Hippo pathway signaling suggests a contribution to AH 
resistance in vitro, and also contribution to acquisition of resistance in luminal A patients possibly involving 
interplay with growth factor pathways. With further investigation, TEAD signaling might provide a new 
therapeutic target in AH resistant breast cancer.  
 
 
The effect of Hepatocyte Growth Factor, Paclitaxel (Taxol), Selenium and Gamma 
Linoleic Acid on Tight Junctions and Metastases of Breast and Lung Cancer 
Kulsoom Negris Zara Amar1 and T Martin2 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK. and 2Cardiff-China Medical Research Collaborative, School of Medicine, Cardiff University, UHW Main 
Building, Heath Park, Cardiff, CF14 4XN, Wales, UK. 
Lung cancer and breast cancer are leading causes of cancer related death worldwide. More so than primary 
brain tumours, breast and lung cancer associated brain metastases are diagnosed. Therefore, the role of tight 
junctions in cancer metastases have been investigated with the aim to find a way to prevent breast and lung 
cancer associated brain metastases. The tight junction were modulated using tight junction strengthening, 
disrupting and chemotherapeutic agents. The expressin of the tight junction proteins Claudin-1 and Zo-1 were 
observed to determine the tight junction morphology, because these proteins are normally expressed when 
tight junctions are present and strong. The weaker tight junctions get, the lower these tight junction proteins 
are expressed.  
Tissue culture, transepithelial resistance and immunofluorescence procedures were used to carry out this 
study. Transepithelial resistance gave a p-value<0.05, therefore, showed significant results between treatment 
with agents and the modulation of tight junctions. Furthermore, immunofluorescence also showed that HGF 
strengthens the tight junctions by increasing the expression of claudin-1 and zo-1; Taxol protected the tight 
junctions without strengthening or disrupting the tight junctions, thus, maintaining stable claudin-1 and zo-1 
expressions; and finally, GLA and Selenium disrupted tight junctions whereby suppressing the expression of 
tight junction protein claudin-1 and zo- 1. This study gave only preliminary results, and further studies involving 
methods such as ECIS is suggested to achieve more reliable results, and the development of new brain 
metastases management strategies.  
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Examining the Activation and Targeting of Zinc Transporter ZIP7 in Breast Cancer 
Iain L Ballantine and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK. 
ZIP7 (SLC39A7) is a zinc transporter of the LIV-1 subfamily, it is responsible for the transportation of zinc 
stores in the endoplasmic reticulum. ZIP7 has also only been recorded to be located in the endoplasmic but 
studies of fluorescent microscopy of transfected wt ZIP7 has always shown a perinuclear region which is not 
normal for an ER located protein. ZIP7 has also been associated with MAPK, mTOR and PI3K pathways in 
breast cancer, ZIP7 overexpression along with its Mediated zinc release has also been shown to causes 
phosphate inhibition in aggressive forms of Anti-hormone breast cancer. High levels of Zinc in the nucleus has 
been linked to DNA replication which is important for mitosis in cells. Yet there is no known zinc transporter 
which actively transports zinc into the nucleus. Due to ZIP7s perinuclear ring our aim is to investigate ZIP7 
localization on the inner nuclear membrane which would allow it access to the nucleus and it could potentially 
be the zinc transport for the nucleus.  
We used fluorescent microscopy on three different microscopes to image the different coverslips of MCF-7 
cells transfected for wt ZIP7 and tagged for ZIP7 and markers of the inner nuclear membrane. The results of 
the microscopy were promising with some evidence of localization of ZIP7 and important nuclear membrane 
bound proteins: Lamin B receptor, Lamin A/C and Emerin.  
Our data shows very positive results of ZIP7 localizing in the inner nuclear membrane, but further analysis 
through the use of other inner nuclear membrane proteins is required or through the use of electron 
microscopy. The confirmation of ZIP7 being located in the Inner nuclear membrane could influence the drug 
discovery targeting ZIP7 in Anti-hormone breast cancer.  
 
 
Analysing a novel series of fluorinated antiandrogens for prostate cancer treatment 
Laurie Elin Davies1 and A Dart2 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK.and 2Cardiff-China Medical Research Collaborative, School of Medicine, Cardiff University, UHW Main 
Building, Heath Park, Cardiff, CF14 4XN, Wales, UK. 
 
Prostate cancer is androgen-dependent and a major cause of male morbidity and mortality worldwide. 
Moreover, better non-steroidal antiandrogens are urgently required to treat it because the current clinical 
standards of bicalutamide and enzalutamide have widespread resistance and only moderate antiproliferative 
effects. Fortunately, the insertion of lipophilic fluorine atoms can improve the binding affinity, pharmacokinetics 
and physiochemical properties of anti-cancer drugs. Thus, this project aimed to see if a novel series of 
fluorinated bicalutamide analogues were more effective at treating prostate cancer than bicalutamide and 
enzalutamide in vitro.  
AR-dependent LNCaP cells and AR-independent PC3 cells were treated with twenty-four fluorinated 
antiandrogens (A-X), bicalutamide and enzalutamide at 0-100μM for 96 h in triplicate. Percentage cell viability 
was normalised to DMSO using MTT assays, and IC50 values calculated using non-linear regression in 
GraphPad Prism v6.01. The effect of the most promising compounds - I, J and O -, upon relative PSA 
expression and the cell cycle in LNCaP cells were then analysed through qPCR and FACS after PI-staining.  
Regarding LNCaP IC50 values, One-Way ANOVA with Tukey’s HSD post-test showed that compound I 
differed significantly to bicalutamide (p=<0.05). Kruskal-Wallis with Dunn’s post-test then showed that 
compound J differed significantly to bicalutamide (p=<0.01) and enzalutamide (p=<0.05). Compounds I, J and 
O also downregulated PSA expression during qPCR. Furthermore, compound O caused slight DNA 
fragmentation during FACS analysis, but did not produce a statistically significant dose- response.  
Regarding PC3 IC50 values, Kruskal-Wallis with Dunn’s post-test showed that compound I (p=<0.05) and 
compound J (p=<0.001) differed significantly to bicalutamide, and compound J to enzalutamide (p=<0.05).  
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Thus, novel fluorine modifications have made compounds I and J significantly stronger AR-antagonists than 
bicalutamide and enzalutamide, with an additional unknown mechanism of action due to their activity in the 
AR-negative PC3 cell line which should be explored in future work.  
 
 
Exploring mechanisms of Herceptin resistance induced by prolonged endocrine 
treatment in breast cancer 
Lauren Evans and JMW Gee 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK. 
Prolonged endocrine therapy is a mainstay treatment for oestrogen receptor-positive (ER+) breast cancer, 
encompassing both luminal A (ER+/ERBB2-) and luminal B (ER+/ERBB2+) patients. Unfortunately, 
approximately 40% of ER+ patients acquire resistance to endocrine therapy. Both luminal A and B tumours 
may, in some patients, be treated with Herceptin (potentially alongside further antihormones) to control such 
relapse. Unfortunately, however, many patients show only limited Herceptin responses. Intriguingly, prolonged 
endocrine treatment is capable of inducing Herceptin resistance in vitro, although the underpinning 
mechanisms remain unknown. This project aimed to identify changes in candidate growth factor (ERBB) or 
non-candidate signalling that may contribute to antihormone-promoted Herceptin resistance by studying 
prolonged endocrine-treated luminal A- (tamoxifen) and luminal B- derived (Faslodex) breast cancer cells in 
vitro.  
Long-term antihormone-promoted Herceptin-resistant (TAMRLT; FASRLT) and matched Herceptin-
responsive (TAMR; BT474(con)) lines were studied under basal conditions or following 7-day Herceptin. 
Affymetrix 1.0ST microarray analysis and RT-PCR discriminated deregulated basal mRNA expression of 
candidate ERBB receptors. Western blotting or ICC was used to investigate protein expression, activation, and 
localisation for deregulated ERBB2, ERBB4, downstream kinases, and ER. Transcriptome interrogation using 
bioinformatic tools was employed to identify non-candidate pathways.  
Herceptin significantly downregulated ERBB2 in TAMRLT and TAMR cells; however, this was not seen in 
FASRLT contrasting the matched Herceptin-responsive cells. Prolonged antihormone treatment promoted a 
shift in ERBB signalling away from ERBB2 (TAMRLT) and ERBB3/pAKT (FASRLT) towards increased ERBB4 
in both Herceptin resistant models, which also retained MAPK activity and lost ER. Moreover, non-candidate 
metabolic processes and NOTCH signalling were significantly induced in TAMRLT and FASRLT, respectively. 
The induced candidate and non-candidate signalling may feasibly underpin antihormone-induced Herceptin 
resistance in luminal A and B breast cancer cells. Findings from this project provide avenues for future 
therapeutic exploration in vitro, and perhaps ultimately in the clinic, with pan- ERBB and γ-secretase inhibitors. 
 
 
 
Investigating the Differential Effects of OH14+/-TRAIL in the Bulk and Stem.MCF-7 
Cell Population 
Adam Harvey1 and R Clarkson2 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK and 2School of Biosciences, Cardiff University, The Sir Martin Evans Building, Museum Avenue, Cardiff, 
CF10 3AX, Wales, UK. 
 
Breast cancer is the second leading cause of cancer-related mortality worldwide in women. Intra-tumour 
heterogeneity is presumed the primary cause of therapeutic resistance and disease progression. Breast cancer 
stem cells (bCSCs) are hypothesised to drive both carcinogenesis and intra-tumour heterogeneity. Ensuring 
the therapeutic elimination of these cells is essential in preventing relapse and metastasis. The inhibition of 
the endogenous apoptosis inhibitor; cFLIP, selectively sensitises bCSCs to TRAIL- induced apoptosis. 
However, this does not translate to the bulk cell population of a tumour. This study investigated whether the 
inhibition of the endogenous inhibitors of apoptosis proteins (IAPs) could sensitise the bulk cell population to 
the effects of TRAIL and a newly formulated cFLIP inhibitor, called OH14. The differential protein expression 
of key apoptotic components were compared between the bulk and stem population of an MCF-7 cell line 
using Western blot analysis. In addition, different combinations of OH14, TRAIL and SMAC mimetic were 
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tested on the stem and bulk population. The cell viability of the bulk population was measured by CellTitre-
blue assay, while the tumoursphere and colony forming capacity of bCSCs were measured with both 
tumoursphere and colony forming assays. The expression of cIAP1 was significantly higher in the bulk 
population compared to the stem population. Furthermore, the use of a SMAC mimetic sensitised the MCF-7 
bulk population to OH14/TRAIL. However, contrastingly the SMAC mimetic increased both tumoursphere and 
colony formation.  
In conclusion, the SMAC mimetic alleviated apoptosis inhibition and sensitised the bulk population to 
OH14/TRAIL, however enriched the stem population. These differences in cell responses to therapeutics 
highlight the importance in considering these differences when designing therapeutics to prevent both tumour 
growth and metastasis.  
 
 
Investigating the efficacy of a cFLIP inhibitor in pancreatic cancer cell lines 
Emma Johnson1 and R Clarkson2 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK and 2School of Biosciences, Cardiff University, The Sir Martin Evans Building, Museum Avenue, Cardiff, 
CF10 3AX, Wales, UK. 
Pancreatic ductal adenocarcinoma (PDAC) is a notoriously difficult disease to treat with a bleak outlook for 
those who are diagnosed. It progresses in a stepwise manner, which gives the opportunity for patients to be 
genotypically profiled and thereby treated in a targeted manner. The TRAIL pathway is upregulated in 80% of 
PDAC patients and is able to selectively induce apoptosis in cancer cells. TRAIL agonists have been 
developed but results in clinical trial have been disappointing, possibly as a result of the TRAIL pathway also 
causing migration, proliferation and survival. OH14 is a targeted therapy which is believed to bind to cFLIP 
allowing TRAIL-induced cleavage of caspase 8 and thereby initiating apoptosis. This project aimed to assess 
the efficacy of OH14, confirm the mechanism behind its action, clarify aspects of the TRAIL pathway and to 
compare the effect of OH14 and TRAIL treatments on cell migration in the surviving cell population.  
Primary cell lines derived from resected pancreatic tumours were used to determine OH14 efficacy. These 
were selected from as potentially TRAIL responsive based on the expression levels of TRAIL-R related 
pathway components. Cell Titre Blue was used as an indirect indication of apoptosis in cell lines and Boyden 
chamber assays were used to measure migration.  
OH14 resulted in a loss of viability increasingly over time when given to PDAC cells (15-23% 48h, 32-35% 
72h). Furthermore, there was cross talk between the different arms of the TRAIL pathway. Apoptosis induction 
by OH14 was partially attributed to caspase 8 interaction, but pharmacological inhibition of caspases failed to 
completely rescue the loss of cell viability, suggesting that other survival-related pathways may also be affected 
by OH14. OH14 treatment of pancreatic cancer cells left a significantly less migratory population than TRAIL 
treated cells, demonstrating that this is potentially a safer treatment for patients.  
In conclusion OH14 induces apoptosis in PDAC cell lines and leaves a significantly less migratory population 
than TRAIL treated cells, indicating its appropriateness for further research and clinical trials.  
 
 
Statins as anti-cancer agents for breast cancer 
Aliki Kadi and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK. 
Evidences suggest and represent statins as a novel anti-tumour therapy for many types of cancers, including 
breast cancer. Statins inhibit the enzyme-3-hydroxy-3-methylglutaryl-coenzyme-A- reductase (HMGCR, 
HMGCoAR). Also, statins have pleiotropic effects, which allow them to decrease the vascular inflammation 
and they can be aused in autoimmune disease, because of their immune-modulatory capacity. There are 
different types of statins, but this project only focused on simvastatin and pravastatin. Also, in this project, we 
tried to investigate the effects of statins on breast cancer cell growth, on cellular migration and on breast cancer 
cell signalling. MTT assay and Ki67 assay used to evaluate the viability and proliferation of triple-negative 
breast cancer (TNBC) cells, western blot and Protein array used to determine whether statins affected the 
activity of intracellular non-receptor protein kinases. Cellular migration was investigated by using Wound 
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Healing Assay. SPSS was used for the statistical analysis of the data collected from the experiments. Both 
agents inhibited cellular proliferation and migration in the two TNBC cell models with simvastatin being the 
more potent agent. This was accompanied by a reduction in EGFR activity. Protein array studies revealed that 
statin treatment also decreased expression and activity of FAK, a key protein involved in cellular migratory 
responses along with  STAT2. 
Overall, our findings suggest that statins exert anticancer activities potentially through the modulation of EGFR 
and other signalling pathways that control proliferation and migration. Whether this is a direct effect or through 
regulation of cellular cholesterol remains to be determined. 
 
 
Investigating The Activity and Post- Translational Modifications of Zinc 
Transporters ZIP6 and ZIP10, during mitosis. 
Frances MacDonald and KM Taylor 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK. 
Zinc, which is the second most abundant trace element in the human body, participates in cell growth, cell 
division, differentiation, and development. Disrupted zinc homeostasis therefore contributes to disease, such 
as cancer. Only recently have we truly learnt to appreciate its participation in cell signalling and regulation of 
gene expression, and therefore understand its involvement in cancers of various tissue types. ZIP transporters 
are known to regulate zinc homeostasis, and it has recently been discovered that ZIP6 and ZIP10 of the LIV-
1 subfamily regulate cell division by zinc influx. Furthermore, both transporters are associated with breast 
cancer spread. In this study, we report confirmation of preferential expression of ZIP6 and ZIP10 in mitotic 
cells, and of a second ZIP6 cleavage at the plasma membrane, by immunofluorescent staining of MCF-7 cells. 
To our knowledge, we are the first to allude to a complex N terminal structure of the ZIP6/ZIP10 heteromer 
that might reflect the previously reported ectodomain of ZIP4 homodimers. This was realised by both 
simultaneous, and separate incubation of cells with ZIP6 and ZIP10 N-terminal binding antibodies. Proximity 
ligation assay and western blotting analysis have permitted the analysis of ZIP6 phosphorylation by candidate 
kinases CK2α and GSK3β, and for the first time we allude to a hierarchical phosphorylation of ZIP6, as is the 
case for many transmembrane receptors and channels. These findings provide greater insight into the 
ZIP6:ZIP10 mitotic paradigm that could be harnessed for therapeutic benefit in the future.  
 
 
Does ADAM15A Form a Complex with c-Abl, Matriptase and Hepsin and Does It 
Affect ADAM15A Regulated Intramembrane Proteolysis? 
Philippe Schmutz1 and Z Poghosyan2 
1 Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales UK. and 2Medical Genetics, School of Medicine, Cardiff University, UHW Main Building, Heath Park, Cardiff, 
CF14 4XN, Wales, UK. 
A disintegrin and metalloprotease 15A (ADAM15A) is a type I transmembrane glycoprotein that is implicated 
several advanced cancers. ADAM15A is involved in the degradation of the ECM and multiple pro-survival 
mechanisms. ADAM15A is known to interact with intracellular proteins such as tyrosine kinases like c-Abl. The 
ADAM15A ectodomain is shed and the intracellular domain (ICD) undergoes regulated intramembrane 
proteolysis (RIP) to release a signalling peptide intracellularly. The ICD is known to be RIPed by a serine 
protease, matriptase or hepsin. This research project uses co-immunoprecipitation and western blotting to 
establish which interactions exist between ADAM15A and the serine proteases and between c- Abl and the 
serine proteases. It was found that ADAM15A interacted with the serine proteases. The interactions were then 
tested to see if they were c-Abl dependent by using a chemotherapeutic drug Nilotinib which is known to inhibit 
c-Abl directly. Nilotinib did not seem to have an effect on the association between ADAM15A and the serine 
proteases, however the association between ADAM15A and c-Abl was upregulated with the downregulation 
of c-Abl activity.  
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Radiochemical synthesis of   18F-radiolabelled ProTides for Positron Emission 
Tomography 
Alessandra Cavaliere and AD Westwell 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Positron Emission Tomography (PET) is a highly sensitive imaging technique used in cancer diagnosis, 
treatment planning and monitoring of therapy response. [18F] is an optimal PET label considering its half-life 
(110 min) and imaging resolution. One of the major challenges in [18F]-PET research is the installation of the 
weakly nucleophilic [18F]fluoride into a precursor molecule to access novel [18F]-tracers. Fluorinated 
nucleosides represent an important class of diagnostic probes for PET imaging as well as anticancer and 
antiviral therapeutic agents. However drug resistance still represents a major problem. The ProTide approach 
is a strategy to synthesize prodrugs of the nucleoside monophosphates which overcome their main resistance 
mechanisms. The challenge of the project is the [18F]-fluorination (hot fluorination) of ProTides which may be 
potential new PET imaging agents and could thus represent a model system to visualize pharmaceutical 
effects and bioactivation of ProTides directly in vivo.  
The pro-nucleotide multistep synthetic chemistry has been applied for the synthesis of ProTides. The [18F]-
radiolabeling of the precursor molecules was performed in an Eckert & Ziegler automated synthetic Modular 
Lab  placed into a shielded hot cell. The radioactive reaction mixtures were analyzed by radio HPLC, and radio 
TLC. Two different approaches have been followed to access two chemically distinct radiolabelled ProTides. 
The 3’-[18F]FLT ProTide was synthesised via a late stage [18F]fluorination of ad hoc synthesised precursor 
molecules (Figure 1). 
 
 
Figure 1: Radiochemical synthesis of 18F- FLT ProTides 
 
The 2’-[18F]FIAU ProTide was synthesised via an early stage [18F]fluorination approach (Figure 2).  
 
Figure 2: Radiochemical synthesis of 18F-FIAU ProTides 
 
These radiolabelled probes could provide evidence for the in vivo behaviour of this class of compounds by 
answering key questions about their metabolism and uptake directly. 
In addition, the project focused on the synthesis of two novel classes of non-radiolabelled fluorinated 
ProTides. A series of uridine based ProTides (FIAU ProTides) and a series of coumarin based FLT ProTides 
have been synthesised and evaluated for their antiviral activity and fluorescent properties respectively. 
 
 
 
Nutritional abnormalities in patients receiving long-term home parenteral nutrition 
(HPN) 
SR Dodington1, R Price-Davies1, AG Cosslett1, P Spark2 & SJ Hiom2 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK; 2St Mary’s Pharmaceutical Unit, 20 Fieldway, Cardiff, CF14 4HY, Wales, UK, 
The last two decades have seen an increased drive to administer parenteral nutrition (PN) to patients in their 
home environments, thereby reducing associated hospital costs and improving patient quality of life. The 
occurrence of deranged nutritional biochemistry results has baffled PN experts for years because PN additives 
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are marketed for the general needs of patients and PN is tailored to each patient’s requirements (both 
formulation and regimen). This thesis documents the investigations into HPN population characteristics, the 
extent of nutritional abnormalities (deficiencies and excesses) in a cohort of long term (LT) PN patients in 
Wales. Both cross-sectional and longitudinal retrospective study designs were employed alongside small-scale 
laboratory efforts to investigate stability of vitamin D in PN additives using High Performance Liquid 
Chromatography (HPLC). Characteristics of the HPN population in Wales were shown to be variable in terms 
of PN requirements for a predominantly female sample population (2:1); in whom 78.6% of patients received 
PN for indications relating to short bowel syndrome (SBS). A database analysis of micronutrient test results 
revealed a high prevalence of deficiencies of vitamin D and selenium, as well as excesses of manganese and 
water-soluble vitamins; which can lead to clinically relevant effects in patients. The sample population was 
shown to have impaired bone health since first receiving PN; respective sites of the femoral neck and total hip 
presented 58% and 60.8% of patients had osteopenia, while 28% and 19.6% had osteoporosis. Evidence in 
the literature links these clinical outcomes of metabolic bone disease (MBD) to patients’ inadequate vitamin D 
status. A final study exploring the adequacy of the trace element (TE) preparation Additrace®, found it lacking 
in selenium and excessive in manganese for the general requirements of the PN population. Clinician-directed 
supplementation of PN outside of Additrace® was associated with better micronutrient status in patients and 
more test results within range. 
 
 
The effect of L-dopa and neuroprotective agents on cell replacement therapy for 
Parkinson’s disease. 
Osama Elabi1, EL Lane1 and S Dunnett2 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK.  2School of Biosciences, Cardiff University, The Sir Martin Evans Building, Museum Avenue, Cardiff, 
CF10 3AX, Wales, UK. 
 
Parkinson disease PD is the second most common neurodegenerative disease affecting 1.8% of population 
aged over 65 years. The current medications that control the symptoms of the disease are associated with 
limited efficacy and induction of side effects (dyskinesia) at later stages of the disease. One promising future 
therapy in PD is cell replacement therapy, however clinical trials declared inconsistent outcomes and 
developing dyskinesia related to the graft. Studies later suggested suboptimal conditions contributed on these 
outcomes. This thesis builds on this knowledge endeavouring to support cell transplantian therapy in Parkinson 
disease in models that are more closely aligned to the clinic thorough considering anti-parkinsonian 
medications in the model. It is addressed the low survival and efficacy problem of the transplanted cells 
examining neuroprotective agents that have previously shown the ability to protect nigrostriatal dopaminergic 
neurons against toxic challenges. In addition, this thesis characterises stem cell transplantation, the potential 
cell source for transplantation that can overcome the many practical and ethical issues surrounding foetal 
tissue. In the first part of the thesis, the investigations on finding neuroprotective agents to support graft survival 
and efficacy was achieved in the unilateral 6-OHDA lesioned rat model, treated with chronic L-dopa, (the gold 
standard anti- Parkinson medication), prior to, and following, cell transplantation. The results revealed for the 
first time that Glucagon Like Peptide-1 (GLP- 1) receptor agonists (exendin-4 and liraglutide) were capable of 
improving graft size and the motor and behaviour recovery results from peripheral administration. Importantly, 
this protection was affected by the presence or absence of L-dopa treatment, as exendin-4 supported the graft 
only in absence of L-dopa while liraglutide supported the graft only in the presence of L-dopa. While other 
neuroprotective agents (ghrelin and ghrelin receptor agonist) failed to support graft survival or efficacy in the 
same animal model. In the second part of the thesis, the characterisation of different source of stem cells 
derived dopaminergic neurons revealed for the first time that these cells can survive and function in the striatum 
of 6-OHDA rat model primed with chronic L-dopa treatment and exposed to L-dopa treatment for 16 weeks 
after transplantation. I show, for the first time, that these cells are capable of ameliorating L-dopa induced 
dyskinesia. 
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Development of analytical methods for the stability assessment of parenteral 
nutrition 
Sophie Emery, AG Cosslett and R Price-Davies  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Parenteral nutrition (PN) provides intravenous nutritional support to patients with reduced gastrointestinal 
function. A PN bag comprises the basic building blocks of the food groups: lipids, glucose, amino acids, 
vitamins, electrolytes and trace elements. Recently there has been an increase in demand for extended 
storage periods for PN bags, to ease management of an increasing home care market. Prior to a PN 
formulation being deemed safe for a patient, a laboratory simulation is carried out on the proposed admixture 
under the requested storage and administration conditions. Currently only the physical stability is assessed; 
physical testing provides no information on the quantity of each component remaining in the bag after storage. 
Consequently, there is a need for assessing the chemical stability of PN to indicate the quantity of each 
component that remains in the PN bag. A commonly used amino acid product, Aminoven® 25, contains 16 
amino acids; this work aimed to develop a HPLC assay capable of quantifying the amino acids in an aqueous 
PN bag containing Aminoven® 25. Fluorescence detection was used as it is a highly selective method of 
detection, which was preferable due to the number of components in PN. To detect the amino acids, as they 
don’t naturally fluoresce, derivatization was carried out using ortho-phthalaldehyde to form a fluorescing 
derivative. The developed assay resulted in validation of thirteen of the amino acids in Aminoven® 25. In 
addition, the method was shown to be unaffected by the iv presence of aqueous PN components, so this 
method is suitable for quantifying thirteen amino acids in aqueous PN containing Aminoven® 25. This assay 
can be used for assessing the stability during stability testing and confirming the quantity of amino acids after 
compounding for quality control release. 
 
 
Exploring Focal Adhesion Kinase (FAK) as a therapeutic target in triple negative 
breast cancer 
Samuel Rhys Jones, AD Westwell and SE Hiscox 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
Triple-negative breast cancer (TNBC) is an aggressive cancer subtype that displays poor prognosis due to a 
lack of targeted therapies and an early pattern of spread. Recent evidence also points to a correlation between 
cancer “stem-like” cells (CSCs) and the inherently aggressive traits of TNBC. As such, targeting signalling 
pathways which support metastasis and CSC populations may represent an important therapeutic strategy to 
treat these tumours and improve current patient outcomes. The non-receptor tyrosine kinase FAK (focal 
adhesion kinase) is known to influence cancer development and progression, with its upregulation common in 
several cancer types. Indeed, FAK can regulate various cellular processes associated with disease 
progression including, cell survival, migration and stem-like behaviours. Therefore, we explored the influence 
of FAK in TNBC cells and the potential benefit of its targeting in this subtype. Whilst assessment of FAK 
expression and activity across a panel of breast cancer cell lines representing the major clinical subtypes 
revealed that FAK was not significantly augmented in MDA-MB-231 cells (model of TNBC) versus other 
models, MDA-MB-231 cells displayed a FAK-dependent migratory and invasive behaviour involving FAK-
mediated activation of Akt and STAT3. These observations also extended to cell proliferation, with 
pharmacological or genetic FAK inhibition leading to perturbed cell cycle progression. Whilst FAK did not 
contribute to the maintenance of a CSC subpopulation, FAK was necessary for their anoikis resistance and 
mammosphere self-renewal, the latter regulated by FAK-dependent modulation of β-catenin through GSK3β 
and interaction between the FAK/Wnt signalling pathways. Using computational modelling, several novel FAK 
inhibitors that targeted FAK kinase-independent scaffolding function were developed and screened to assess 
in vitro efficacy in TNBC cells. Of all 45 compounds, ‘compound 9’ showed significantly improved ability to 
reduce cell proliferation and migration versus the lead compound, chloropyramine. As expected, this agent 
had little effect of FAK phosphorylation but appeared to reduce focal-adhesion targeting and subcellular 
distribution of FAK and significantly inhibited cell migration and growth. Our in vitro data support a case for 
FAK as a promising therapeutic target in TNBC with an ability to suppress both tumorigenic events and those 
associated with metastasis. Targeting FAK scaffolding function may represent a novel approach to developing 
FAK inhibitors that can circumvent resistance traditionally associated with kinase inhibitors. 
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Exploring the impact of anti-oestrogen resistance on the capacity of breast cancer 
cells to modulate bone cell function and their sensitivity to bisphosphonates 
Dionysia Lymperatou1, B Evans2 and SE Hiscox1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences and 2Medicine, Cardiff University, King Edward VII Avenue, 
Cardiff CF10 3NB, Wales, UK. 
Acquired resistance to endocrine therapy is a major limiting factor for their clinical effectiveness, resulting in 
disease relapse and an associated poor prognosis. Acquired resistance is also associated with the 
development of an invasive and migratory phenotype in vitro that may promote metastatic spread in vivo of 
which bone is the most frequent site. However, it is not currently known whether endocrine resistance affects 
the ability of breast cancer cells to modulate bone cell function important in establishing bone metastases or 
whether a resistant phenotype alters sensitivity to agents commonly used to treat bone metastasis such as 
bisphosphonates. Thus, this thesis aimed to explore the bone cell modulatory function of endocrine resistant 
and sensitive breast cancer cells along with their sensitivity to the bisphosphonate, zoledronic acid. This thesis 
demonstrated that breast cancer cells were able to directly induce osteoclast differentiation from both murine 
and human precursor cells. Importantly, this effect was more prevalent in tamoxifen resistant and triple 
negative breast cancer subtypes. Our data also suggested that the breast cancer-mediated osteoclastogenic 
effect involved Src kinase, whilst bisphosphonates acted as anti-tumour agents in tamoxifen resistant cells 
through inhibition of EGFR/AKT/mTOR pathway. In conclusion, this thesis suggests that acquisition of 
endocrine resistance confers a bone modulatory ability to breast cancer cells that may contribute to the 
development of bone metastases. However, this thesis reports the novel finding that acquired endocrine 
resistance augments the sensitivity of breast cancer cells to bisphosphonates, thus representing an opportunity 
to target resistant disease clinically. 
 
 
Defining endocytic pathways to characterise the cellular uptake of extracellular 
vesicles 
Hope Roberts-Dalton1 and A Cocks2, JM Falcon-Perez3, E Sayers1, J Webber2, P Watson4, A Clayton2 and 
AT Jones1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK.  2Division of Cancer & Genetics, Tenovus Institute, Heath park, Cardiff University, Cardiff CF14 4XN.  
3CIC bioGUNE, CIBERehdParque Tecnológico, Bldg. 801-A, Derio, 48160. Bizkaia SPAIN.  4School of Biosciences, 
Cardiff University, Cardiff, CF10 3AX, Wales, UK. 
There is a need for vectors that, with high efficiency, can deliver small and macromolecular therapeutics into 
cells and defined intracellular locations. Extracellular vesicles (EVs), including exosomes, are naturally derived 
nanovesicles generated in and released by numerous cell types. As extracellular entities they have the 
capacity to interact with neighbouring cells and distant tissues and affect physiological processes as well as 
being implicated in numerous diseases including tumorigenesis and neurodegeneration. They are also under 
intense investigation as delivery vectors for biotherapeutics. The ways in which EVs interact with recipient cells 
to influence cell physiology and deliver a macromolecular payload are at the early stages of exploration, but 
are believed to involve endocytosis. For endocytic characterisation a significant challenge is having the ability 
to label exosomes directly or indirectly with fluorescent probes to qualitatively and quantitatively monitor 
exosome-cell interaction and uptake without compromising functionality. In this thesis, techniques to inhibit 
different pathways of endocytosis were investigated and further developed order to establish high content in 
vitro platforms to study the uptake mechanisms of potential drug delivery vectors focusing here exosomes as 
a model system. These techniques involved siRNA depletion of prospective endocytic proteins and chemical 
inhibitors of endocytosis. A simple and rapid method for fluorescent labelling purified Du145 exosomes 
covalently was for the first time utilised to allow comprehensive analysis of the 2 cellular uptake of 
differentiation competent prostate cancer derived EVs in live cells using confocal microscopy. For endocytosis 
analyses, depletion of key endocytic proteins and the use of chemical inhibitors (Dynasore, EIPA, Rottlerin 
and IPA-3) indicated that a fluid phase endocytosis and/or macropinocytosis-like mechanism dependent on 
dynamin were involved in exosome internalisation. Over a period of six hours exosomes were observed to 
increasingly colocalise with lysosomes, indicating a possible intracellular terminus with significance with 
respects to utilisation of exosomes as drug delivery vectors. Overall this labelling method, when used in 
conjunction with established models of endocytic inhibition, provides new opportunities for analysing the 
cellular dynamics of exosomes and other extracellular vesicles as biological entities affecting cell and whole 
body physiology as well as investigating their potential as drug delivery vectors. The work also further 
enhances our ability to study multiple endocytic pathways as potential routes for entry of other drug delivery 
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vectors to gain important information towards the design of more efficient formulations targeting a number of 
diseases. 
 
 
 
In-vitro characterisation of targeting ligands for enhanced delivery across the 
blood-brain barrier 
Jack Sim and M Gumbleton 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK 
The blood-brain barrier (BBB) is the most extensive and restrictive barrier to brain delivery for therapeutic 
agents. A low proportion of low molecular-weight agents can cross into the CNS. This decreases further as 
the molecular weight increases, meaning therapeutic antibodies, oligonucleotides and other supramolecular 
entities effectively cannot reach therapeutic levels within the CNS. Targeting ligands against receptors thought 
to undergo transcytosis across the brain microvascular endothelial cells (BMECs), can boost CNS delivery of 
therapeutics. Understanding these mechanisms, in an in-vitro setting, has proved challenging, due to the 
constraints of cell culture systems and the difficulty to replicate the in-vivo environment. With even the most 
extensively studied targeting receptor, transferrin receptor, not producing clear evidence to suggest the 
occurrence of transcytosis. To understand in-vitro trafficking of brain targeting ligands a pulse-chase assay, in 
combination with sub-cellular localisation microscopy was developed and compared to the current 
permeability-based assay method. The characterisation was done by comparison of transferrin receptor 
ligands; native holo-transferrin, the 8D3 antibody and a low-affinity variant; with the non-specific uptake probe, 
dextran. The method could distinguish between the two endocytosis methods, with concentration-dependent 
efflux efficiency observed with the targeted probes. The combination of techniques was then applied to the 
novel targeting ligand, Rabies-Virus Glycoprotein (RVG) peptide, to assess its suitability as a brain delivery. 
Studies were performed to confirm the target receptor of the RVG peptide, including competitive uptake, siRNA 
knockdown methods. The RVG peptide demonstrated desirable delivery characteristics, and the target 
receptor was confirmed as the α7 nicotinic acetylcholine receptor. Finally, attempts were made to develop a 
total internal reflection fluorescence (TIRF) microscopy assay for the assessment of ligand arrival at the 
basolateral membrane of BMECs. Initial work for this was performed with the transferrin receptor and 
transferrin, using both labelled ligand and photoswitchable receptor constructs. In summary, the pulse-chase 
assay provides a complementary technique to permeability assays for the assessment of brain targeting ligand 
trafficking in BMEC cell-lines in-vitro. 
 
Design and synthesis of novel CYP24A1 inhibitors 
Ismail M Taban and C Simons 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
CYP24A1 (25-hydroxyvitamin D-24-hydroxylase) is a useful enzyme target for a range of medical conditions 
including cancer, cardiovascular and autoimmune disease, which show elevated CYP24A1 levels and 
corresponding reduction of calcitriol (the biologically active form of vitamin D). Calcitriol has antiproliferative 
and pro-differentiating properties, however use of calcitriol as a therapeutic drug is limited by hypercalcaemia. 
An alternative approach is the use of CYP24A1 inhibitors to prevent the metabolism of calcitriol. The aim of 
this research is to design and synthesise novel inhibitors of CYP24A1 to enhance the endogenous levels of 
circulating calcitriol. Furthermore, it is important to develop compounds that are selective for CYP24A1 over 
CYP27B1 so that the generation of calcitriol itself is not blocked. In order to understand the requirements of 
inhibitor binding to the enzyme-active site, it would be useful to have a 3D structure of both human CYP24A1 
and CYP27B1. However, to date, no human crystal structures are available for either of these enzymes. 
Therefore, a homology model for CYP24A1 has been developed and published. A CYP27B1 homology model 
was developed, using a combination of homology modelling, molecular dynamics simulations, and molecular 
docking to understand the satisfactory explanation of the binding selectivity of the CYP27B1 model with the 
natural substrate and with selective inhibitor complexes. Docking results for CYP27B1 showed amino acids 
Arg107, Asn387 and Asp320 have an important role in binding interactions to form hydrogen bonds with 
inhibitors. The development of potent and selective inhibitors from three azole series was investigated. 
Development of series one using pyridine, imidazole and triazole as the haem binding group was synthesised 
successfully. The compounds exhibited weak potency and IC50 ranging between 10.2 to 28.4 μM against 
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CYP24A1. Owing to the low CYP24A1 inhibitory activity the compounds were not evaluated against CYP27B1. 
Series two, bis(3-methyl-1-phenyl-1H-pyrazol-5ol) derivatives, was synthesised successfully. Two compounds 
were moderate CYP24A1 inhibitors and so were further evaluated against CYP27B1. However, these 
compounds showed enzymatic inhibition (IC50 = 0.57 μM and 0.41 μM) against CYP27B1, that is they were 
more selective for CYP27B1, which could be rationalised from docking experiments. A series of (E)-N-(2-(1H-
imidazol-1-yl)-2-(phenylethyl)-3/4-styrylbenzamides have been synthesised using an efficient synthetic route 
and shown to be potent inhibitors of CYP24A1 (IC50 0.11 - 0.35 μM) compared with the standard ketoconazole. 
Molecular modelling using our CYP24A1 homology model showed the inhibitors to fill the hydrophobic binding 
site, forming key transition metal interaction between the imidazole nitrogen and the haem Fe3+ and multiple 
interactions with the active site amino acid residues. 
 
 
Detection of prostate cancer biomarker using molecularly imprinted polymers. 
Vibha Tamboli, CJ Allender and JL Bowen  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
 
Successful treatment of prostate cancer (PCa) depends on early diagnosis and screening, which currently 
relies on the measurement of serum prostate specific antigen (PSA) levels. The overarching aim of the project 
was to generate molecularly imprinted polymers for PCa biomarkers, with subsequent integration with a 
sensing platform to allow for rapid, point-of-care detection and monitoring. The initial work involved the use of 
simple PSA epitopes for epitope imprinting using conventional imprinting techniques. A four amino acid 
sequence from the C-terminus of PSA was imprinted with methacrylic acid (MAA), acrylamide (Aam) and urea 
monomers to obtain bulk imprinted polymers. Apparent Kd of 102 μM, 154 μM, 194 μM were obtained for MAA, 
AAm and urea based bulk mini-MIPs respectively. Epitope imprinting was further developed using a surface 
imprinting approach, via electropolymersiation of dopamine to detect an epitopic sequence from pro-PSA. An 
improvement in Kd from bulk-imprinted polymers, with an apparent Kd of 2.9 μM was obtained with the surface 
electrochemical MIP sensor. However, both epitope imprinting techniques lacked the requisite sensitivity to 
enable measurement of clinically relevant concentrations of PSA (nM range). As a consequence, a more 
sophisticated technique called “hybrid” imprinting was developed to build an electrochemical MIP sensor. The 
hybrid imprinting approach utilised an aptamer with established affinity towards PSA in combination with a 
polydopamine electropolymer to imprint PSA. The resulting aptamer lined polymer pockets exhibited high 
selectivity and affinity towards PSA (apparent Kd 0.3 nM). The apta-MIP sensor was also able to discriminate 
between PSA and a homologous protein (human Kallikrein 2) and was resilient to fouling from serum proteins. 
The apta-MIP sensor was further translated to a MOSFET device whereby successful detection of PSA at 
clinically relevant concentration was obtained in human plasma.  
 
 
Mechanisms of virucidal action of alcohol and metallic ions against nonenveloped 
viruses 
Leonam Viera Goncalves1 I Fallis2 and J-Y Maillard1 
1School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 3NB, 
Wales, UK and  2School of Chemistry, Cardiff University, Main Building, Park Place, Cardiff, CF10 3AT, Wales, UK. 
Studying the mechanism of action (MoA) of biocides against pathogenic microorganisms is crucial to 
understand their efficacy and limitations, and to develop more efficient microbicidal formulations. Combining 
alcohol and zinc has been reported to enhance microbicidal activity, but the reasons for such activity are 
unknown. This study focuses on the impact of combining ethanol and zinc salt at pH 10.5 against 
nonenveloped viruses. The study is focused on three different aspects: i) virucidal activity screening of 
ethanol:zinc combinations against bacteriophages and human viruses; ii) impact of ethanol:zinc combinations 
on virus structure, particularly the viral capsid and nucleic acid, using Transmission Electron Microscopy 
(TEM); Atomic Force Microscopy (AFM) and agarose gel DNA electrophoresis and iii) chemical speciation and 
stability of ethanol:zinc combinations over time. The combination of ethanol with zinc salt was found to be 
more effective against viruses than control formulations containing sole active ingredients and/or excipients 
only. Activity test of 40%(w/v) ethanol with 0.1% (w/v) zinc salt with excipients (RB- 002 formulation) against 
F116 and adenovirus type 2 (AdV2) at 60 min contact time yielded 0.68 ± 0.02 and 5.26 ± 0.10 log10 reduction, 
respectively. In comparison, 0.1% (w/v) zinc salt only with excipient (RB-002G formulation) showed no virucidal 
activity against bacteriophage F116 (0.14 ± 0.02 log10 reduction) and AdV2 (0.80 ± 0.12 log10 reduction) in 
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suspension. Differences between activities against bacteriophage MS2 and poliovirus type 1 were similar as 
the ones found between F116 and AdV2. Formulation containing 40%(w/v) ethanol with 0.1% (w/v) zinc salt 
produced a range of structural damage to F116 and attP AdV5 indicating possible capsid alteration. Effect of 
the combined formulation on viral capsid was confirmed with AFM with a possible decreased in virus capsid 
stiffness and significant virus capsid height reduction over 10 min contact time. F116 DNA damage was 
detected upon exposure to 40%(w/v) ethanol with 0.1% (w/v) zinc salt with excipients, but no damage was 
detected on AdV2 DNA through electrophoresis analysis. The alcohol/zinc formulation system at pH 10.5 was 
shown to have promising virucidal activity against non-enveloped viruses at room temperature following an 
alteration of the viral capsid, and possible damage to the viral nucleic acid. This study also showed the 
limitations of using bacteriophage as surrogate for mammalian viruses. 
 
 
A mixed methods approach for assessing student and staff perceptions and 
experiences of a new collaborative transnational pharmacy programme 
Pei Nee Wong, ML Hughes, R Deslandes and DN John  
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
This doctoral thesis reports on a longitudinal, mixed methods investigation of staff and students’ views, 
expectations, and experiences of a collaborative pharmacy programme between Cardiff University School of 
Pharmacy and Pharmaceutical Sciences (CU) and Taylor’s University School of Pharmacy (TU). Despite a 
growing body of empirical research on transnational staff and students’ expectations and experiences, 
longitudinal mixed methods studies are rare. This study combined a qualitative interview-based and focus 
group approach with a quantitative questionnaire-based method. The overall aim is to gain a better 
understanding of the teaching and learning experiences of staff and students in a transnational education 
(TNE) programme. The qualitative element explored staff expectations and experiences in the early stage of 
the collaborative programme while student expectations and experiences were investigated at different points 
in time throughout their 4-year pharmacy study. The quantitative element investigated and compared the 
learning environment perceived by participating students in TU and CU. Data collection took place over a 
period of 36 months and comprised four phases. In Phase 1, staff and students’ initial expectations and 
experiences of a new collaborative pharmacy programme were explored using staff interviews and student 
focus groups. In Phase 2, a sample of students from CU and TU were recruited to participate in a questionnaire 
study to assess students’ perceived learning environment. In Phase 3, a number of studies were carried out 
using focus groups in order to find out students’ pre-arrival expectations and post-arrival experiences. Phase 
4 involved a self-administered questionnaire with graduate students to assess students’ opinions about their 
overall experiences at the universities. The study revealed staff and students' expectations and their actual 
experiences in relation to the delivery of a transnational education. It was found that those students who 
participated were able to cope with sociocultural adjustment in a new learning environment. The study also 
provided indications of the need for training and professional development for staff to teach in a transnational 
environment. Finally, Malaysian students who come from a teachercentred pedagogy background should be 
informed and trained earlier before their transfer to lessen the impact brought about by intercultural differences 
in teaching and learning. 
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Design, synthesis and evaluation of novel c-FLIP inhibitors in order to sensitise 
breast cancer cells and breast cancer stem cells to TRAIL 
Gilda Giancotti1, R Clarkson2, AD Westwell1 and A Brancale1 
1Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK and  2School of Biosciences, Cardiff University, The Sir Martin Evans Building, Museum Avenue, Cardiff, 
CF10 3AX, Wales, UK. 
 
Antimicrobial drug LbL-assembled delivery system for orthopaedic nanocomposite 
bone cements. 
Yazan Al Thaher, S Latanza, S Perni and P Prokopovich 
Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University, King Edward VII Avenue, Cardiff CF10 
3NB, Wales, UK. 
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